<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1210234332
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CEREZYME 400 U powder for concentrate for solution for infusion 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IMIGLUCERASE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        5984.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GENZYME IRELAND LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GENZYME IRELAND LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Sanofi B.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A16AB02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cerezyme contains the active substance imiglucerase and is used to treat patients who have a confirmed diagnosis of Type I or Type 3 Gaucher disease, who show signs of the disease such as:&nbsp;</p><p>anaemia (low number of red blood cells), a tendency to bleed easily (due to low numbers of platelets &ndash; a</p><p>type of blood cell), spleen or liver enlargement or bone disease.&nbsp;</p><p>People with Gaucher disease have low levels of an enzyme called acid -glucosidase. This enzyme helps the body control levels of glucosylceramide. Glucosylceramide is a natural substance in the body, made of sugar and fat<em>.</em> In Gaucher disease glucosylceramide levels can get too high.&nbsp;</p><p>Cerezyme is an artificial enzyme called imiglucerase - this can replace the natural enzyme acid glucosidase which is lacking or not active enough in patients with Gaucher disease.&nbsp;</p><p>The information in this leaflet applies to all patient groups including children, adolescents, adults and the elderly.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Cerezyme &nbsp;</strong></p><p>-&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to imiglucerase or any of the other ingredients of this medicine (listed in section 6).&nbsp;</p><p><strong>Warnings and precautions&nbsp;&nbsp;</strong></p><p>Talk to your doctor&nbsp; or pharmacist before using Cerezyme:&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are treated with Cerezyme, you may experience an allergic reaction while you are being given the medicine or shortly after. If you experience a reaction like this, you should <strong>tell your doctor immediately</strong>. Your doctor may test if you have an allergic reaction to imiglucerase.&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some patients with Gaucher disease have high blood pressure in the lungs (pulmonary hypertension). The cause can be unknown, or it can be due to heart, lung or liver problems. It can occur whether the patient is treated with Cerezyme or not. But, if you suffer with any <strong>shortness of breath</strong> you should tell your doctor.&nbsp;</p><p><strong>Other medicines and Cerezyme &nbsp;</strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.&nbsp;</p><p>Cerezyme should not be given as a mixture with other medicinal products in the same infusion (drip).&nbsp;</p><p><strong>Pregnancy and breast-feeding&nbsp;</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Cautious use of Cerezyme during pregnancy and breastfeeding is recommended.&nbsp;</p><p><strong>Cerezyme contains sodium&nbsp;&nbsp;</strong></p><p>This medicine contains 41 mg sodium (main component of cooking/table salt) per vial. This is equivalent to 2% of the recommended maximum daily dietary intake of sodium for an adult. It is administered in 0.9% sodium chloride intravenous solution. This should be taken into consideration by patients on a controlled sodium diet.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>Instructions for proper use&nbsp;</u></p><p>Cerezyme is given through a drip into a vein (by intravenous infusion).&nbsp;</p><p>It is supplied as a powder which will be mixed with sterile water before it is given.&nbsp;</p><p>Cerezyme is only used under the supervision of a doctor who is knowledgeable in the treatment of Gaucher disease. Your doctor may advise that you can be treated at home provided you meet certain criteria. Please contact your doctor if you would like to be treated at home.&nbsp;</p><p>Your dose will be specific to you. Your doctor will work out your dose based on how severe your symptoms are, and other factors. The recommended dose is 60 units/kg body weight given once every 2 weeks.&nbsp;&nbsp;</p><p>Your doctor will keep a close check on your response to your treatment, and may change your dose (up or down) until he/she finds the best dose to control your symptoms.&nbsp;&nbsp;</p><p>Once this dose is found your doctor will still keep a check on your responses to make sure you are using the right dose. This might be every 6 to 12 months.&nbsp;</p><p>There is no information on the effect of Cerezyme on brain-based symptoms of patients with chronic neuronopathic Gaucher disease. Therefore no special dosage regimen can be recommended.&nbsp;</p><p><u>The ICGG Gaucher Registry&nbsp;</u></p><p>You can ask your doctor to register your patient information into the &ldquo;ICGG Gaucher Registry&rdquo;. The aims of this Registry are to increase the understanding of Gaucher disease and to check how well enzyme replacement therapy, like Cerezyme, works. This should lead to improvement in the safe and effective use of Cerezyme.&nbsp; Your patient data will be registered anonymously&ndash; nobody will know it is information about you.&nbsp;</p><p><strong>If you use more Cerezyme than you should</strong>&nbsp;</p><p>There are no cases of overdose of Cerezyme reported.&nbsp;</p><p><strong>If you forget to use Cerezyme &nbsp;</strong></p><p>If you have missed an infusion, please contact your doctor.&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people):&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives/ localised swelling of the skin or lining of the mouth or throat&nbsp;&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash<strong> </strong>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people):&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sensation of tingling, pricking, burning or numbness of the skin&nbsp; - &nbsp;&nbsp; increased heart rate&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bluish skin&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fall in blood pressure&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal cramping&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the joints&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infusion site discomfort&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infusion site burning&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infusion site swelling&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site sterile abscess&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest discomfort&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rigors&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; backache&nbsp;</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people):&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaphylactoid reactions&nbsp;</p><p>Some side effects were seen primarily while patients were being given the medicine or shortly after. These have included itching, flushing, hives/localised swelling of the skin or lining of the mouth or throat, chest discomfort, increased heart rate, bluish skin, breathlessness, a sensation of tingling, pricking, burning or numbness of the skin, fall in blood pressure and backache.&nbsp; If you experience any of these symptoms, please <strong>tell your doctor immediately</strong>. You may need to be given additional medicines to prevent an allergic reaction (e.g. antihistamines and/or corticosteroids).&nbsp;&nbsp;</p><p>Reporting of side effects&nbsp;</p><p><strong>To report any side effect(s):</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:623px"><tbody><tr><td style="vertical-align:top"><p>&bull; &nbsp;&nbsp;&nbsp; <strong>Saudi Arabia: </strong></p></td></tr><tr><td style="vertical-align:top"><p>- &nbsp;&nbsp;&nbsp; <strong>The National Pharmacovigilance and Drug Safety Centre (NPC) </strong></p></td></tr><tr><td style="vertical-align:top"><p>&bull; &nbsp;&nbsp;&nbsp; <strong>SFDA call center : 19999 </strong></p></td></tr><tr><td style="vertical-align:top"><p>&bull; &nbsp;&nbsp;&nbsp; <strong>E-mail: </strong><u>npc.drug@sfda.gov.sa</u><strong>&nbsp; </strong></p></td></tr><tr><td style="vertical-align:top"><p>&bull; &nbsp;&nbsp;&nbsp; <strong>Website: </strong>https://ade.sfda.gov.sa/ <strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&bull; Sanofi- Pharmacovigilance: </strong><strong>KSA_Pharmacovigilance@sanofi.com</strong></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.&nbsp;</p><p>Do not use this medicine after the expiry date printed on the labelling after the letters &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.&nbsp;</p><p><u>Unopened vials:</u>&nbsp;</p><p>Store in a refrigerator (2C &ndash; 8C)&nbsp;</p><p><u>Diluted solution:</u>&nbsp;</p><p>It is recommended that Cerezyme is used immediately after it has been mixed with sterile water. The mixed solution in the vial cannot be stored and should be promptly diluted in an infusion bag; only the diluted solution can be held for up to 24 hours if it is kept cool (2&deg;C &ndash; 8&deg;C) and in the dark.&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Cerezyme contains&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is imiglucerase. Imiglucerase is a modified form of the human enzyme acid</p><p>-glucosidase produced by recombinant DNA technology.<em> </em>One vial contains 400 units of imiglucerase. After reconstitution, the solution contains 40 units of imiglucerase per ml.&nbsp;&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: mannitol, sodium citrate, citric acid monohydrate and polysorbate 80.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Cerezyme looks like and contents of the pack  
Cerezyme, 400 Units, is presented as a powder for concentrate for solution for infusion (in a vial, pack size of 1, 5 or 25).  Not all pack sizes may be marketed.  
Cerezyme is supplied as a white to off-white powder. After reconstitution it is a clear, colourless liquid, free from foreign matter. The reconstituted solution must be further diluted. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer </strong>&nbsp;</p><p><strong>Marketing Authorisation Holder&nbsp; </strong>&nbsp;</p><p>Sanofi B.V., Paasheuvelweg 25, 1105 BP, Amsterdam, the Netherlands&nbsp;</p><p><strong>Manufacturer &nbsp;</strong></p><p>Genzyme Ireland Limited., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي سيريزايم على المادة الفعالة إيميغلوسيراز ويستخدم لعلاج المرضى الذين تم التأكد من تشخيص إصابتهم بمرض غوشيه من النوع الأول أو الثالث، ممن تظهر عليهم علامات المرض مثل: فقر الدم</p><p dir="RTL">(انخفاض عدد خلايا الدم الحمراء)، والميل إلى النزف بسهولة (بسبب انخفاض عدد الصفائح الدموية - نوع من خلايا الدم)، تضخم الطحال أو الكبد أو أمراض العظام.</p><p dir="RTL">الأشخاص الذين يعانون من مرض غوشيه لديهم مستويات منخفضة من إنزيم يسمى حمض بيتا-</p><p dir="RTL">الغلوكوزيداز. يساعد هذا الإنزيم الجسم على التحكم في مستويات سيراميد الغليكوزيل. سيراميد الغليكوزيل هي مادة طبيعية في الجسم، مكونة من السكر والدهون. يمكن أن يصل سيراميد الغليكوزيل إلى مستويات مرتفعة لدى المصابين بمرض غوشيه.</p><p dir="RTL">سيريزايم هو إنزيم اصطناعي يسمى إيميغلوسيراز &ndash; وهو يمكن أن يحل محل إنزيم حمض بيتا- الغلوكوزيداز الإنزيم الطبيعي الذي ينقص أو لا ينشط بشكل كاف لدى المرضى الذين يعانون من مرض غوشيه. &nbsp;&nbsp;</p><p dir="RTL">تنطبق المعلومات الواردة في هذه النشرة على جميع فئات المرضى بما في ذلك الأطفال والمراهقين والبالغين والمسنين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;لا تستخدم سيريزايم &nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه إيميغلوسيراز أو أي من المكونات الأخرى لهذا الدواء )المذكورة في الفقرة رقم 6).</p><p dir="RTL"><strong>المحاذير والإحتياطات </strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل استخدام سيريزايم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تواجه رد فعل تحسسي أثناء علاجك بسيريزايم إما أثناء إعطائك الدواء أو بعد إعطائه بفترة قصيرة. إذا واجهت رد فعل كهذا، يجب أن <strong>تخبر طبيبك على الفور</strong>. قد يجري طبيبك فحصًا إذا كنت تعاني من رد فعل تحسسي لإيميغلوسيراز.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يعاني بعض مرضى غوشيه من ارتفاع ضغط الدم في الرئتين (ارتفاع ضغط الدم الرئوي). يمكن أن يكون السبب غير معروف، أو يمكن أن يحدث بسبب مشاكل في القلب أو الرئة أو الكبد. يمكن أن يحدث ذلك سواء تم علاج المريض بسيريزايم أم لم يتم .ولكن، إذا كنت تعاني من أي <strong>ضيق في التنفس</strong>، فعليك إخبار طبيبك.</p><p dir="RTL"><strong>أدوية أخرى&nbsp; وسيريزايم&nbsp; </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت أي أدوية أخرى مؤخرًا، بما في ذلك الأدوية التي يتم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">لا ينبغي إعطاء سيريزايم مع مزجه بالمنتجات الطبية الأخرى في نفس كيس التسريب (بالتنقيط).</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية </strong></p><p dir="RTL">إذا كنت&nbsp; حاملاً أو مرضعة، تعتقدين أنك قد تكونين حاملاً أو تخططين لإنجاب طفل، استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء. ينصح بالتزام الحذر مع استخدام سيريزايم أثناء الحمل والرضاعة الطبيعية.</p><p dir="RTL"><strong>سيريزايم يحتوي على الصوديوم </strong></p><p dir="RTL">يحتوي هذا الدواء على 41 ملغ من الصوديوم (المكوّن الأساسي لملح الطعام) في القارورة الواحدة مما يعادل 2% من الحدّ الغذائي الأقصى اليومي الموصى به من الصوديوم للشخص البالغ، ويُعطى على شكل محلول وريدي من كلوريد الصوديوم 0.9%. يجب أن يأخذ المرضى الذين يتبعون نظامًا غذائيًا منخفض الصوديوم هذا المحتوى بالاعتبار.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>تعليمات للاستخدام الصحيح&nbsp; </u></p><p dir="RTL">يتم إعطاء سيريزايم من خلال التنقيط في الوريد (عن طريق الحقن بالتسريب الوريدي). &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">يتوفر سيريزايم على شكل مسحوق يتم خلطه بالماء المعقم قبل إعطائه</p><p dir="RTL">يستخدم سيريزايم تحت إشراف طبيب لديه دراية في علاج مرض غوشيه فقط. قد ينصحك طبيبك بأنه يمكن علاجك في المنزل شريطة أن تستوفي معايير معينة. يرجى الاتصال بطبيبك إذا كنت ترغب في تلقي العلاج في المنزل.</p><p dir="RTL">ستكون جرعتك محددة لك. سيقوم طبيبك بتحديد الجرعة بناءً على مدى حدة الأعراض لديك وعوامل أخرى.</p><p dir="RTL">الجرعة الموصى بها هي 60 وحدة / كجم من وزن الجسم تعطى مرة واحدة كل أسبوعين.</p><p dir="RTL">سيراقب طبيبك استجابتك للعلاج عن كثب، وقد يغير جرعتك (بزيادتها أو تنقيصها) حتى يصل/تصل لأفضل جرعة للتحكم في الأعراض.</p><p dir="RTL">بمجرد العثور على هذه الجرعة، سيظل طبيبك يراقب إستجابتك للتأكد من أنك تستخدم الجرعة المناسبة. قد يتم ذلك كل 6 إلى 12 شهرًا.</p><p dir="RTL">لا توجد معلومات حول تأثير سيريزايم على الأعراض المستندة إلى الدماغ للمرضى الذين يعانون من مرض غوشيه المزمن العصبي. لذلك لا يمكن التوصية بجرعة خاصة بذلك. &nbsp;</p><p dir="RTL"><u>سجل مرض غوشيه ضمن المجموعة الدولية التعاونية لمرض غوشيه&quot; </u><u>ICGG</u><u>&quot; </u></p><p dir="RTL">يمكنك أن تطلب من طبيبك تسجيل معلومات المريض في&quot; سجل مرض غوشيه ICGG&quot;. تتمثل أهداف هذا السجل في زيادة فهم مرض غوشيه وفحص مدى فعالية العلاج التعويضي بالإنزيم، مثل سيريزايم. ينبغي أن يؤدي هذا إلى تحسن في الاستخدام الآمن والفعال لسيريزايم. سيتم تسجيل بياناتك دون الكشف عن هويتك - لن يعلم أحد أنها معلومات عنك.</p><p dir="RTL"><strong>إذا استخدمت من سيريزايم أكثر مما ينبغي&nbsp; </strong></p><p dir="RTL">لا توجد حالات جرعة زائدة مُبلغ عنها من سيريزايم.&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام سيريزايم&nbsp; </strong></p><p dir="RTL">إذا فاتتك إحدى جرعات التسريب الوريدي، يرجى الاتصال بطبيبك.</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا المنتج، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع سائر الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، على الرغم من أنها لا تحدث لدى جميع من يستخدمه .</p><p dir="RTL"><strong>شائعة</strong> (قد&nbsp; تُؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص):</p><p dir="RTL">- عسر التنفس</p><p dir="RTL">- السعال</p><p dir="RTL">- الشرى/تورم موضعي للجلد أو بطانة الفم أو الحلق</p><p dir="RTL">- حكة&nbsp;</p><p dir="RTL">- طفح جلدي</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائعة</strong> (قد&nbsp; تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الرأس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالوخز، اللسع، الحرقان أو تنميل الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة معدل ضربات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميل لون الجلد إلى الأزرق&nbsp;&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الوجه&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنج في البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانزعاج في موضع التسريب&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة في موضع التسريب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في موضع التسريب&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكوّن خراج معقم في موضع الحقن&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الراحة في الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمّى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعياء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الظهر</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة</strong> (قد&nbsp; تُؤثر على ما يصل إلى شخص واحد من كل 1000 شخص): &nbsp;</p><p dir="RTL">- تفاعلات تأقية</p><p dir="RTL">&nbsp;</p><p dir="RTL">لوحظت بعض الأعراض الجانبية بشكل أساسي أثناء إعطاء المرضى الدواء أو بعد إعطائه بفترة قصيرة.</p><p dir="RTL">وشملت هذه الأعراض الحكة، احمرار، الشرى/تورم موضعي للجلد أو بطانة الفم أو الحلق، ألم في الصدر، زيادة معدل ضربات القلب، جلد مزرق، عسر التنفس، إحساس بالوخز، اللسع، الحرقان أو تنميل الجلد، وانخفاض ضغط الدم وآلام الظهر. إذا واجهت أيًا من هذه الأعراض، <strong>فيرجى إخبار طبيبك على الفور</strong>. قد تحتاج إلى إعطاء أدوية إضافية لمنع حدوث الحساسية (مثل مضادات الهيستامين و/أو الكورتيكوستيرويدات).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبيّة</strong></p><p dir="RTL"><strong>للإبلاغ عن التأثيرات الجانبيّة:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربيّة السعوديّة:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong><em>-&nbsp; </em></strong><strong>المركز الوطني للتيقّظ الدوائي وسلامة الأدوية</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مركز الاتصال للهيئة العامة للغذاء والدواء: 19999</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>البريد الإلكتروني: </strong><strong>npc.drug@sfda.gov.sa</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الموقع الإلكتروني: </strong><strong>https://ade.sfda.gov.sa/</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>سانوفي &ndash; قسم التيقّظ الدوائي: </strong><strong>KSA_Pharmacovigilance@sanofi.com</strong></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدرج على الملصق بعد الحروف &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><u>القوارير غير المفتوحة:</u></p><p dir="RTL">يتم حفظها في الثلاجة (2 درجة مئوية - 8 درجة مئوية)</p><p dir="RTL"><u>المحلول المخفف:</u></p><p dir="RTL">يوصى باستخدام سيريزايم فوراً بعد مزجه بالماء المعقم. ينبغي تجنّب تخزين المحلول المخلوط بالماء في القارورة ويجب تخفيفه على الفور في كيس محلول التسريب؛ يمكن الاحتفاظ بالمحلول المخفف فقط لمدة تصل إلى 24 ساعة إذا ظل باردًا (2 درجة مئوية - 8 درجة مئوية) وفي الظلام.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;ماذا يحتوي سيريزايم </strong></p><p dir="RTL">-&nbsp; المادة الفعالة هي إيميغلوسيراز. إيميغلوسيراز هو شكل معدّل من الإنزيم البشري حمض بيتا غلوكوزيداز المُصنّع باستخدام تقنية الهندسة الوارثية. تحتوي القارورة الواحدة على 400 وحدة من&nbsp;</p><p dir="RTL">&nbsp;&nbsp; إيميغلوسيراز. بعد إعادة التكوين، يحتوي المحلول على 40 وحدة من إيميغلوسيراز في كل 1 مل.</p><p dir="RTL">-&nbsp; المكونات الأخرى هي: مانيتول، سترات الصوديوم، حامض الستريك أحادي الهيدرات وبوليسوربات 80.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر سيريزايم 400 وحدة، على شكل مسحوق لتحضير مُركّز للتخفيف قبل الحقن بالتسريب الوريدي (في قارورة، تحتوي العبوة الواحدة على 1، 5 أو 25 قارورة). قد لا يتم تسويق جميع أحجام العبوات.</p><p dir="RTL">يتوفر سيريزايم على شكل مسحوق أبيض إلى مائل إلى الأبيض. بعد إعادة التشكيل، يصبح سائلًا عديم اللون صافيًا وخاليًا من المواد الغريبة. يجب تخفيف المحلول المعاد تشكيله.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق والمُصنّع </strong></p><p dir="RTL"><strong>مالك رخصة التسويق </strong></p><p>Sanofi B.V., Paasheuvelweg 25, 1105 BP, Amsterdam, the Netherlands</p><p dir="RTL"><strong>المُصنّع </strong></p><p>Genzyme Ireland Limited., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ابريل 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cerezyme 400 Units Powder for concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 400 units* of imiglucerase**.
After reconstitution, the solution contains 40 units (approximately 1.0 mg) of imiglucerase per ml (400 U/10 ml). Each vial must be further diluted before use (see section 6.6).
* An enzyme unit (U) is defined as the amount of enzyme that catalyses the hydrolysis of one micromole of the synthetic substrate para-nitrophenyl -D-glucopyranoside (pNP-Glc) per minute at 37°C.
** Imiglucerase is a modified form of human acid -glucosidase and is produced by recombinant DNA technology using a mammalian Chinese Hamster Ovary (CHO) cell culture, with mannose modification for targeting macrophages.
Excipients with known effect:
Each vial contains 41 mg of sodium.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion.
Cerezyme is a white to off-white powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cerezyme (imiglucerase) is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant non-neurological manifestations of the disease.<br />The non-neurological manifestations of Gaucher disease include one or more of the following conditions:<br />&bull; anaemia after exclusion of other causes, such as iron deficiency<br />&bull; thrombocytopenia<br />&bull; bone disease after exclusion of other causes such as Vitamin D deficiency<br />&bull; hepatomegaly or splenomegaly</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Disease management should be directed by physicians knowledgeable in the treatment of Gaucher disease.<br /><u>Posology</u><br />Due to the heterogeneity and the multi-systemic nature of Gaucher disease, dosage should be individualised for each patient based on a comprehensive evaluation of all clinical manifestations of the disease. Once individual patient response for all relevant clinical manifestations is wellestablished, dosages and frequency of administration may be adjusted with the goal to either maintain already reached optimal parameters for all clinical manifestations or further improve those clinical parameters which have not yet been normalised.<br />A range of dosage regimens has proven effective towards some or all of the non-neurological manifestations of the disease. Initial doses of 60 U/kg of body weight once every 2 weeks have shown improvement in haematological and visceral parameters within 6 months of therapy and continued use has either stopped progression of or improved bone disease. Administration of doses as low as 15 U/kg of body weight once every 2 weeks has been shown to improve haematological parameters and organomegaly, but not bone parameters. The usual frequency of infusion is once every 2 weeks; this is the frequency of infusion for which the most data are available.<br /><em>Paediatric population</em><br />No dose adjustment is necessary for the paediatric population.<br />The efficacy of Cerezyme on neurological symptoms of chronic neuronopathic Gaucher patients has not been established and no special dosage regimen can be recommended for these manifestations (see section 5.1).<br /><u>Method of administration</u><br />After reconstitution and dilution, the preparation is administered by intravenous infusion. At initial infusions, Cerezyme should be administered at a rate not exceeding 0.5 unit per kg body weight per minute. At subsequent administrations, infusion rate may be increased but should not exceed 1 unit per kg body weight per minute. Infusion rate increases should occur under supervision of a health care professional.<br />Infusion of Cerezyme at home may be considered for patients who are tolerating their infusions well for several months. Decision to have patient move to home infusion should be made after evaluation and recommendation by the treating physician. Infusion of Cerezyme by the patient or caregiver at home requires training by a health care professional in a clinical setting. The patient or caregiver will be instructed in infusion technique and the keeping of a treatment diary. Patients experiencing adverse events during the infusion need to immediately stop the infusion process and seek the attention of a healthcare professional. Subsequent infusions may need to occur in a clinical setting. Dose and infusion rate should remain constant while at home, and not be changed without supervision of a health care professional.<br />For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.<br />Medical or healthcare professionals are encouraged to register Gaucher patients, including those with chronic neuronopathic manifestations of the disease, in the &ldquo;ICGG Gaucher Registry&rdquo; (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity</u><br />Current data using a screening ELISA followed by a confirmatory radioimmunoprecipitation assay, suggest that, during the first year of therapy, IgG antibodies to imiglucerase are formed in approximately 15% of the treated patients. It appears that patients who will develop IgG antibody are most likely to do so within 6 months of treatment and will rarely develop antibodies to Cerezyme after 12 months of therapy. It is suggested that patients suspected of a decreased response to the treatment be monitored periodically for IgG antibody formation to imiglucerase.<br />Patients with antibody to imiglucerase have a higher risk of hypersensitivity reactions (see section 4.8). If a patient experiences a reaction suggestive of hypersensitivity, subsequent testing for imiglucerase antibodies is advised. As with any intravenous protein product, severe allergic-type hypersensitivity reactions are possible, but occur uncommonly. If these reactions occur, immediate discontinuation of the Cerezyme infusion is recommended and appropriate medical treatment should be initiated. The current medical standards for emergency treatment are to be observed.<br />Patients who have developed antibodies or symptoms of hypersensitivity to Ceredase (alglucerase) should be treated with caution when administering Cerezyme (imiglucerase).<br /><br /><u>Sodium</u><br />This medicinal product contains 41 mg sodium per vial, equivalent to 2% of the WHO recommended maximum daily intake of 2 g sodium for an adult. It is administered in 0.9% sodium chloride intravenous solution (see section 6.6). To be taken into consideration by patients on a controlled sodium diet.<br /><br /><strong>Applicant Proposal:</strong><br />The Applicant would like to propose correction of the sodium content to clarify the sodium quantity per vial i.e. 41 mg. The Applicant considers that the corrected quantity will better aid management of patients on a controlled sodium diet.<br />The Patient leaflet text is also proposed for revision aligned with the SmPC revision.<br /><br /><u>Traceability</u><br />In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />Limited experience from 150 pregnancy outcomes (primarily based on spontaneous reporting and literature review) is available suggesting that use of Cerezyme is beneficial to control the underlying Gaucher disease in pregnancy. Furthermore, these data indicate no malformative toxicity for the foetus by Cerezyme, although the statistical evidence is low. Foetal demise has been reported rarely, although it is not clear whether this related to the use of Cerezyme or to the underlying Gaucher disease.<br />No animal studies have been carried out with respect to assessing the effects of Cerezyme on pregnancy, embryonal/foetal development, parturition and postnatal development. It is not known whether Cerezyme passes via the placenta to the developing foetus.<br />In pregnant Gaucher patients and those intending to become pregnant, a risk-benefit treatment assessment is required for each pregnancy. Patients who have Gaucher disease and become pregnant may experience a period of increased disease activity during pregnancy and the puerperium. This includes an increased risk of skeletal manifestations, exacerbation of cytopenia, haemorrhage, and an increased need for transfusion. Both pregnancy and lactation are known to stress maternal calcium homeostasis and to accelerate bone turnover. This may contribute to skeletal disease burden in Gaucher disease.<br />Treatment na&iuml;ve women should be advised to consider commencing therapy prior to conception in order to attain optimal health. In women receiving Cerezyme treatment continuation throughout pregnancy should be considered. Close monitoring of the pregnancy and clinical manifestations of Gaucher disease is necessary for the individualization of dose according to the patient&rsquo;s needs and therapeutic response.<br /><u>Breast-feeding</u><br />It is not known whether this active substance is excreted in human milk, however, the enzyme is likely to be digested in the child&rsquo;s gastrointestinal tract</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cerezyme has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tabulated list of adverse reactions<br />Adverse reactions are listed by system organ class and frequency (common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100) and rare (1/10,000 to &lt;1/1,000)) in the table below. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<br /><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAzkAAAHbCAYAAADoAVS5AAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAFiUAABYlAUlSJPAAAOMdSURBVHhe7N0LXFRl/j/wj+OQWyrq7uK/Qax+aV7QtJvVGq4Qht3WtguWpmaWl7AkbyRlAWailpkWeMW8rRZ46aYJYuKGl6R2V5Ob6W7KAFtUctPNhHn+z7kMMwPDMCgCjp93r0nmOec85zlnznme853znGdaCAlEREREREQewqD/S0RERERE5BEY5BARERERkUdhkENERERERB6FQQ4REREREXmUBht4oEWLFvpfREREREREjhpzvLMGDXIas+BEnoTnD5FrPEfoUsTjlsimsc8HdlcjIiIiIiKPwiCHiIiIiIg8CoMcIiIiIiLyKAxyiIiIiIjIozDIISIiIiIij8Igh4iIiIiIPMplFOQUIvujaKyY1Bm+K3JQoacSEREREZFnaeQg5zi+mNZOHSdbffm+jPgSiz7NOUvORAy2zt/C9zwDlAqU7hyJ4IdjMO7dSjXFUL0sNV6+6DhlKaLf3YfMqiIq+QyCr9P55cv3KQxdsxNpZa63SWXZhVWDvOAV8YUMv+rHYk5C0qxeejmUcq5EfOYplHw0F8vq2J/1dxyfRe+udxkvirI0JK8Ziqd8bfvca9SbePXjbBTps1xW5P7YvmoCIgZ4OeyP6H0FsJSsR/Rnl+VeoctaKY4u61p1PlS9Bq9CWlXV6KTud5hO1NhcX49c1u0c0YUQDaReWRXHiQgT5DImYVqeLc7pyTUdE7umeqt5G6fvEgV66vmqzA4TIdXXWZkqEoKNAiEJYnelnianlh1ZKjbG+AuTXDcCI0VUVrE+TVEicpd2keUKFWHZ/9OSKo+Ig/GBIlAp68jVIrW0KjMnZP4HhqnzwhQp4opdzVtN2QYx70+thM/kTWK3vo5K8waREG6qf15uqMyLEreM3XnB+/7CyP2VOUmMNHYT/jGJIjHvrJ5eLvL3TRbTA4xu7PPmrX6notwfWVH6ds8XUXvzbcdz6W6RvFg5Dus6t4guLfU7R/S2w1WdKOv+5X5jRVRVfULU8Op13Dq5Hqlq39Fb+C85LH7UkokuSfWrxy9ck3VXO4vRmPpEKQqj1mJ5LXcfLOZ1eOdzPwyXkUbjMqJNr/F44rWD+Dr5fgSmxSImbBWSyl181WfohX7PrcObb/ihYt27mL3/F32CMyew781CPLzoTzAVfoplKXlu3p2qQOn+BLyzfwhCxz2AwLbax2foNAxj3v4YH5q0u1QNpnw7Vk1/C4fbN2WvxgqUZ01FWN947Hh9LdJeC0Wo3xX6tNbw/dPbmPvBAkz7z7O498WPcPgy+DbWYp6N8OAYLOz2Ib5ZPR3R/X3lEatrG4iQFz7D33b0gw/7ZBLVoQM6tq06e4iaHbV9n70A8wNykDVrI5IavLcGkedqsqtXS8s7EPrCEAQWrsbsxKNOLvLN+CZuDzovnwk/PcXRaRTsn2LrqhP0EsIPFDjmo3RvsnbrCorB9u/P6BPcJS+iQ5apgQvS3kT4RmfltOcN7z+0kv8WIPfET7XOa8l5G8/4zsRTz7+O2cE5OLxyF9LdqrfO4L///l55ugjp3/7gmL/hZgx+tQNaKn/rXeGqbndXdQu078qhdf2zWDJxIFbZR0q3t83IzIvH8LezYJEBzsqxQzH2g9OoeDNY3Ye2rnWu9r39s09ZKMlaiHnD2qjrU/JPK1OCFmuachs+Dhvzf1OXdMryT6TMS8C6iocR+te+8NGT7Rk6jcbTI65FxaoojNx8AhaHMhxCfsoDCGpxI/omndDL6Fh+r1FvY3FWiTqlitwvGUuC5HLWffgUhm7L1bsLyG3IXIYP5LHlNWgV/nVyI1a96Ove9lyw40h7ZyFWFYZi3PT70cfpGSyP23tmYnJOgV33hkLkfjbc1tVPfmYTt+c4TD/vz03vNjel40OYmPOD3XoGI+iDHBQ7rPtG9IpNt+sCqqijbHo3xVFej2Ji1nHb5yI/k+H7Cms9z4jqpT7Hmawfvlpv6zpbsw5xPF/Uc+HdFLuuzE15vrlRtk8j5fR2av1prqorneVFjeKqjlAvLQqPIbPQvn2p1hYrn9Gsz22fpf2xkvUddk2T7ZTv84g263k4tHPKsbcGSdZpRJ5Av6NzweqVVXGceMFvudh9LltsHtXaaZcCazepYr1rm2N3tXKRv2OI8B+XqHXZqjwi9s9RupbZdx87KDaP8BY+05LFESXrsm1i5fPXif5udVdzpHVzg908Trqrqazd66qn28sTB2cE6tNry6d2yn4Zo3f185m82q7rVjWVh0TqVGdd2OT6Z3UXfRK/F5Vy/TnxfWy3wJVlJvvZ9o++b9zf9+WiJCVY6+Knlm+JeD09X65HLpN8vwhUbre/9o4IW5uprk/dFqPRZbeqmvvemXO29YYsE/s+tyvDEwtE3H+OqtvlE3tArrdS7yr4gAg9cEouay2bMr98qfvrjDB/2E8YAxaIxDJlpXki4w0/2+dU1d1SvgLHi9CFX6rHmDvbUxu3zx/ruuvVNVErv61LX4HIlp+7SX4eynFwzn7/1fNzq7TrUgqEiMDFW7Rjsur4GyUenrtIvK529yxX96vDeVpH2RzzDxR9YtaIDWYlf3l+K3WHy+OCPInb54jK3e5qEfr0+hxnyjF7na1tsbYhgW/r9YXWHTnAOEaEZSrHvdbddpTSjo3ZLA5Vypq3yc63epbtiVli0pda2WrmRe6o13Fb2/WItd6vlq4dG/fqbZn22Vq7KteoO2fvFN+fXCSm+QRq88tjZufYW0TgxmztODO/LxY8wTqVLq761eMXrsHWVq+CyxNWDXJkhWp/UtouDO0CAf3kdrjQdmicdA7z/apdpAZXqxDcfibHUdWFdlWDWTM4qcxLFInqMzx19Jut2nbtrTVv9585khWZ/jyGVnkpjeQKEXfE/pkhnVzXdGM3/UJW57D+YyI13FRt+lIxbEGm9l7fN/Xb99Ztqrafq82jqnPf2wcvrive6p+R0zKo9IrfIT8tzVY27fO1vbeW41YRmFykpjgtuxvHUm3cO3/c3x/2tH1R/eJE3w92F4Hn/7k5C9ad7DOp+jrcK5uz/Ov/BQFd2urXONY8vmuoUZe5c5xZg4QZdsvJ4CR9tHiylZ4m810Z1Kpa3VPzfGiK8+1Cyua0vFSneh23NT5reWztjRJzleDDZA1MbZTPJNj+WKxx/NReTyrL+r2QajvOnBwHRA2tfvX4hWvKhy0kA9r0m4wXRjk+m2Mxr8SElOcwvtvv1PfVWY5uwSbzfExs31K/RStf7SdifiFQceh7nKxIR/LyfwK3XIfuF3ULkxDf80p1/S07h2NicQQW5X2DzAk3Ou1WpXQXy92QgG8THkagXi5Djyl4aao3KtanYqtbfW2NaNMzGvP3/AsH4wMRiEIULRyLib0DanYlaDcCz75XicPxW7BVfZ6oAqVffYKtrw1AgLp+H3TueRUOD30QfWf9DfGZJXKZ8dgwxd/2jEc1de37XHc2oUn5wO8G+el8ewxZ1UbBs5XfG93GH8O5+XfDpHZhGY4Xntol9/SlqBTH9iQjxdQVvUzWZ5kU1+K2wf1gKkxB0leunh+7eAzNuGxEzp1Bwb8OIv3uG+CvPxOpdg+9632s/zUWYe0Mah2ZuLs3ul/7R7t61Ajv2x/BSNM3SE893GR1SXMuG9lJeQZBLZX2tQ063bUfO/6ciiPmBMT5t9Nn0Bh6xCH1nHLc/aB1MZwQobbFddPqXvO79qPFeqFdiNLOue5uT3QpaeIgRzLcjEEj7pQXNNqzORblWZxlKegSHwLnzxtUoDwvF18YZyCuuFIJCR1fyWNwx+lc5GZdhFP0xq52DZsiFGHZ/5PrLUB2vA9OvfsVMvUpTpVvwycbDiNtsI9eqSivrgheUArUawACSR3oYDd2l+5G8mIl2DmCrJefw/DN1udOFN7o+sAIjEl/H/H75MWiZQ8+fOYaPHPf9XoDJy/mx36M/XMsOBU1QgZKPfX+4LVFKnXve2vw1jBkQNe5O27U37nDOGIQHpYXGrWT++TBSYjoGIe4jZnqcx+W/G3Yue8sfIJ6oZd1Ub2v8oDfr0JCy8mYsSoYJn1S06n//oDcQvN3tidvbKx5NWWD5l7Zmn3cTJeR2o5ZK62O/FZ/56Btd3T3Nzbhl0HNuWzkICQBuytlm1q2DSue2Iv0rwvgfFgh7ZmcaTf1wGP/vAV3vRKFCLcaKu04Nk7fhYLq7bi8nikY20O/RiC6tDXoJen5McI7OBKzg4tQuOFz7M1chgnbX8TMfu316dVpF0B3V3yLtBwZHFx0ZvxjyydIQW/0eTZYvwNSnQk9xq/Eh8PXImZkXC2jsFWgdN8aLB71Lc5Vr1SK42TFdMSNAQgqav4Wjjqa1m7syovCGCd5GPyexXMxp5C24BNk5WzBrIcfx/iq0ckkGSzdGZkJc14iEmM6wLjwMdxT6yhljb3vZfG6jcb4Ua2BlB1IOvqrnlqdfkcAtyJgUJ86gxFDp2cQHhuKxw6Hoq8MNFv6bcOBkWnYHXGHfgfOjK/n3ovbE4dg0qnVSBzRD53UER2anqHbI3g8WDY/LveHPf3OVY0HVq18q32r25jcK1szqKTokqMfW3Wo6Fj9i6u66PnWev7V/eWBse/F7mFQm+ZcNnKqzf0Y8+Y0jFr7OAbN/0r9Us5GBq1fjcWT/Y/i5LITyHwtFAGdZVvpFu04rsg4hHRXo8YSXeKaR3VmGIjHXhoIU1ocHg3KcnEXR6Nd6CUj6eFwuxGvFGYcCN+AtLaPYvDw+nQBq81pFKSMx/RXzDCOnIa37+1c+8WgoR8eiVuB+RURGB62Druq3w1R76L0ReTQbjXzaDcCz0R1kQ3nFsRnFOuJtbhyP5Yn17zjY/AdgLv8jU4aKT/c8sgQhKTMQWDgN+j6YF+7IOA4doRvUQMag18oQl87hJyUYGBtBtJruZtT575v6PrScDNCwoYgEElY/uZ258FX+TZ8vP4EjGNexqJBf9QTa6M1DLclD8OE+Bz9W6xk7H7uTttdnJJPkPSe/Mz79UVAm2bW4stzZegboa73h8KSifS5SvdFb3QdOBghSMfWL7+3O270u3IBwxHW//d6WuOyKHfVmmnZ6FJ3Fa6+/joXXR7lMZaRgNcHXF/Pi3o9X6Wr8nOzEJ1tN6Ja+XbE7/lZryOLULhpn+OXVmW5yNkzCA8/ekuT3RVuzmUj5wx+M7EoPRS9Ip9F4NJv7drcEziYtA1ppj4I7OGtp7lLr3vTpsjrlXccRwYsT0L4ef3oOlHz00yu4Kx3c07g1F+edHEXR2e4E4PH3SwbsLVIerAHOlZ1/boP4wPuQoDh/yHwxckYg1iEv7BEG3rTchhpm9NRjkIUjuuJK6uGQ3ZGNoDqEMG347bB25E+8j2sjR2G4Lq+8WsTiueWhWF46mjcO3GB+svzWkVRiJxlU/DCsMG1dKWyXuxtQ9KMRYh3MQRxC8NpFD4+DvdUG/IzNzEW7+8ZhXGjb63RSGnP/RSh6OZxiKoWBHi1eB7D5lmf5SlCwbEitBxxGwKUbTVch+tuukrvwvAL9sYfQKEhoI59X4EzJaegbEHFzyU4pWQrWcp+xE/KHz8Xo8habNmwqt0KfytB0Rn7FteeEW3uWIG/pY/GMOXbrGn2Q1zqw2feNwov/99K7Hjnr3pwrF0kO+2WoTcMhYvs+yLrL32oWIu164b+LZclPwmbtmXpx4u2H0qsZbd35kf8fFb+63J7LpS+P5LvR8CqR3Hr6Oq/hC33yb5oTHxiP85O7K8GboYekXjjjZbyuA/HvTvz1WPSkh+P158sx8DXHsfDaiB3IZ9bKUrVDT+DohLrt9tnUXZKudt3Fr+UnNbPA9vnYl2He2Vz1kXI2TqJrJQ2JRbvjcpBWuybjkOSq8M/D8eIh/8PM6cPsKsv3TnOrPm2hswYMf7tbfXHX3Lhc2sHeVDrX0SkzMTQl1K0ulW2P7tiYrFatktRavvWNOebu2WrWX86Ly81BqXOX4Al8Qacem44Amcl6W2g9U64vLZRelYoXaw3JOGg2lBVouLLBCTJY6G27pXWXhIV66YivJfdcdxtDzpUdWknusSJBuJeVvqIN3Je68thBKvPR4th6lCIiprzKiOJ2UZ2Ka/6tXt1mmmUCP0sx25UM8dRyIwj3xN/l/kHG0eK0NUpYndpvpP87V+9hX/MGhG1NcshT230kWrzOox0ZR0GtNo8Va/qo5xYRz+xn6e2EWzOieKtsWJp8f9E/pexYrn6K8ja/LWOsKYqETlLuzvJ85j4NCpF5FXtJyWfTdrQ0Cq74UXl/lOHVFXVtu9P19yWkOV2Qzpb0xJEZqYyUo9dmqtRkHTqCHbqr/nbllN+8X/mR/afUc396TBSkd022c9T9VI/y0q7eUJEYPx+Yf5FGanOqO6fI/vH1Sj72u8XqaPa2KfVtT32lGXqR27HkaViY537Q1d5RByMt82rzBe1N18/Hpwcg+5+bjVeyrH7hUhxOLeUtG9EVm2fi6uyWUcbqlpOGfnnSLVzl6MBXQ6Uz7relCHu1423G41SedkNvWxV3+OsdLfYoY6mqaQ7q3+d1JHrDmhDTjf1+VbPshmnp4iT1do9xzqVXFH2V93qut6RrMOE69OVz6C4bJtYoYy8ph6Dyk9KnNDyCYwUUd9+4eSYrlZP1qh7F4hF1UZwI2pIynHWmFoo/5MrvWDKNwANlBU1uOPYOWg89q7ejmj753EuSxUoP7IQb51+FtF3dNDTdJbDSLl/M459GKWOktSYeP4QucZzhC5FPG6JbBr7fGjcKzlqAspzRZPwVO9IxwEHLlMW82yMvq89AvtVC3AUht+j9ZD76hidjYiIiIiaO17NeaQKlH81HEEyYlbH2R/9fxg3zb7v+eWqAmfyj+Jn8ybExNk/0yRZMrF3djIKhvDBWyIiIqJLHYMcj2TEVZ264Xrlaj0wElG73mA3NZX+0P6XQRh+fDSCvPUfNPV9CkPXFeBc+NMI5X4iIiIiuuTxmRyiZoDnD5FrPEfoUsTjlsimsc8H3skhIiIiIiKPwiCHiIiIiIg8CoMcIiIiIiLyKAxyiIiIiIjIozDIISIiIiIij3JpBDmWTBxYPwFTOj6EiTm/6olEREREREQ1NW2QU5aG7asmIGKAlzqsnPLyGvUmovcVwFKyHtGfFcmZSnF0xUP408hlWFjUSluOiIiIiIioFk0U5FSgPDsaEfffg4fSuuCqeSdwTgh17Oxzcf3Q/5snEdw+AssLf5ZzeqPb+H8gd2kXfVkiIiIiIqLaNUmQYzHPRnhwDBZ2+xDfrJ6O6P6+MOrT0DYQIS98hr/t6AefCj0NV+Hq66+D8gP+RERERERErjRBkHMcae8sxKrCUIybfj/6OC1Ba/jeMxOTcwqgdFirjSV/I1a96GvX1e1tLM4q0adKyrM8sb3g28IXHadsRmZePIa/nQUtdjqNgr1P4ylfuWzQy4jOPoodw1cizaJOJCIiIiKiS1TjBzklyUjeUAqYuqKX6Qo90QlDP4xedHftd28sGfhoxgTMuHorflS6upVtwJz/vITwyZv1QKUUucuG45kOH+CQKMCPb92A/y6MRVpbbZMtORG4Y94AjMqthNj9CsblTcaob9VJRERERER0CWvkIKcCpQe3YF2h/PPGrvDXA47zU4pfcozodUsX+Chv29yOW++4Cvj2GLLKlCinCObcIhj/4I0OynRDHwRHzUSgOq0C5Xm5KPpDO/i0VsrQGr4hi7H2RmVGIiIiIiK6lDX+nZyGYgjGsxk/Y3dIe5RnLsMHs4ZgxIJSfaLCB517XoXDQx9E31l/Q3xmCdBuPDZM8YdR/temc3cMXP0Ybh39Jl79OFuGRF1w74ZnEXjp7hEiIiIiIpIa+ZJeCy4a6oaJ9kzONegwrxQ5g9ZgzVRvfYrCG93Gfoz9cyw4FTUCE3v3VJ/LSVPv5MgN7zEf76ePxvDUCMz+qz86qs/l2D3PQ0REREREl6RGv29h6PYIHg82Aik7kHT0An7Ys3wj3gp9Wn0mp2CtMkJbB7TUJ1Ux9MKdkZkw5yUiMaYDjAsfwz0vfoTDapzTGr53vY815iM4sC4Uo3JjERP8CqLNv6mLEhERERHRpanxO2cZBmLoG6EIRBKWv7ldDzicsGQifW46Mp1Or0Dp/gS8s7+37ZmcGo5jR/gWNX+DXyhCXzuEnJRgYG0G0svOoXRbJGYrAY0MhO4YkYg12XGYXvR37Mmy7/JGRERERESXmiZ4AsWINneswN+S70fAqkftnomxOo2CfdGY+MR+nJ3YH73UEv4XRzNyUYhspH/7gwxxrN3eCpD5j+Ny2bMo2B+HHV+dUXNA6UHE7zkDrxbPY9g8a6BUhIJjRWg54jYEtG0JXJGB2TNWYGO+cuemAuX5uShoeRcG+tt3eSMiIiIioktNEwQ5CmU0s4/x6ZGlWNdvO9KVZ2KqfusmHkuKHkd04rMIVkdfO44vpvVCv1fM8u8jODz0T7hmRQ7QYyYWxfvAGHknOga9hnktpuDl1wbCVPgNkva2x4iBV+F/7dcg+a+pWDPQS+Z9K/783WvYsfhh9DFYIE4PwqLY/vB68zo5zQttJ7ZG13/ORbSfi2GtiYiIiIio2WshJP3vC6IEKA2UFdFlh+cPkWs8R+hSxOOWyKaxz4cmupNDRERERER0cTDIISIiIiIij8Igh4iIiIiIPAqDHCIiIiIi8igMcoiIiIiIyKM06OhqREREREREzjTm6GocQpqoGeD5Q+QazxG6FPG4JbJp7POB3dWIiIiIiMijMMghIiIiIiKPwiCHiIiIiIg8CoMcIiIiIiLyKAxyiIiIiIjIozDIISIiUpRvxLyb2qFv0glU6EkNw4yv53SG1zNbcNiiJ10SKlCeuQwfvBuEjjeuRFqjlv0irbssDdtXTcCUjg9hYs6veiIReaJGDXIsORMxuEULdQi5Fr7PYGJWiT7FjmUXVg3y0uZRX77wXZHTwA3O5agCJR/NxbKSS6qFJSKqhwqU7hwE36r2w8kr6CVMTEhCkvk3fRmqVclyvH7PBAyblIYi30b+TvSirPs4voh5CA88swwLi1rpaUTkqRq11jL0iEOyKEDOp8MwCqsQP/EdxOdXa2gMwRiTeg6V2WHweyEVBXL+grE9YNQn03my/BPJr59Cpf6WiMjzGOF9j9JulCB3aRf5PhRh2f9Tf5dBfZXuxo7R/0H5q0MxtPNfEPRBDoq0BTVthuGlf5XgUOi1Ddzm+OG2l/NwLuER9LmU+k+0C8M8cyoSgpugBb4o6+6Cu9/K048NIvJ0TVDdmtD9/mcw0F9WXGnRmDgitmagQw2sEDnLnsWThy+l1pWIqIG1DcTgpxLxfsYizAj4AmnDpmHiV8X6RCIi8iRNdtVbmTsWi9YNRqAMdMIjN2JXmRvdqCyZyFgShCC124EvOk5ZY+tyYN/PNus77Jrmixa+TyJ8osmuq4Kt65t91zmviC9kGKCoQHnWQswb1kaffzCC3k1Bmlq2Uhxd1lVPvw1BKT9VS3PsVmfJX4231XxkHh9kIn/7BIS76P/rfP5iu/zt1+tY/haDVyHN8hsK9j6Np3zl+6CXEZ19FDuGK/2Yi5Gz5F7cHXYYFRVzMbF9S7lfXka83m3Nkr8Rq16U+0rNS657yQFkqpOq9YcuTkPyrF5aNxA1/xJ1n1el+T6F4fsKq7afiKi5MnQKwytvhSIQ25D02hb9eY/TKEifixWTOtvV5cfxxbR2ev1Y/TVUe6ajJB4vKfWus3nUulnWs+YkJDk8W1KI7E8jZVvTTq7rEMz7pyBigNJN+0b0ik3X62ArWa6q6TLPoJcQfqDAVtfKdvFArFIPK23iZmTmxWP421n6dLms03ZBnVhvV5btwia9vfAaFYeNDl9Q1l1OW/stX7LNGLot1/FOmtwvuZ8N18or26NBKb/W7H3gTj5ynq/WD9XzUcr6NhY76x6PEuR+MEjLy0kbVnv7SESXBNFA6pVVZapY7hch4op/EdnxfYRJLmscs1kcqtSnS5XZYcLvhVRRoL8XlYfEzrG3iMCN2eJH5a35fbHgidYCIQlid+V/xa6p3moZgEDRZ/ZO8f3JRWKaT6AIPfBfkZ98vwiESZiWZ4tzWm6qyuxJok/MfjU/IaeUHRgmAoxjRFhmsfY+c5IYZbIvW7kwf9hPlvdWEZhcpCTYpdnlr27fcD0fpaxKWYaIsOz/qe9rcDl/uV5++3UqtPKaQpPUsqn76y8JIrVUKai2jE/vFXLfKPOWiNylXQRMkXKf23aysp6J/pNFVJayXrlM+mgx0mhUt6OyOE5EyG1X92lghAhbu18cUdYjl5kRYBTGka+L8TMSxW5lfZUHxeZR1s9Cy5vqpwFPRSKPVL9zRK/zEOqy3k0INurzlIuSlGC1LYJDW3FMfD6pWtuUFyXGyHrSJ/aA1nYUvy8mvf8ffX6FtU14QLY/p+R0u7pUrSMrHdbl88QsMenLfFFZtZx9mWW9vGOI8B9nrWuPiP1z/O3mKRE5sg31X3JYK4tsJ1Mn+1WV33W74CbrfgocL0IXfqm1A/o+sO2nusqpbZsxYIFILFNWnicy3vCr9vlY54kSceaz8n2BvD4IFMG3y3VXtS3u5KOkXSd8piWrZbWV/219GeuxIa8VYtaIDcq6nLRhrtpH22ddN9btRDaNfT402NrqVXD1ol4JcpTaRKnIlEBHVvbWSkmZpVqQUyPokdWM1lBYL/5dNGp6JWecvstx+W3jxSTrvHKelUGtqlVg1ddR/b1GKVuIfcMoG7XprSaIqDylolZUW1d1dc5/TA3iHAPBY2Ln6Fv0bdXK1Wr0Jofpnw9zFeQojaMMGh0CJ209VfNZGweH4KXaPCo3LijIJTaERK7V7xypT5Bjq89r1OXVlW0Q8wPsL5ir0758Ur5UqwqCFE7qUmfrqpEml7O1lTo9aFLas59lfZwabhJ9Er+3lbd4qRi2IFO+r6tdcJOzdqB6Wh3lLBBn1M/D1gbXbEu1wOkRx8+rxrq1z7X2fKxfVs6wK4sWoDzZyprm7NionuZG++gm1u1ENo19PjSDhzRM6DF+HdZNBYremoqhy7+tdvtaUYpje5Jhftd+1BwvtAvZhUIUIPfET3B5B9kwEI+9NBBYuBNbraOLWf6JLclDMaPH77S3R7cgcXdvdL/2j3YPnBrhffsjGGn6Bumph+W63NxdbbujR8BKxNw+FkPX7ERamQHe9y/FIn1dNdQ5fxcEPjsCd69ahdkZev/xkmR8kjoBod2UeYxo07k7Bq5+DLeOfhOvfpwt92EX3LvhWQTWVmRLBvZuPoy0wT76/lReXRG8oBQoPIbMQj4nRURkY8bXiyMQcXw8otZNRGgbJ5VreRKWTEtC+pj3kBpxB3z05POltEubzPO1bsbWerr9RMwvBCoOfY/Dlk7o3PMqHB76IPrO+hviM0uAduOxYYq/bBXOo104T3WVM9dyJbqNP4Zz8++GSenmvGY4XnhKab+tZBu/bT1W+XRHL9MVepoz3nXkcwYF/zqI9LtvgH9b60a2hu9d72P9r7EIa+fmhrN9JPIIDVzVnSdDHwTP/xibR/0HWc8NR+DSb1GmT9IUwfxdEYzTd6FABoIyOLN7aaOvud4QLViZjLcwO/Go2ufWkrsFKffdKEMsRQXK83Lxrfp3NTIA6e5v1CtqPa0uhmCMXrMCCwZuRtLoEAR531dzFB97bsxv6DYa40elYevmf8gK/X/I3bAMe94OQYC+4YYe8/F++mgMT43A7L/6o6P1uZnalOUiZ09PBCYXVdufyisRcbUFZEREHuV6+F/TRv+7NqdRkDIe019pjz6LpmOmn5MLccth7IqeqgZBr8Q8iAsfRU1rl74wzkBccWXNejp5jAxWfoduYz/G/jkWnIoagYm9e6rP5WjPkZ5Hu3BeLG6UU5lNe5ZmwO9XIaHlZMxYFay3vwqtjXdLQ+XjCttHIo/QPIIchaEfHolLxIonlEBnGsasP4zKqtL5wO8GH1RkHEJ6+Xk+9dduCIbGXI3CTfuQbvkVRzefQsCf/qBP1L7xulG/K2T/4KGVse916F6PvWXoNBpTNv6A/L1RmPvEXqQNC8UgFz8wV+f8hpsREjYEAW8uxeysI/j7nHsxPqSzLLmV9m3VGvMRHFgXilG5sYgJfgXRtf0WhBK8DTiKzH8crz34IiLySDKAyEjAul0VMI55AuPVO+K1s5jfxKsPpCAzdiVSnQ4vfRr5m57FyAW3IHTrbEQ7C4LqTWuX7q74Fmk5pXqaE4ZeuDMyE+a8RCTGdIBx4WO458WP9B8drWe7cF4MbpTTjK/n3ovbE4dg0qnVSBzRD51a6pPqpa58tGsFpOxA0tEL+KFPto9EHqH5BDmKNvdjzFtz1KE9t7yRjqIrWugTvNF14GCEpE3B8LB3HEdJKU9C+Ioc193VVH645ZEhCEnZgvidO/Fu4WiE2t26NnR7BI8HF+lBkJ6oUL/RGYSHH70FJjfWoipZjfDV38tmVDYw/aPx0sZD2DX1JLIyaqkw3ZpfNnj9nsHI4K1YPn4KXgkNwcNV5a9A6bZIzFYaLtng3TEiEWuy4zC96O/Yk1VLoyODygGP+6Eo8lkEzvq86ps/tfHf9yqis/lL0ETkmSz58XhjWhLSTGMwbmqw67su5duxavpbWBUwH3HP93PSBU3WmVkvI/LJf6Ii9lXE3dFeT79wWruUjKSHw6uNIGbGgfANSLP8gB3hW9SAxuAXitDXDiEnJRhYm4H0snP1bxfOU13lzDz1CZLeM8PYry8CnHXzw7W4bXA/mApTkPTVL3qaEyV15XMVrr7+OtlWJyH+uVmOd63k5xi/52f9TR3YPhJ5BFdVe5MwdJqENza+gjG2+88qrbtWa1Ssm4rwXu31PrLy1W0POtx3vdyQum9TV1XE964DXrjJsbEyDMTQN0IRmDITQ19K0YaJVLofxMRi9YuTEdVPabi0bm8jjIeQufMf6jzK0KCbd2bhNxSicFxPXBnxBUpwBq0mzMQo63CU5bn4939awb9fl1r6aLs5v/5skU+6CaHj7rK7RS9dkYHZM1boQ3rKijg/FwUt78JAf2/5Xq/41b7E/0P5lwlIKmmDrg+MkPv5CLKi7keQt7UvtRc6JNyMR7r/ThbrR/x8Vi7+WwmKzuiVvOUXFBcpg3qW4scy630m674/g6ISVv5E1Eypz3EMxdP9wjH3+HAM2zQbi/zb6RMrcKbklFqXF31XoF+oK8/hjMfYPY8jLG6Mw3M4FvNChO+QcynP4YyPx8ZhK7Fxon0QdBrmFZFYpjwHaq1Lvz2GLPWCWdbRNbpIW9cv//q5BKeUJMOdGDzuZll3r0XSgz3Qser5kPswPuAu/NlQDq8Wz2PYPOuw00UoOFaEliNuQ0Dblq7bBUsGtjzVBi2CYlz/Vl1ZLnKzZF1v3w5UbxvqKGfPdnq3b703hiU/CZu2ZenP0vyCvfFfwxIci/dG5SBt9FR1KGeL0kUwdbUMMOQsKc8gyO9lxFv+5GY+rYG0WMT4210r/CUXPrd2kPM5a69KUapukDXNu+720d39R0RNRzQQ97KyjmCiD6epvBxG7rLShm/u89xOu9HQpMoj4mB8oAjUlzWOXCAWKcMuW0dgqcrXcfQzG334yWBn61SUi/x9k8V0ZfQcJR/TKBG67kDViG+aApGzMVgrgzL9sxxRnB0mevtMFmErd2jDZxavE1Gf5trmQ0jV0NdO1WN+ZfQdk2l5tfKfE8VbY8XSk/8QSeEmreyBkfrQl7qybWKFMuS2LPOwvQVyCU2leYNIsC6D3sI/Zru6DdooP0qa9RUqwtI32IZCtaZlHnRz35Mryr4jotq5d45YR9uyr6ccX8aR88XMtz7T6uoqTpaTbdORI9XrQfuXUtfl1WzT7F+mSLH2+0XV6s1A8cgjPnbvlRHIUsTJauu3jSDmpF2S7Y7WPhwTn0aliLysKH26SfhM3qRvWx3tgnXYZId1OarRDjjbnqrRxlyV0/aTDGr7Fr9fmH+JE9OVobiryiuVptrKqrRVX34qlvb3lu3SehF3RCm3u/nsFjtilCGslfmUfbJCW97ptcIRu5+gsKbpI77V0j5qE+vefwplOhFpGvt8aKH8T670ginfcjRQVlSrCpQkP4q7Sxbjq6HO+oXTpYrnD5FrPEcuEksaZs/5f5gxsyfblPNRx/7jcUtk09jnQ7Prrka1U/qRv/50Tzwz2H7AASIiovNxGgXb0/D7p7qwTTkv3H9EzRmDnOaufCPeHOClRr8t/VZg56LnMM7dsf6JiIicsWRi7+yF+Oj/JiOsc0OMBneZ4f4javbYXa25Ux5ufDoIj669C4EbFyHxiR61DF5AlzKeP0Su8RyhSxGPWyKbxj4fGOQQNQM8f4hc4zlClyIet0Q2jX0+sN8TERERERF5FAY5RERERETkURjkEBERERGRR2GQQ0REREREHoVBDhEREREReZTmEeSUpWH7qgmY0vEhTMz5VU804+s5neH1zBYctuhJjc1puYiIiBpZo7VHF9j2WjKwaagvglJ+0hOIiJpGMwhyjuOLmIfwwDPLsLColZ7WHDTXchERkeerQMlHc7GsRIk0LqH2qCwDB7cWIffET3ILiIiaTjMIcrrg7rfykLu0i/7eyg+3vZyHcwmPoE+TlLK2chEREV1kln8i+fVTqFTfNGZ7dD5tbymOLuuKFkExiC//C0JG9MHDAzrg2JK+8PKKRLwaqBERNa7m0V2NiIiIdIXIWfYsnjx8qTTR3uj6QCwWDxTweu8N/D2vAwo/Xo8lxucRlfYCxrXjpQYRNb4mqnkqUJ61EPOGtUGLFr7oOP0L5FX7osdiTkLSu0HoeONKpNlNs+SvxtvqcoMR9EEm8rdPQLh9/+SyNCTP6gXfFi20vKesRHxmiT5RrjdzGT7Q8z2StxiRA7zs+h7XXS6FJX8jVr3oq/5yq1qOJQeQaV3eRf51lp2IiC6MJRP7EyIQ+1fluZBjyP1gEIKsdfUHOSjSZ1M41uUt4DXqbSzOsrYXhcj+KBorJnWG74pDyE95QOZzI/omnYAFp1GwfwoiZP2uLXsjes36HGll9g1GtXmCXkL4gQJbFy5ZzgOxSlultFObkZkXj+FvZ8m8ZYCz5F7cHXYYFRVzMbF9S7TwfRnxJUZ9QUWJbbt8n8LwfYW2fBUy74wlQfp2K/mvQZL5N32i67bIedtb9/Ya2vngmraVMJe2RAc9jYioSYkGUp+sKvOixBhjsAhOMYtz8r+yI9PF1P7eMo9QEZb9PyGK40SECWqeCEkQuyutC6aK5X7DRVhmsfbWvEhM8xmiLaMo2yDm9vUW/ksOix/V99vEiidaC5gmiqi8s475Bo4Xwz7/TpiT7xc+PvNFYlll3eWSlHVO9J8sorKUMpSL/PTRYqTRKEzLs0Wlq/yLv3JddrqsNeCpSOSR3DtHSkTu0i5aHYzewj8mUSQqdb8oENnxfYRJpvVJ/F7W7lLlQbF5hLfwiT2gtxcbxPwAo97mVIqSlGA5v5KPSfg8sUDE/eeoSJ3sp85frLYV94rQA6fkgrKtODBMBMr5lHZAzVtpG3YMEf7jEsXuUtmAVR4R++f4y/ysbUmJyJHlqWqrKg+peduW17fDFCniiq0NoHXbAkWfmDVig1lul7INo2Qb59BOHhI7x94iAjdmq3lXmt8XC5R20DqPq3a0lrZXaxtdba9WNuPI92S5Toido2+R+f1X5GwMFgHGGXbbcPlh3U5k09jnQ4Otze2C6w2LrXJUWCtvWzChVMQJwdYGR0tSKuDprSZoAYvqnCjZNl5M0hsNNQ/7+RV6pW2cvks2c5KzfBVulUtpmGTjkVykTVYdE7umykDI2hjVlr/LstPljg0hkWvunyOyblUDlFsd6+rqAYGsq1fc9nu7earV5VJldpgIcbiY1yjpwfYX707ameV+EY4X93bz/CzXlRpusgVciuKlYtiCTP293vY4DXLs2kknaUrZ/F5I1cqhqrY/6mqLnLRhdW6vPSV//Ys/+312uWLdTmTT2OdDo3dXsxxdjWXrb0D3a/8I+5vvbmnbHT0CViLm9rEYumYn0soM8L5/KRb1+J3MOAPpSSdg7HsduttvVbvBGDzcGxXrU7HVxcOPbpVLrmPv5sNIG+yj37JXXl0RvKAUKDyGzEJbd4AaXJWdiIguLkN39O5/NZCyA0lHf5Xvg/Fsxs/YHdJe62Y8awhGKHW5Gww94pB6LhZh7X5A9qeRmDchAvML9YmS5egWbDLP17qaWduK9hPVeSoOfY/Dlk7o3PMqHB76IPrO+pvWpbrdeGyY4l//dtFBKY7tSYb53UF6l23l5YV2IbtQiAJ1xDPLebRFdW2vg7b90O/uLgjoc/UFbgsR0YVp5CCnAuV5ufhWf1dvslEavWYFFgzcjKTRIQjyvs/Wx7osF7lZzgas9IHfDT51BCFulkuuI2dPTwQmFymhaLVXIuJcBSyuyk5ERI1OeybnGnSYV4qcQWuwZqq3PqUu2jMq027qgcf+eQvueiUKESZ9Eixqe/KFcQbiiitrthXJYxBo+B26jf0Y++dYcCpqBCb27qk+l+P4TM/5KIL5uyIYp+9CQfX1igIUjO0Bw3m1Ra62txpDP4Qm5yDxjvZ6AhFR07jkhjwxdBqNKRt/QP7eKMx9Yi/ShoVikPIgaNvu6O5vVL8ly3XWTpi6opfpCv3NeVLWMeAoMv9x/LyCk9rKzt8SICJqJNa2oHwj3gp9GjOu3oqCtdMR3b8DWuqzuFaB8q/G4sn+R3Fy2QlkvhaKgM6t9WkKA9p07o67K75FWo6LO0OGXrgzMhPmvEQkxnSAceFjuOfFjy7wx6+1L/UqMg4hvbz2jOrXFtW1vUREzVMjBzlGeN/+CEaavkF66mHUdre7ViWrEb76e1nltoZv/2i8tPEQdk09iayM4/jB0B8BodfauiJUKUJe7in4THoIobUOY+lmuQz9MOBxPxRFPotAh5FlZCOw71VEZ7sYKc1F2Xk3h4joYtPvcowYhIfbAaX7E/DO/t7odUsXGRrUxwkcTNqGNFMfBPZwfufH0O0RPB6cjKSHwzF0W65dHW/GgfANSLP8gB3h2qibBr9QhL52CDkpwcDaDKRf0N0cb3QdOBghaVMwPOwdu5HipPIkhK/IgaXebVHd20tE1Bw1/p2cdk9h0jv94PNmOAbFpqtDLytdBj7ZdUpOTEJ8zwAEpfwEnPkRP5+VSd8eQ1ZVpX8GrSbMxCjrcJnlufj3f1rBv5/SSF2Jbk++jvkBWxH/3DzE5ytd006jIGUShq0PQ/TIm7WGrLZubW6V6zd0fWAExpiOICvqfgR5W/tbe6FDws14pPvvXHSbc1V2IiJqWN8gff027FLbD60tiFr0JF6ZFACTfrflRhTod+bPomB/HHZ8dUZbtPQg4vf8WEs3ZmsX6MPanRpluOYNSTiofjtWiYovE5BU1h+Dx90MU+FaJD3YAx2rno+5D+MD7sKfDeXwavE8hs3T2holACs4VoSWI25DQFulWb4KV19/nVxe6Wb9P5QreZacVoM0pS0pKrF+oVaKUrWhtKUZuo3G+FGtUbFuKsJ7tdfXK1/d9qDDfdfLLa+jLarR9rqxvfyxTyJqjkQDqV9WBerQkoFyGXWYzzk7RGq8MvzkfDHzoyxRpo/couSpvfSRY4rXiahPc+2WDakaJtOq0rxBJISb9OXshxDVRogJqcpTvhxGrlG4Lpd1PTXXsV0dJtRl/m6UnS5fyvFCRLVz/xyxjSYW8O4SMUMZFlouaxy5QCzSh03WWIeVlvVxYISYtD9PnFKXU+rmb8RBddQyW33uMJKY9ecJlOGlJ6+WbcwJbWS2wEj95wUU5SJ/32QxXV8/TKNE6Gc5ep1/THwalSLysqL06Uo+m7Thpq2qfgJhlBj290/FcmXEs6ryKCOlHdHW6ZCmjxRXeUQcjA/U25pq2+6qLaqt7XVre8kZZT8Skaaxz4cWyv/kSi+Y8k1RA2VFdNnh+UPkmvvnSAVKd96LHiHF6J68A7tD/qinEzU+1u1ENo19PlxyAw8QERERERG5wiCHiIg8yFmUnVJGNTuLX0pOa8+dEBHRZYdBDhEReYjj+GKaL/wez0AhjuDw0D/hmhU5DHSIiC5DfCaHqBng+UPkGs8RuhTxuCWy4TM5REREREREF4BBDhEREREReRQGOURERERE5FEY5BARERERkUdhkENERERERB6FQQ4REREREXkUBjlERERERORRGOQQEREREZFHYZBDREREREQehUEOERERERF5FAY5RERERETkURjkEBERERGRR2GQQ0REREREHoVBDhEREREReRQGOURERERE5FEY5BARERERkUdhkENERERERB6FQQ4REREREXkUBjlERERERORRGOQQEREREZFHYZBDREREREQehUEOERERERF5lBZC0v++IC1atND/IiIiIiIictRAYYdbGjTIacyCE3kSnj9ErvEcoUsRj1sim8Y+H9hdjYiIiIiIPAqDHCIiIiIi8igMcoiIiIiIyKMwyCEiIiIiIo/CIIeIiIiIiDzKZRjkFCL7o2ismNQZvityUKGnonwj5t3UDn2TTtjSGkUFyjOX4YN3g9DxxpVIs+jJTVYeq1r2ExEROSpLw/ZVEzCl40OYmPOrnniJcFp2M76e0xlez2zBYWubVB+WDGwa6ouglJ/0BCKixte0QY5euUYM8FKHlVNeXqPeRPS+AlhK1iP6syJ9xoZSgdKdIxH8cAzGvVuppzWxkuV4/Z4JGDYpDUW+zSXmbIb7iYjIHSXxeMlXa09cv25roIvw4/gi5iE88MwyLCxqpaddKi5S2csycHBrEXJP/MQvyIioyTTRVXUFyrOjEXH/PXgorQuumncC54RQx84+F9cP/b95EsHtI7C88OcGriCN8L4nFebsMIToKVXaDMNL/yrBodBr5VyNqF0Y5plTkRBcba1NVR6Vi/1ERNTMlfm8hQ3ms2qbIsQx7JrqDZgiEVdcqaVVHsH+2edwrEEuwrvg7rfykLu0i/7+UlJb2f1w28t5OJfwCPq4fZVQiqPLuqJFUAziy/+CkBF98PCADji2pC+8vCIRX3I+t4SIiM5fkwQ5FvNshAfHYGG3D/HN6umI7u9ru5BvG4iQFz7D33b0gw+/AiIionqwFOSheN4oDOt0hZ7ihKEX7nw+DAPKeOHdcLzR9YFYLB4o4PXeG/h7XgcUfrweS4zPIyrtBYxr11x6KhDR5aIJap3jSHtnIVYVhmLc9Ptr+ZaoNXzvmYnJOQXQOqydRsH+KXbd2m5Er1mfI83aQNn3Kc76Drum+aKF7/OINv9WNT15Vi/4KssGxWD792e09Coy//S5NZ4/seRvxKoXZV569wavUW9jcVaJPlVnycRX64fiKb17hNN5aihE7mfD9WUGY1DKr3DsFOa8PMq6DsQq2+GLjlM2IzMvHsPfzrL7JtI+X2VbX8LE7Tn6PpQueD8pqn0Wch3hBwr0Mtg/x3MI+SkPIEh+VspzRRZlub1Pa2ULehnR2UexY7jdM0hERA3A0DMWG+710d+50G48NkzxV79gc6eut5iTkGStH6u3QQ5KkPvBIFn3yfl8n8LwfYWy/tPvcuj523eVs+RMxGBr+uBVep0o68t90Zg3rI2WLvMZui23qi53XV7H5zyP5C1GpKyvbc/XyOlZC/W8ZVsy/QvkVdsMdVurPydave53sg8M7XxwTdtKmEtbooOeRkTUZEQDcTur4jgRYYKAKVLEFVfqia5V5kWJMcZ7ReiBU/LdOVF2YJgIhEmYlmeLSnFM7Jrqra4fCBR9Zu8U359cJKb5BGrzVx4Um0d4C59pyeKIsrqybWLl89eJ/vry5+R/JSnBwqQub01TVqovF3tA/Ki8L9sg5gcYBUISxO6qYueJjDeus+VdmSoSguU8gW+LxLLatq1cmD/sJ4wBUSLOfFa+LxDZ8YEi+HZr3pXOyyNKRE58H+G/5LBWnspDInWyn910pSx+wjhytUgtVdat5NtH5tNb9En8vgH2k6Jc5O8YIvzHJYrdyjoqj4j9c/zlOkJFWHa5Q7l9nlgg4v5zVC2jsg+Ls8OE318S9LLJfJLvFz69V9jty8tbA56KRB7p/M8Rve6rrc1xp66XabE+d4jgFLNaF1bK+ixEqeesy8j6OXdpF61ujVkjNih1u5LvqNZ2+Wj1XiBuFYHJRepSGq1NM4UmiUPqfNp7H5+ZehthzfsBx7q6tvJa21ilLg4cL4Z9/p0wK/Wtz3y1XdLa02B9W+S6jkwXU/srbYNSj//PcXm7feCqHba2UUo5jSPfk9t/QuwcfYvM778iZ2OwCDDOcLu99zSs24lsGvt8aLC1uVdwu4DCvgGpg9KgBNtXknolbJy+S17KK6yNgF5JV9EDimDHdVkbKFvl7CRNBiwrbvu9XWNUvaHUKnnHyls2YumjxZOtaq/QtYbiEcdyWoMj+walRhmPidRwkxqwWMssipeKYQsy1ffa/NW3v3qZL3A/yXIu94tw3LZqn4WzfWv93FuN3qQ34opj4vNhDHKs2BASuXb+50hdQU5ddb3+BVJVeyPpX/C0ctkGOUvT8jaO2exQF2oBgT6PElB1sy+PXJ35fTH/IZOWVmd5JSdtikoPkBzrZyflrKVNct0O25HTphuN1dZzeWLdTmTT2OfDJdFJ1tAjDqnnYhHW7gdkfxqJeRMiML9Qn+iK5QCSl/8TuOU6dK/vlhqC8WzGz9gd0l679T9rCEYsKNUnKs6g4F8HkX73DfBva828NXzveh/rf1XK6myFpTi2bT1W+XRHL5OL/uJO+aBzz6tweOiD6Dvrb4jPLLHrbiHz3ZOMFFPXavlei9sG94OpMAVJX/2ipznh5n6yHN2CTeb5mNi+ZVU3iRbtJ6qfRcWh75FbrcuDjRFtOnfHwNWP4dbRb+LVj7NRhC64d8OzCLwkjkAi8lh11fWWXBxKLYLPDb6yFtYpz/REZuLX+XfDpCe5pwsCnx2Bu1etwuyMYi2pJBmfpE5AaLffqW8t5nTsPhoM/2vaqO8Vhk6jMf2jAlnGP7rRNtXOcnQ1lq2/Ad2v/aPtOVg31asdbtsP/e7ugoA+V9d7PUREDaWRLzG1i90b9Xfu0/oCT7upBx775y2465UoRLjTspTlIjfr/Ecv0Po9X4MO80qRM2gN1igj9FQpgvm7+g5xfT7LWHmj29iPsX+OBaeiRmBi757qczlaf+ja8rXu7wJ1KM9aYxC39lMFyvNy8YVxhm2EIvtX8hiXAYuhx3y8nz4aw1MjMPuv/uioPpdT17NLREQXn8u6Xqkfv2y4ofQN3UZj/Kg0bN38DxTif8jdsAx73g5BgFp/avXst+qctXPdNtXGvbxrV4922NAPock5SLyjvZ5ARNT4Gv17dEO3R/C4Mlxyyg4kHXXnR9NkxfzVWDzZ/yhOLjuBzNdCEdC5tT7tIirfiLdCn8aMq7eiYK0yAlwHtNQnaXzgd4NPPbajAejfHprzEpEY0wHGhY/hnhc/wmFLJ60shceQWagPIuDAV/3m7sI+bC1gurviW6TluPetoSPtLtca8xEcWBeKUbmxiAl+xTboARFRU6irrm/bHT0Gyup10z6k1/pNUT0YbkZI2BAEvLkUs7OO4O9z7sX4kM76HQ/rF1Pp2Prl97L1c6LOtuliaKJ2mIjoAjR6kAPDQAx9IxSBSMLyN7fX/mvKlkykz01HpuVHHEzahjRTHwT2cOfbKjvtBmPwcG9UrE/F1nqN0V+B0v0JeGd/b/S6pYuti4KDq3D19dfBJLcj/rlZjnclyrcjfs/P+ht7bnYfc+o4doRro+MY/EIR+toh5KQEA2szkF52BboOHIyQGg2jfvclYDjC+v9eT3PCzf2kBajJSHo43GGkH+XXsQ+Eb3AxUprcn9siMVsJaGSgdseIRKzJjsP0or9jT9b5BExERA3BjbrecB2uu+kqIGUmhk6z3j1XyPr1ywQk1fv3X2Qg0+8ZjAzeiuXjp+CV0BA8bNe92WDqhZtMhSgcF457PrAbHVPWs3vj9yKvzrapNkZ43/4IRpq+QXrqYbjT49vmxPm3w0RETaTxgxylgr9jBf6WfD8CVj1q94yGlTZ05sQn9uPsxP7oZWij36U4rN1BkMFPxoYkHFRr6EpUqI3M6Vq6a3VB4IuTMQaxCH9hCTbmy4tsi8xnczrKZRVfOK4nroz4Qv5lwZmSU/hN/lX0nTJsta2bV+Y/jsv3Z1GwPw47vtKHVC49KIOYEngHx+K9Ua2BtFjE+LfXnlFRXn/Jhc+tzgbQlI2MukwO0kZP1YcWldubulo2nHJyyjMI8nsZ8SXnqpVH49XieQybpwR+yrsiFBwrQssRtyGgrQGGHpF4442WasN47858NdCx5Mfj9SfLMfC1x/FwG+Wjrq1bm5v7yRCAweNulkHaWiQ92AMdrdvb4j6MD7gLAQYX3SGuyMDsGSu0vJWLg/xcFLS8CwP92WAS0UVk+QXFRbV1N3Onrm+v1Y8y8Cha+BiCvK3PJF6D6/f2RqAaoFjr1jMoKrHe2S9F6c9n5b/2aTrDQDz20kD4pJsQOu4ux+d62j2FSe/0k2kpSBvW066enYBFt/ZCpzrL+3PtXZD1vH3eDMegWK0tUbq+fbLrlJyYhPieAdrQ1md+hFr0b48hSw3q9J4LLtth94I9izkaz3h5oeP0FL0tIyK6SEQDqX9WytCVS8XGxYEiUC6rLK+8jCPni5kfZenDcurKtokVT7SW003CZ/JqkZh3QhtNJjBSRH37hTYKTFUeTobnzIoS05UhNtX83xN//3y0CDaOFKGrU8Tu0t/shj7WX+qIMqf0IZjl+8AIMWl/njilzhciAjdm28pXulvsiFGGUVaWVcq3QsQdKdYn1qI0VSSFm7R1mUaJYV9+Kpb29xb+Mevlsr/UUp7/ik+jUkRe1bYo69qkDeVsVXlEHIy37U9lX0btzddGt7GOllOVb333k3U95SJ/3+Sq+ZTyh36WI/fHaX2EHmv+9qPunBPFW2PF0pP/sG238tll1bGfLiPKPiGi2tX/HLGOGmark9RX9RHHZC1Vd10v68fMt8VctR1S8pHTFifrQ+k7q1uPaG2UQ5p9fauNVmYyLa9WFqsCkfPpMDGqaijoCBG2zVoW1+VVhusPqVqvfNUYVU7mvTFYbyd6C/85O0RqvDL0s9b2ltkPIa2+9FHXXLXD9ajL1RFG1fxr7hNPpOxDItI09vnQQvmfXOkFU75paqCsiC47PH+IXPOsc6QCJcmP4u6Sxfhq6LW4HEcgs2QtxJwWz2FmT21UOU/Fup3IprHPhyborkZERHT5UrsSP90Tzwy2DjhwmbEcRvLKHhjS3bMDHCJqWgxyiIiILrbyjXhzgJf6TWZLvxXYueg5jHP6e2qezWJOwruzTuLKmMHowysQIrqI2F2NqBng+UPk2iV/jlgysOXpIDy69i4EblyExCd61HN0NLoUsW4nsmns84FBDlEzwPOHyDWeI3Qp4nFLZNPY5wNvFhMRERERkUdhkENERERERB6FQQ4REREREXkUBjlERERERORRGOQQEREREZFHYZBDRETU3JVvxLyb2qFv0glU6Enuspij8fTvIhFfYtFTiIg8H4McIiIij1WB8ux0JJ89jszC3/Q0IiLPx9/JIWoGeP4QucZzpJ4su5Aw6AFE3voJ/vnyMczr44XRRzrhHxOG4rnOn+Dk/Lth0meli4fHLZFNY58PDHKImgGeP0Su8Rypr9MoSI/H5n/+gjNnTiBjhwl/vPP/4epW/w+9nh2GUL8r9PnoYuJxS2TT2OcDu6sREZHHsZiTkDSrF3xlo9qixY3oNetzpJVZ1DscqwZ5qY2t+vJ9WX9WpRRHl3XV033huyIHFksmMpYEIahq3qcwdFsuitQ1VKA8cxk+kOvwGrQK/zq5Eate9FXn8xoVh4351bqGlaUhuao8vug4ZSXiM0v0iQoZlOx9Gk/5yulBLyM6+yh2DF+JNPUxGiVgmYsVkzqr5ap6JkeW70CskqeS32Zk5sVj+NtZ+vRW8O7gjSuuOIvffmulphARXVZkRNUgGjArossOzx8i1+p1jpRtELE+d4jgFLM4J99WZoeJEJiET+wB8aMyvfKQSJ1qEjBFirjiSiVFlycOzuou+iR+LypFuTB/2E8YAxaIxDJlnjyR8YafLEeoCMv+nxDFcSLCBLVcCBwvQhd+KY7I2SrzosQYo1GYlmer61bJ8szt6y38lxzW1l+2Tax4orVc/0QRlXdWnUUpo99fEkRqqbKucpGffL/w6b1C7K6sFCUpwcKkrEdugy3fEpET38eWp7JNk/1s0ytTxYr+cp1zvhTmX+LEC37LxYHiVJEUbhLG6btEgTIPXXSs24lsGvt84J0cIiLyIGZ8vTgCr46eg3X3dIJRphi6hSFmTgeU/nJau8th6IPgV2dietFmLEvJs90ZKfkE65ZPxaJHr4UBlTh96hfgTzchoI3SVF6Nbv26w4R/I+tkOdAuDPPMqUgIlmu44naETQpALzmbwXcA7hoIFG7ah3T1Lkwpjv7tVcz4fwsRN+5G+ChJbe7Hs0vnIwJxeGNxOgphQXleLor+0A4+rZV1tYZvyGKsvVGZ2QDve1Jhzg5DiPK2ShHMuUUw/sEbHZS3yjZFzUSgcrdKfR+MZ/eWIDPyTrT9egs2mXdibeFdeOydApzj8zhEdBlgkENERJ7DkotDqUXwucFXCygUhl64MzITv9pf3LcbgWffq8Th+C3YWq4EBhUo/eoTbH1tAALUltEb3cYf0wICpavZmuF44aldMiCpJ0sG0pNOwNj3OnS3b3HbDcbg4d6oWJ+KrSUy7uncHQNXP4ZbR7+JVz/OliFMF9y74VkE1tpK+6Bzz6tweOiD6Dvrb1rXt3bjsWGKvxrY2RjRpmcAAkz9EMjncIjoMsIgh4iIPEdZLnK/rNTfuOKNrg+MwJj09xG/7xcZjOzBh89cg2fuu94WJOjP5Az4/SoktJyMGauC638HRClPlrNftvGB3w0yDCs8pg7tbOgxH++nj8bw1AjM/qs/OqrP5dg/s1OdDMLGfoz9cyw4FTUCE3v3VJ/LUZ87qsbgF43EgukIVe9IERFdHljjERGR52jbHT0cuovVzuD3LJ6LOYW0BZ8gK2cLZj38OMZX3e0w4+u59+L2xCGYdGo1Ekf0Q6eW+qT6kOXp7m9ExaHvkeusPKau6GVS1tkavne9jzXmIziwLhSjcmMRE/wKos0ufttGv0NlzktEYkwHGBc+hnte/AiH69huIqLLAYMcIiLyHIbrcN1NVwEpMzF0mv2djQqUf5mAJIdf/ffDLY8MQUjKHAQGfoOuD/a13akp+QRJ75lh7NdXfybnPBn6ISD0WlmeHUg6+queqChCXu4p+Ex6CKHtgNJtkZitBDQycLljRCLWZMdhetHfsSerVJ+/uuPYEb5FDWgMfqEIfe0QclKCgbUZSHdyN4eI6HLDIIeIiDxIFwS+OBljTIUoWvgYgrxb6sNCX4Pr9/ZGYDvHZs/QYwpemlqEopvHIWrQH/VUyXoHJuMQ0sstsOQnYdO2LP2ZnF+wN/4ASpx1RTvzI34+K//9rQRFZ5Rgwxvdnnwd8wO2Iv65eYhXh5Y+jYKUSRi2PgzRI2+GD+R8V2Rg9owV+tDTMiDLz0VBy7sw0N9bfX+m5BR+k2sv+q5AH8Ia8GrxPIbNS0emGtMUoeBYEVqOuA0Bbdm0ExE12FhuDZgV0WWH5w+Ra/U7R86Jssy3xVxlmGa5HBAiAhcni93q8MzVlYicpd0dh3xWKXlMEqPUYaLl8vH71aGYpxuNwmfyJnFk/zgRouatv0yRYu33i2zDSutp1iGqK80bREK4SZ/WW/jHJIpEffhoZV3FW2PF0pP/UId4VucJjBRRWcXqNNsQ0vorJEHsrvyv+DQqReRlRYnpAUaZblLL5XwbqakonxcRaRr7fGih/E+u9IIp35Q1UFZElx2eP0SuXbxz5Dh2DhqPvau3I5qjj1EDY91OZNPY5wPvaRMR0WVK6zb2VO9IuwEHiIjIEzDIISKiy0gFyr8ajqAWynM6bdBp9P9h3LQB/HFMIiIPwyCHiIguI0Zc1akbrleimsBIRO16g93UiIg8EJ/JIWoGeP4QucZzhC5FPG6JbPhMDhERERER0QVo0Ds5REREREREzjTmnRx2VyNqBnj+ELnGc4QuRTxuiWwa+3xgdzUiIiIiIvIoDHKIiIiIiMijMMghIiIiIiKPwiCHiIiIiIg8CoMcIiIiIiLyKAxy6sliTkLSu0HoeONKpFn0xIuuENkfRWPFpM7wXZGDCjXNjK/ndIbXM1twuNHKUU1ZGravmoApHR/CxJxf9UQiokvFaRSkz61WtzYEZ3W2M41Xj1vM0Xj6d5GIL2mqBoOIqHE1bpBj2YVVg7zUIeRsr9sQlPKTPoOiFEeXdbWb7tvAjc8FkOVfPXo4hk5KQ5FvY+26CpTuHIngh2Mw7t1KPa05OI4vYh7CA88sw8KiVnoaEVFTUurLQfB1aGOcvYaqX8xYciLw9IDIBq5bm2OdXYHy7HQknz2OzMLf9DQiIs/WuEGOIRhjUs9BlG3DiidaA6ZIxBUfxO6QP+ozKLzRbXwOyg4Mg+mhBKSWmlEwtgeM+tQmpZQ/ZQcSghuzNEZ435MKc3YYQvQUjR9uezkP5xIeQZ8muR/XBXe/lYfcpV3090RETU2rLwtEiV43hSIs+3/q7zJUvWT7s8T/Z3VuQ484fF6jbr1QtdXZzlzketyyCwl3/w4dp3+BstsewWN+9+AZ0xdYOawNvCK+QKE+GxGRJ2qSy2O0CcHQMXfCWFTbDwIZcVXbfgiLHY7gtk1TxFoZrsN1N12lvyEiokuKbH+Gv3lD1RdnBlMv9DUW6e88jOFO3Dfrdbx6zW6sX56Ogq45WD73CMzd47BhUgBM+mxERJ6oiSIII7yDI7F0wELMTjzqpCvacaTMbouA7r/T3ytOo2D/FEQMsHZ3uxG9Zn2OtDJb/2JL/mq8PayNnDYYQR9kIn/7BITbPSuiPk8zq5felcFueftudL4va32WHbrWaV0baldH2eyfXcn6Drum+cr1PI9os4tuA3KZZGtZg2Kw/fsz+gRNbc8G1bUPHPJt4YuOU1YiPrNEn1iB8sxl+EDP90jeYkTKbbL1F5fTsxZinpq/XHb6F8izW7eVJX8jVr0ot1FdhyzHkgPItC7vIv86y05EdCEsaZg9+ztcdf9SLOph375oDA7dpa1dqe3T7LtPy3p/79N4ylepo19GdPZR7Bju7FlNC05nR+vtg2wbYtP1+lBOcVaPK3X0mqEY5fWobC+OI2NJEIKUdfs+heH7Ch3aS4e6Vk4fui0XjuFaK3h38MYVV5zFb7+xWzERXV6a7jaJ4U7cO6EPisLWYHm1ByEt5o14J+AuBNiVzmJ+E6/+ORvfv1UEIc6h7MCN6Bj1DIZ/oAdJym35O3fi+Kv5cnoydg3YhXdG2zUI5Rsx/5YFWPanFJwUApXZf4afXH5oXAaK1G5o+7B5VGt9ZslZWi1clc3i8OxKKdK3nkDX8BmYVpGJrHzHwKWKJQNbwh7CyLKF2FkpID7thx+2paFcn2woiUfk7UNrPhvkxj6YN+AhGWx9gENqt42VmFP4Iibe84oWcJUsx+v3TMAwJd8/fo05mffj+VdD0OHT48g9Y5HbORvhfbdh55hcnBMn8e/R+/D5escm1ZK/GJNCMnByfLYsQzny033RedIA3JOQA4ur/MsOui47EdEFqUB5RgKS/tBCf1+TRe0ufQjmD/vZ3eVwlibnzYnAHfMGYFRuJcTuVzAubzJGfatPtFPxxWa89vM4zP2yWOZxJU69vBjxR3+V9a2zelxrL+4dnYR1Fb8gfdNeHBuSjN2VB7H5ns3YGPM50q3NpazP3wp9GjOu3ooflTYt41Z0mdsbHe0DNMsefDAuAot/eQRjnu8H32M98PSMW9G7OBLDF6ezuxoRebSmC3LQGp0Gj8ZkbMGylDy7i9lSfJeYhTuHdKnqTqAqL8IJ3ITAHt7yjRFtegTgdlMhir4r0L65KsvFd0Xe8PG+UnkHQ6cwvLrapOdhxteLI/Dq6DlYd08nNc3QLQwxczqg9JfT2roNv0d7n5bKXzaG7ujd/2r9jQsuyvaDw7MrPgh4NADXdp6EN3/cjcQ72quLOzqN/E0T8XjhQiTOC0Ev5RNqcz+enng/2mgzwNIuDPPMqTWfDXK5D0px9G+vYsb/W4i4cTfKkkgy32eXzkcE4vCG0uDZ53vF7RgX0hWdQrbhxx+nI/Sqb/BR5EJ8Hv8edqj7UG5nr5kYN0rNSSc/u0/WIHPhy4ju2U6+bw3fu2ZidPhVKIxai6WYUHv++NpF2YmIzkcS4nteKS/6lQt/L7S9cxeK6qxUWqFtB6Uut9capj79cKP+Tg2Y8nJR9Id28GmtVNKyrgtZjLW2GaoY7w7FggBf2dha80jH1i+/R4XTerxaezF0KIZ1usLWFqXsQJISIMn1l+5PwDv7hyD0r33V+lypMyNfGwijcYbtWVdDMJ7dW4LMyDvR9ust2GTeibWFd+Gxdwpwbv7d7K5GRB6tCYMcqd0QDI05g8PxW7C1XP96qmQ9Jm5/GuP9ZMVuR3lANPVcLMLa/YDsTyMxb0IE5tt/DdW2O3oErETM7WMxdM1OpJUZ4G3tkmDJxaHUIvjc4Ktd3CsMvXBnZCZ+bYCKvs6y1YflAJKX/xO45Tp0r++n43IfZCA96QSMfavl224wBg/3RsX6VGx1MbSo5ehqLFt/A7pf+8faAw+5jr2bDyNtsI9+UaG8uiJ4QSlQeMz1qD6uyk5EdF7sBx44h7LMJ+BfUduzoPVhRJvO3TFw9WO4dfSbePXjbBTJAOXeDc8isFFaVW39N+LfyDppvcev8alwNoKanL9nAAJM/RBYrW0lIvJUTRvkwA+3PDIEIWmrMPtz5W5OBUq/SgVeutlJ4KE99zLtph547J+34K5XohBhP5MhGKPXrMCCgZuRNDoEQd73IeiDnKq7PLlfXsyhPOsoW30oZc06z05ade0Dp/n6wO8GGfq5DEK0by2d9MRwJNeRs6cnApOVbnv6SEZVr0TEuQpYXJWdiOiCKXfZhyBQG1jtghl6zMf76aMxPDUCs//qj47qcznW5xsvPkO38YiYWoD09duwS322NAsZyVkoDPyT00DG4BeNxILpCG3TxM0+EVEjafLaztBtNMaP+o92N6fkH/jwmRvwyO2/16dayYvsr8biyf5HcXLZCWS+FoqAzjWflTF0Go0pG39A/t4ozH1iL9KGhWJQ0glYlLsEA+V1/KZ9tv7MDca9sjUWV/ugu78RFYe+R66zfWDqil6mC/yGT1nHgKPI/Mfx8wpOais7n8shogZhCMTMmT1rvxtdL0p33PexxnwEB9aFYlRuLGKC9ecbG4OhD4Imz0Skz2qs7d4SLVrei2GWWCSum8hAhohIavqa0HAzBo24E6a0VYiOWIT3Xn4a49pVL9YJHEzahjRTH/25FydKViN89ffyglg2PP2j8dLGQ9g19SSyMo6j2Drsc8pMDJ222TbqmRKgfJmApAv6BWg3ylYfbnYfc8rFPvjB0B8Bodfa9em2KkJe7in4THoIoTX2u5UR3rc/gpGmb5Ceerj2h1UN/TDgcT8URT6LQIeR7+R+3vcqorNdjJTmouy8m0NEzUsFSrdFYrYS0Bh64Y4RiViTHYfpRX/HnqxSfZ6LTBlIpt9JXP3aLqwpUO6WF+DHt59CKLujERGpmsHXPdpw0rODc5C1/BwCgq5z8i2btUvVYaTlyAbEkomMDUk4qF5tV6JCBip/Ly5FqwkzMco6xGZ5Lv79n1bw79cF3uiCwBcnY4wyGMDCxxDk3VJ/XuQaXL+3NwLVi/trcdvgfjAVfoMtMmOL0gUtPR57spUR0JSHVwO00WrKD+Kbr2Tat/9AWoHyjV3dZUsqOQ3zd+5equtlRSzCX1iCjflyHRaZ9+Z0lMvwonBcT1wZ8QVKzvyIn8/K2b89hqyqYOJMrfvAB1ei25OvY37AVsQ/Nw/xSr7KNqZMwrD1YYgeebP2vFJt3draPYVJ7/SDz5vhGKQPgaoMX/rJrlNyonX//IauD4yQ+/kIsqLut9vPXuiQcDMeUYYEr7XbnKuyExFdDBUoz0lHRkUFig5kIUutSrUvdUYYDyFz5z+0us6chM07s/BbVR28GyVXZGD2jBVaHa3kk5+LgpZ3YaC/8mWXfK938a34uQRKLamknSk5JfOwS3Najxc5aS9KUarOeAZFJbaBB94tnIeJ7a31rPXlOEx13U4jP/F2+LYYjEE782XOREQeQjSQC8uqROQu7SIQkiB2V+pJ1ZVtEyueaC3XYxI+k1eLxLwTYtdUb4HASBGVVSxE8ToR9WmuyNkYLAJlWYAQEbgxW/yoLy7EOVGW+baYq+ahT1+cLHaX2q2wNFUkhZvU6caRC8SizEKRs7S7XN8SEbU1S5QVx4kIk7Ks9RUqwrL/57ps334hEoKNdsvcKgKTi/QV1kaWNStKTA/QljOOfE/8/fPRItg4UoSuThGZJxc5L0ed+0CISvMGkaBvI9Bb+MckyvKe1aZlh4mQqjzlyxQp4ortP5ACu7zlsnN2iNT4LrJ888XMj7Kq1lNzHdvV/ewyfzfK7smU/UFEtXPvHDknSlKChclax1hfNeoyhZN5q9ogu7rONEqEfpYjimX91dtnsghbuUPWZ7+J4q2xYunJf1S1GVVtkbU9s8vXOD1FnKy2LuOwUWJ49Xr8yEEn7cURrT1xSJNtSFW7Y023f+ltglvKhfnDflrZnO4nuhDK50FEmsY+H1oo/5MrvWDKN0gNlBXRZYfnD5FrPEeqKUtG9II/YGL0bdXudp9G4Y6xCG+xCImD63MfvBTZsz/FDy8/2UgjxF0eeNwS2TT2+cCqjIiI6FJiyUBSQASKnujtpDtvK7RtHYzQO/+gv3ePJT8JK24KcPgRbiKiSxmrMyIiokvJmWP4T+tcJC1fj/hM+2GrlWdJF+Idw314uNaBZKpTlnkTszL6I/LBaxto5DkioqbH7mpEzQDPHyLXeI44UgdD2BqP+ElpSFNTesM/ZgYmPvogwnq1U1Oo6fG4JbJp7POBQQ5RM8Dzh8g1niN0KeJxS2TT2OcDu6sREREREZFHYZBDREREREQehUEOERERERF5FAY5RERERETkURjkEBERERGRR2GQQ0REREREHoVBDhEReZBCZH8UjRWTOsN3RQ4q9NTLWwXKvxqOAV5hiDb/pqddJJYMbBrqi6CUn/QEIqKmwSCHiIg8RAVKd45E8MMxGPdupZ7WzJSsR/RnRfobD1SWgYNbi5B74icGmETUpBjkEBGRhzDC+55UmLPDEKKnNC+nkf/5aqS3aqG/byxGtLljA748F49ovyv0tIZUiqPLuqJFUAziy/+CkBF98PCADji2pC+8vCIRX2LR5yMiajwMcoiIiC66CpRnvYzIkT+i0uN+AN8bXR+IxeKBAl7vvYG/53VA4cfrscT4PKLSXsC4drzUIKLGx5qHiIg8lAWns6MRMcALLVrciF6x6chUbipYdmHVICWthfbyfVm/26DfkVDTfeG7ZCfSEyIQ+1flGZNjyP1gEILUaYMR9EEOHDudKUHMQswb1kZfXs7zbgrSypR8lWlTMXHQYqyr+BZpg33k9Ntsz61YMpGxJEjP2xcdp6xBkvXZmbI0JK8ZilFej2Ji1nHbfL5PYfi+QluXMJnHgdhe8FWX34zMvHgMfztLm65MWz8BUzo+hIk5v6qza1yVWZ+euQwfzOoFr0Gr8K+TG7HqRV91Xq9RcdiYb3u+x9DOB9e0rYS5tCU66GlERE1KNJAGzIrossPzh8i1+pwjldlhIgQm4fPELDHpy3xRKcqF+cN+woRQEZb9P32mQyJ1qknAFCniiiu1NFWeODiru+iTmC2ylnZR1wv0Fv4xiSIx76ycXiCy4/vIvHrLeb4X59RlzomyA8NEgHGMCMss1t5nThKjTBDGMZvFIT17rVy3isDkIi1BIcuxc+wtInBjtvhReWt+Xyx4orVASILYXflfsWuqt16GQNEnZo3YYJZlqDwoNo+yzqNkUiJyZJn8lxxW81C3bbKfMC3Pltt+zC4Pu+13p8zFcSJCvleXDRwvQhd+KY7I9Mq8KDHGaFTz17a/ROTKfWUc+Z4s3wmxc/Qtcj3/FTkbg2X+M6rt38tLfY5bIk/X2OdDg62NJzLR+eP5Q+Rafc4Ra5Bjuwh3nqZcxE83drMLViSZ9oLfcj14OCdKUoJlQFM9MKkWZFSmipVBrRzzdrKssyBHSfN7IVWGTlbVl9MCCMcApXraMZEabqq2HUvFsAWZ+nsnebhZZmW+hGCjXUBVS5qVuk/tA6DLG+t2IpvGPh/YXY2IiC5P7Ubg2fcqcTh+C7aWa93KSr/6BFtfG4AAV62joTt6978aSNmBpKO/wnJ0CxJ390b3a/8Ioz6LOgjC7Y9gpOkbpKceRqGe6qgUx/Ykw/zuIPiq3cWUlxfaheyS8xeoI5RZO4655oPOPa/C4aEPou+svyE+s0Ru23hsmOJvVx5H51/mOrTth353d0FAn6trXTcRUWNgkENERJcp5YH5ERiT/j7i9/0ir/z34MNnrsEz911fjwv0SpTn5eJb/Z2Dtt3R3d+IikPfI9dptFIE83dFME7fhQKh9qywexWgYGwPNxtpb3Qb+zH2z7HgVNQITOzdU30ux/ZsTXUVF1DmOhj6ITQ5B4l3tNcTiIiaBoMcIiK6bBn8nsVzMaeQtuATZOVswayHH8d4d4dZNnVFL9OVaNO5O27U77w4+20YY9/r0N1pa+sDvxt8UJFxCOnqnaQLYOiFOyMzYc5LRGJMBxgXPoZ7XvwIh51ma7yAMhMRXRpYhRER0WXMD7c8MgQhKXMQGPgNuj7YFyZ9Su30OzAjBuHhdgYYuj2Cx4OLULhpH9Ltg4qyXOTskfM8eksteXqj68DBCEmbguFh72BxVomeLpUnIXxFjpvd1Y5jR/gWNaAx+IUi9LVDyEkJBtZmIL2WuznnX2YioksDgxwiIvIgtq5YFT+X4JSedqbkFJQBj21pNoYeU/DS1CIU3TwOUYP+qKfa+wbp67dhlxownEZByiRELXoSr0wK0AIBw0AMfSMUgSkzMfSlFH2Y6sPYFROL1S9ORlQ/reuWwdQLfY2HtGdtyrcjfs/PMtgYjfGjWqNi3VSE92qvP5cjX932oMN918tGWguoHJWi9Oez8t8zKCrRhoT2avE8hs3Th8iWyxQcK0LLEbchoK3SzFvn/zeyTpYrM7hdZiXoyc2qdq/nzI9Qs/utBEVn7CMkIqJmRBl9oCE0YFZElx2eP0SuuXeOWEcR04c9li/j9BRxUh0xzD5tl91oZooSkbO0u5MRwWyjjQW8u0TMCDBqy49cIBapwy7bKxf5+yaL6fo8MI0SoesOqEMu29iGn/afow3HrKo8Ig7GB4pAa/ms+VtHMdPToY56dsRuSGhb2qdRKSIvK0pfv0n4TN4kdpcqK7AfQlp52Y8w57rM2mhw1uWU6ZFi7feLbMNK62mX8xDRdVH2ERFpGvt8aKH8T670ginfPDVQVkSXHZ4/RK5d3HPkOHYOGo+9q7cj2uF5nAqU7rwXPUKK0T15B3aHOLvLQ1Q71u1ENo19PrC7GhERXca07mdP9Y50f8ABIiJq9hjkEBHRZaYC5V8NR1AL5fmXNug0+v8wbtoAJw/an0XZqVL1319KTjsdhYyIiJonBjlERHSZMeKqTt1wvRLVBEYiatcb1bqpKY7ji2m+8Hs8A4U4gsND/4RrVuQw0CEiukTwmRyiZoDnD5FrPEfoUsTjlsimsc+HBg1yiIiIiIiInLlkg5zGLDiRJ+H5Q+QazxG6FPG4JbJp7POBz+QQEREREZFHYZBDREREREQehUEOERERERF5FAY5RERERETkURjkEBERERGRR2GQY698I+bd1A59k05cnj/4VpaG7asmYErHhzAx51c9sZlq9p9VIbI/isaKSZ3hyx8QbBYs5mg8/btIxJdY9JRLXT2OscY6XywZ2DTUF0EpP+kJRERETaORgxzlF6TbqUPIOXt5jXoTr36cjSJ97ktfBUo+motlzfai6jg+i94tL5W0v7+IeQgPPLMMC4taqSl0vipQunMkgh+Owbh3K/W0huD6/GnRwhcdpyxF9Lv7kOkp1/ENpgLl2elIPnscmYW/6WmXsot1jF2gsgwc3FqE3BM/XdxgioiIqA6NHOR0wd1vlUBUpiIh2AiEJGB3pVDHzK40b8Cy3y/E7L8OReDSb5sm0GkzDC/9qwSHQq+FLN2Fs/wTya+fQjO6BHFgMa9DVIG1dMpnk4fcpV30981cQ39WDcoI73tSYc4OQ4ie0jBqP3+EOIeyI1FY3P5dLJ90F3oHv4zo7BJ9ucuYZRcS7v4dOk7/AmW3PYLH/O7BM6YvsHJYG3hFfKEH+Jeieh5jF/V8KcXRZV3RIigG8eV/QciIPnh4QAccW9IXXl6edOeMiIguJc2mu5qh0zCMmb0A8wNykDVrI5Iu+YaxEDnLnsWTh5tpj8Dy7Vg1/S0cbs8ei57BiDa9xuOJ1w7i6+T7EZgWi5iwVUgqv8wvMA134r5Zr+PVa3Zj/fJ0FHTNwfK5R2DuHocNkwJg0mejC+GNrg/EYvFAAa/33sDf8zqg8OP1WGJ8HlFpL2BcO9YxRETU+JpX63NVR/xB6SlVeKxmlxJLJjKWBCGoqlvOGiSZbfNY8lfj7WFt5LTBCPogE/nbJyBcea5ELrc/IQKxf1X6iR9D7geD9DyU+XLs7hidRkH6XMf+7fbPqGR9h13TfNHC93lEq+uV8++fgogBXjIvJb8b0WvW50grUy4qZYCz5F7cHXYYFRVzMbF9S7ncy/o3mhUoz1qIeWpZ9XK8m6Ivp5DTM5fhg3eD0PHGlTiStxiRch1eo6ZgStW65KsqP/1bVDXd173nP2SAs3LsUIz94DQq3gyGr1xW+1bbS59BUWLbV75PYfi+wmr5FiL3s+F4ylcvT9BLmLjdbn+62ncOn6WW/9BtuY537+Q8X60fWpW/16i3sTjLemfCyWels5iTkDSrl7pNjp9JLVyWRf8sZH5eg1bhXyc3YtWLcjvU8sRhY361Y1Ruc7J13UEx2P79GX1CY2oN35BlePMNPyDtTYRvPIpzORMx2Lp9StmtdzAsu7BqkPWYGqo9hyX3x4FYZRuUc2wzMvPiMfztLFjUff6mui9+F7ET5uxo/djX5qvax8o+WDMUo7welZ/7cdu+PZ9jSFXtPJPzhB8osMvH1XmoaAXvDt644oqz+O23BuiG6fK41NkfB+r+WYn4TG0ei91nYf0c7NNaDF6FtKrD1XHbnK6rivyEqj4TuQ9i0+26LDo7XwqR/WmkrIfaybRDMFetp/qyksM54vycMrTzwTVtK2EubYkOehoREVGTEg2kXllVpoqEYKNASILYXamnKYrjRIQJNdMrD4mdY28RgRuzxY/KW/P7YsETrW3zyfyW+w0XYZnF2uzmRWKazxARln1K5C7topYN6C38YxJFYt5ZOUeByI7vI0wyrU/i9+Kc/K8kJVi+V+YzCdPybFEpjoldU731ZQNFn9k7xfcnlXwDReiBU6IyL0qMMd6r/i3k8mUHholAfdlzailKtHWbIkVcsXVjtPkCjGP0ssr3mZPEKLnNxjGbxSFlNus+UNYbOF4M+/w7YU6+X/j4zBeJxf8WqVNN1fJU5ImDs7rr2+Im/TMwTt8l94aVXmZle2PWiA1mua8qD4rNo+z2tSpPZLzhJ4wjV4vUUiXRcX+63nf/FeYP+wljwAKRWKYsq+UFhMrP639q7lradcJnWrI4osxiPV4C35bL/Fbjs6ra5rINItbnDhGcYlbTKrPDRIicxyf2gHrc1FTuuizVPovQhV+q5dE+e6PjupX9NMLbVuaybWLl89eJ/tXLWAtlHW6r7fyxo227LLc+j3JOzAio/nlLcp/NMY0TUep5USJy5Ofov+Swtr/keZc62U8t/2/W/OTLOHK+iNqbL7ep+vFb4Pi5X8AxpO2vcpG/Y4jwH5codivzVB4R++f4y3lsx0qd56HcVyv6ewv/OV8K8y9x4gW/5eJAcapICjfV3Bd1cnVc6hsm9+fcvnJ91n0oj4MVSl1lmqjvY73Myj6zW781zbaPrNvygL5tcl/IeiBQ/wysdUDVMf7ELDHpy3x57mnHtG0f1azbqtd3tS+r0M8J6zYqx4RSB+nl0LbhjFpvGEe+Jz/vE2Ln6Fvk8v8VORuDZV03o1pddf6U9RFdanjcEtk09vnQYGurV8FrXKTJBnxvlJirXgxYAwAbpSH3eyHV7oLE2kjfKgKTi9SL0emtJlRdRKjTt40XkxwaeX1eKycXXtYLBttFqfWi377R1yjzBts34PoFse3CxUmQI7d7ZVCrahe9Tsrn6iJW2VZjN8eARqYpF2815nVFX4fjhZ6z7a2Zpu2n6vtED2yqtre2fael29ZbffutgaD9xZE8PtJHiydb2dJqflb6RbP99ugXxa0cttFeXWWRnH0WTo5fNVgKdvy8apaxdhd2/tSkrdt2MWzdNqPxOcfzJHmw8Ksq3zGRKi/+HY+tpWLYgkztfY1jXFH9wrgBjyG5ncv9IuyOA6laGZR8XJ+HVtbPtvo63eXOcalvZ/XPpXqZnJWxxmeq7wuHvLQ0++WcHWMNmibLOr16QK+m3ehYn1o5m7+B8GKRLkU8bolsGvt8aNruainPIKil0gWiDTrdtR87/pyKI+YExPm302dQlOLYnmSY3x2kd/9QXl5oF7ILhShQR/GxtO2OHgErEXP7WAxdsxNpZQZ4378Ui3r8Ts/DCUN39O5/tSzDDiQdrf9wyYYecUg9F4uwdj9o3T4mRGB+HU8xW45uQeLu3uh+7R/tHv41wvv2RzDS9A3SUw9r3YhcaTcCz75XicPxW7BVfd6iAqVffYKtrw1AQKN8mtrnkWLqil6mK/Q0xbW4bXA/mApTkPTVL3qaM97oNv4Yzs2/Gya1a9NwvPCU8llanUHBvw4i/e4b4N/WukGt4XvX+1j/q7K/a9lISy4OpRbB5wZf+OhJMPTCnZGZ+FVZl57kqK6yuMlyAMnL/wncch26N68OoHbkcRYciaUDViF+/T/1LmEncHBjEYYMuE4/Hn3QuedVODz0QfSd9Teti1W78dgwxd/ueK2uNUx9+uFGpGPrl9/DsRNTbdw7hpTzZZN5vtbd03rut5+onmcVh75HrlyZ++ehEW16BiDA1A+BfvbrdJcbx6UlA+lJJ2DsW+04aDcYg4d7o2J9Kra6/ayhD/xukEfyt8eQVa1rmHXbG4VStw4Eir4rqNaNMNv5CGpt+6Hf3V0Q0OdqF8cMERHRxde0l2TW0aHKtmHFE3uR/nWBk5HIimD+rgjG6btQIINAGZjZvQpQMLYHDIZgjF6zAgsGbkbS6BAEed9X7Xmbi0HrLz/tph547J+34K5XohDh/EpaV4HyvFx8q79zIC8kuvsb3bx4UR7yHYEx6e8jfp8MJix78OEz1+CZ+65vpIsK7fOoSV5Edu4uL3b1wFNPdUrv4z/g96uQ0HIyZqwKtgtCasu/DmW5yP3yPMaxc1kWNynrzqpxudc83NjVdlFuuBP3TuiDU69+pA7sYcl5G0+XRWJ8N+uXATLoG/sx9s+x4FTUCEzs3dPxeZsG484x9CNK5fnyhXEG4oorq5338pU8BoHqZrl/Hhr8opFYMB2hbc6n2nPjuKz1ONADFmfPGtZKnucPTkJExzjEbcxU6zJL/jbs3HcWPkG90Kuxam7lmIkIwZ0L/4bZ6vNAcn9/tQ0ZFYOdBzKGfghNzkHiHe31BCIioqbRtEGOVZv7MebNaRi19nEMmv+V2qDbaBcIFRmHkO5ipChDp9GYsvEH5O+NwlwZMKUNC8Ugd374rsa3ye6QActXY/Fk/6M4uewEMl8LRUDn1vq02jgGAc7KVeMb4FoY/J7FczGnkLbgE2TlbMGshx/H+PP6dvp81HXB5qveqap9M8z4eu69uD1xCCadWo3EEf3QqaU+SaXnX987bPo3zoWb9iHd7WvyuspyqTLjH1s+QQp6o8+zwXZ3+Fqj0/2T8Ua/hZid+C8c3X0AXccFoo/9h6Xf/TLnJSIxpgOMCx/DPS9+hMN17tO6Pnd77hxDHeEtz5e7K75FWk6pnl7d+ZyH58uN47KuLyvqWdcYOj2D8NhQPHY4FH1btEBLv204MDINuyPukKVpLK3hOygWM1/8CVe+3km76x4rj6v9y7GBgQwRETVj7l2TNAKD30wsSg9Fr8hnq/1Ojje6DhyMkLQpGB72juPoQuVJCF+RA0vJaoSv/l5e8sgGuX80Xtp4CLumnkRWxnGZT22bqN8hGjEID9d7iNMTOJi0DWmmPgjs4a2n1c3Q7RE8HlxU80K8LBc5e2Q5Hr3FzbsIfrjlkSEISZmDwMBv0PXBvo04FK7+eejdk2zBmnan6ouA4Qjr/3s9zYmST5D0nhnGfn0R4PQb9atw9fXXye1JQvxzsxx/66V8O+L3/Ky/qcZwHa676Sp5EToTQ6fZ332Q5foywfmQ5HWWxU3n1R3pYjmNgpTxmP6K3K6R0/D2vZ0dv21v8wD++pQfCqNewJ+jQhB6h/1ndRw7wreoAY3BLxShrx1CTkowsDYD6bXezdE/d+M91fJyxb1jSDtfkpH0cHi10ffMOBC+AWmWn8/rPDw/bhyXhn4ICL3WSSBUhLzcU/CZ9BBC3a5rtADutuRhmBCfo9/FTsbu5+5svLs4KjMyZg/D3HsS8NbGcu0u2u55WHSnb827OERERM1IozaXrhnR5o4FWBJvwKnnhiNwVlLVENGGbqMxflRrVKybivBe7bW++cqr2x50uO96uRFn0GrCTIyyDlFbnot//6cV/Pt1gU9Vx6lvkL5+G3apF2vKheAkRC16Eq9U/VZGBc6UnMJvKLTrf15bFxXrN9GHtW+ZlS5PG5JwUH0WoBIV6kX1ldpFkfpt9f+0C+2yP2PoG6EIVC7EX0rRhmm1HMaumFisfnEyovrp34y60f3J0GMKXppahKKbxyFq0B/1VMVp5CfeDt8WgzFoZ77dBWQ1elCgfev8C/bGH8AvVdt7BkUl1ou0UpT+fFb+a0sz9IjEG2+0ROG4cNyrr8OSH4/XnyzHwNcex8NqwFDLvrN+263fmbPkJ2HTtiz9ORilHF/DEhyL9+TnDeW3XvztPu+/5MLnVmWAWmefVRcEyn04xiTTFj6GIG/rcxzX4Pq9vRHo7OKyzrIcQImzz+LMj1B3yW8lKDqjfIj6uhGL8BeWaENLy881bXM6ymVuheN64sqL/sOT8qJYHe76dtw2eDvSR76HtbHDEFz1/IiVN7o9MQXTiw7C+MZTNX7DxKvF8xg2zzqEcBEKjhWh5YjbEGCXT8V6a9cl7XN/Y3oG/DdM0PNy9rmf5zFkuBODx90sz6G1SHqwBzpaj4MW92F8wF34s+FKN85D6/nvijvnjPJMU13Hpdy3T76O+QFbZSA0D/HqEONaXTNsfRiiR96s3YGxBsUZX2Kreqxk4oAsd46yi5TnFP2U4eF/UgO4wkX2zyLqr6rhuLWgUOkCW/FzCU4pecs07dxwlmZ/vtiWtXGybMkn2LQ0C2mDfRzLIF9Oh1EnIiJqLkQDcS8r+6GFrS/H0X2cD1GqpB8RB+MDq4ZQNY5cIBZZR2ErXieiPs1VhyzVpodUDTdtP2JWwLtL1GF0ayxfNY+1TPIVOFyM1OfVXtVGZ7MODSvL7zN5tUjMO6FtW2CkiMrS860aPnaUGLa3QN/GcpG/b7KYbs1bTgtdd0AbklbSRjeyrlOZbjc6m4MSkbO0u5NRjKyjXblaVmE3/K8y9OuJv2ujO1WtW9neI9U+L/tRx6p/HtZhhZVp+khRzpazW6/6OcXvV4f2VUZk8pm8SRsqWFG6W+yIUYYLVuZT9vEKEXdEG3a7xmdVNQKVkvfb2ih96jSZ/+JkW541uC7Lkf3janwWa79fpI6MZZ+m7WOZV1ZU1eeq7NO/fz5aBBtHitDVKS7KoFGWqZuz88f+pQyTvkZEbc2qZchsnTJqmekBJ6OMHROfRqWIvKrtUPa73WdiHRVs8nLxofUcVY7fz3L0Iaedfe7neQxVcXK+WNencOc8rJO754xU63FpU2neIBLCrXWY/dD1VvbHijJ9u8go3iE/kxvl8bqx6ji3HZtOXiGLRGKcMmKdLc04PUWcrHZuOEtzf1ml7rUO7W1Lt72q1d0XmbJOoksNj1sim8Y+H1oo/5MrvWDKN3sNlFUDq0DpznvRI6QY3ZN3YHeI/V2PS9lx7Bw0HntXb0e00+dxSpE9+1P88PKT+gPa1Jw16vlTEo9xd/8Rz2cMdXwepy5yuZd6TsTbI3bhZK0j1l3KmtM5U4HyIwvx1ulnEX1HtZ/XtBxGyv2bcezDqNpHG2wwhciM3oaj08bod2htLPmLcf/b/nh/waBGORaabxtDVDset0Q2jX0+8PL3kqR1gXmqd2StAw4oXa9W3BTQSMNK0yVDXiCnzlyM72Lvrl+AcxloTueMxTwbo+9rj8B+1QIcheH3aD3kvvN4lrC+TiP/w0dxb6cA/MXJM2uGdl0xZMjNHhjsEhGRJ7gMLnPOouyUMjrTWfxSchq1PqPS7CkPIg9HkIyC1RGORv8fxk0b4OQCQwZA6W9iVkZ/RD54LR8OJsmMr+d0Vr9BadGyL+47MweLHJ7jco+l7Ef8pPzxczGK3HnU5ZLR3M6ZCpzJP4qfzZsQE5fiOIS3JRN7ZyejYIi7g5RciFMoPJ4H84b3Eb7dcUh+izkJs99ph4ED/qCnEBERNS8e3l3tOL6YdguCF1iHoDXBtPwLnBzb45K8+LeYozH29his6h6JqPiXEN3T/kdT6VJ2cc8f5cH6IPR73IyKye8iMeZhBNYYkMAVa5dPux9KVX7j6nPrb9VQw1MCr3exbdNijFuk73XTKITGjkDYI8H1/PwugDoowrvYsiwBb6ZrXxEZR87HjEcfxKSHejbiUNbs9kOXJh63RDaNfT5cBs/kEDV/PH+IXOM5QpciHrdENo19PvB7WCIiIiIi8igMcoiIiIiIyKMwyCEiIiIiIo/CIIeIiIiIiDwKgxwiIiIiIvIoDHKIiIiIiMijXAZBTiGyP4rGikmd4bsiR/8xUO2HNQd4hSHa/JuactGUb8S8m9qhb9IJfd0NRfkdjbnVtstNZWnYvmoCpnR8CBNzftUTtR+M9HpmCw431Q89Oi0XEREREVH9eHiQo/yI4UgEPxyDce9W6mkX03F8Fr3b9oOJF5ElJwJPD4g8j+06ji9iHsIDzyzDwqJWelpz0FzLRURERESXGg8PcozwvicV5uwwhOgpGiPa3LEBX56LR7TfFXrahbOY1yGqoFrQ0WYYXvpXCQ6FXivX2nAMPeLweY3tckcX3P1WHnKXdtHfW/nhtpfzcC7hEfRpkqOitnIREREREdUPn8lpKOXbsWr6WzjcvvF2qcHUC32NRfo7IiIiIiJSNH6Q4/DcxQ/I/Ww4nvJtgRYtBiPogxwUo9Au7Ub0ik1HpsMzIqdRsH8KIgZ4yelynqCXEH6gwPGZFLmO5Fm94KtOj8H278/oE3SWTBxYX/PZD0v+Rqx60VfLV768Rr2NxVkl+lRJWS5WydcXHadsRmZePIa/nQWLDHBWjh2KsR+cRsWbwep6vSK+kFtytuZzM0rZ1gzFKK9HMTHrODKWBCFIWZ/vUxi+r9BuO6ptp7IvZn2OtLLzeWCmAuVZCzFvWBuZjyz79C+QVy0bizkJSe8GoeONK5FmN82Svxpvq8spn08m8rdPQHjVPrPPVymjnOfdFLsyyumZy/CBnu+RvMWIlNtje+6n7nIpHD8XuY4lB/RjwnX+rstORERERB5LNBD3sjomdk31VucFQkTg4i0iMe+sEJWHROpUk4BplHh47iLxelaxnLdcmD/sJ0wIFWHZ/9MWl2n5O4YI/3GJYndppVzuiNg/x99xnsqDYvMIb+EzLVkckbOIsm1i5fPXif4wCdPybFHpUAYny8UeED8q78s2iPkBRoGQBLFbyUeUiJz4PsJ/yWFtulLmyX5qnufU96kiIdgojNN3iQLlvUwtSQmWZVPW42zdgaJPzBqxwaxsv1z3qNZ265JJeVFijPFeEXrglJpX2YFhIlDPR12fojhOTDcaHdOc0PIKFsEpZjmfzOvIdDG1v1IOfftlPhEmpUzyZVcGZZuW+w0XYZnK5yHfmheJaT5D9H2mlSnAOEafLt9nThKjZD7GMZvFISUP+3wDx4thn38nzMn3Cx+f+SKxrLLucknKOif6TxZR+jGRnz5ajNS3udJV/sVfuSh786NsAxHVjucIXYp43BLZNPb50Mh3cuyfu2gH/3vuQ6jyTIzBH/0G+8NUmIlTNw/HzJ7t5PTWMPXphxuRjq1ffg/1DoflALY92wMT5z+KwLay6IZeuDNsIkaakrB81T71zkn+pol4vHAhEueFoJeydW3ux9MT70cbZXnJUuuzH6X4JceIXrd0gY/yts3tuPWOq4BvjyFLvTNRBHNuEYx/8EYHZbqhD4KjZiKw1jsrNZ8Hcly3DwKGDsWwTsr2d0fv/lcDKTuQdFS/01BehBO4CYE9vOUbI9r0CMDtpkIUfVcgS1IPlgx8FLkQn8e/hx33dJI5ybx6zcS4UepWatqFYZ45FTJI0xN0Zbn4rsgbPt5Xqm8NncLw6mqT9myRZQ8+jNyC4/HTschf+bxkvv4L8O6aYPismoPw1J8c873idowL6YpOIdvw44/TEXrVN3WXS34m332yBpkLX0a0fkz43jUTo8OvQmHUWizFhNrzx9e1l52IiIiIPFrjd1e7AJajW7DJPB8T27fUuy7JV/uJmF8IVBz6Hicr0pG8/J/ALdehe323zBCMZzN+xu6Q9loXqFlDMGJBqT5R4YPOPa/C4aEPou+svyE+s0RexI/Hhin+F+XCWRlYIPVcLMLa/YDsTyMxb0KEup31ZTm6GsvW34Du1/6x/uVs2x09AlYi5vaxGLpmJ9LKDPC+fykW9fid+lkk7u5dLV8Z2N3+iAw6v0F66mGXo8y5VS4ZoO3dfBhpg31sn3eLrghWPpfCY8gsdDH8t4uyExEREZFnu4SCnAqU5+XiC+MMxBVXKve7HF/JY3DH6VzkZtXrF2McaM9+XIMO80qRM2gN1kxV7qJYeaPb2I+xf44Fp6JGYGLvnupzOef3jIw7tGdypt3UA4/98xbc9UoUIkz6JLdp++xb/V29ycBv9JoVWDBwM5JGhyDI+z71uakiWGrPVwYX3f2NatCZW+uucbNcZbnI2dMTgclFNT9vkYg4VwFLrWUnIiIiIk93CQU5RrTp3B13V3yLtBz7OywNpHwj3gp9GjOu3oqCtdMR3b8DWuqTqijd4yIzYc5LRGJMBxgXPoZ7XvzoIvx4pgwCvhqLJ/sfxcllJ5D5WigCOrfWpzUuQ6fRmLLxB+TvjcLcJ/YibVgoBiXl4Ur5WdyIAuSe+EnrSliNse953E2rTgmYBhxF5j+On1dw4rzsDf2jrERERETU3FxS3dUM3R7B48HJSHo4HEO35dpd+JpxIHwD0to+isHDvVGxPhVbS+oTeVSgdH8C3tnf2/ZMTg3HsSNcG7XL4BeK0NcOISclGFibgfQGv5tzAgeTtiHN1Ed/Jud8ud99zKmS1QhfrTwP1Rq+/aPx0sZD2DX1JLIyjuOM+lkUoXDTPqTbb75692UQHn70FtR+48nNchn6YcDjfiiKfBaBDiPLySBw36uIznYxUpqLsvNuDhEREZFna4IgpxSlP5+V/55BUYn1IvUsyk4pd2fO4peS0/o37bYuTRU/l+CUkmS4E4PH3QxT4VokPdgDHaue07gP4wPuQoDh/yHwxckYg1iEv7AEG/N/AyyHkbY5HeXyUrpwXE9cGfEFfqoqw7+RdbJc/qvdJVLuTGh3Dc6iYH8cdnylDz1dehDxe87Aq8XzGDbPOqR1EQqOFaHliNsQoA6CcB2uu+kqvZvWL9gbf0Cu0YIzJafwm/zLNmBAEczfVb/Mrr5PfOB3gwy1CmXZlbtWlkxkbEjCQTUaqETFlwlIKjmH8px0ZFRUoOhAFrJqi7PaPYVJ7/SDz5vhGKQPx610y/tkl7JHkxDfMwBBKT/JVf8ItQhVAy0ozqDVhJkYZR3aujwX//5PK/j364LWhoEY+kYoAlNmYuhLKdo+kft6V0wsVsvPIKpfe2UJNehx2oXQrXL9hq4PjMAY0xFkRd2PIG/rs1he6JBwMx7p/rva83dRdudBLBERERF5DNFA3MpKH2ZZmVd7KUMifyFSqoZVtqZ9I7KWdrFLg93QzOUif99kMV0Z3lmZZholQj/L0YZ1Vp0TZVlRVdONI98Tf/98tAg2jhShq1PE7tJ8u2GcretThncuENnxfbQhnwMjxKT9eeKUOgR0iAjcmC1KxDHxaVSKyKvK2yR8Jm/ShrK2rtc6hLJc5wbzGbshpPVX4HAx0lpu9XWrCEw+Uq08SlqROvT1iiday/fKelaLxLwT2nyBkSIq65eaedsP/VxDgcjZGCwC1Xl7C/85O0RqfBdZzvli5kdZosx+KGb1ZR1aep2I+jTXblltX9j2tZPPYt0BbehuqTI7TIRU5alMjxRxxfaFdF0u63oqzRtEQrhJz0fOF7Nd3e8u86+z7M2LUn4iqh3PEboU8bglsmns86GF8j+50gumfMPeQFkRXXZ4/hC5xnOELkU8bolsGvt8uKSeySEiIiIiIqoLgxwiIiIiIvIoDHKIiIiIiMijMMghIiIiIiKPwiCHiIiIiIg8CoMcIiIiIiLyKAxyiIiIiIjIozDIISIiIiIij8Igh4iIiIiIPAqDHCIiIiIi8igMcoiIiIiIyKMwyCEiIiIiIo/CIIeIiIiIiDwKgxwiIiIiIvIoDHKIiIiIiMijMMghIiIiIiKPwiCHiIiIiIg8CoMcIiIiIiLyKAxyiIiIiIjIozDIISIiIiIij8Igh4iIiIiIPAqDHCIiIiIi8igMcoiIiIiIyKMwyCEiIiIiIo/CIIeIiIiIiDwKgxwiIiIiIvIoLYSk/31BWrRoof9FRERERETkqIHCDrc0aJDTmAUn8iQ8f4hc4zlClyIet0Q2jX0+sLsaERERERF5FAY5RERERETkURjkEBERERGRR2GQQ0REREREHoVBDhEREREReRQGORekAuVfDccArzBEm3/T05obM76e0xlez2zBYYue1EAs5iQkvRuEjjeuRFoD501E5HnqUR+Xb8S8m9qhb9IJ2dIQEVF9NW2QY8nE/oQIzBvWRh1WTn0FvYSJCcn4uiQZbw/fiUJ91gZRsh7RnxXpb5qBi1GextpGyy6sHj0cQyelociXsTIRNQelOLqsq6090V9eEV84tCWWnIkYbD/P4FVN/EXNcXwWvbth2zsiostck12dWvIXI3LgTfjzHh+UP5GBH4VQx84Wu0ZhVKsEvNvzXrzk11KfuyGcRv7nq5HeqiF/tNSINndswJfn4hHtd4We5q6LUR5nefrhtpfzcC7hEfRpyE/bEIwxKTuQEGzUE4iImpo3uo0/JtuSAmTH94EJtyIwuQjn5t8t/7Yx9IhDctkGzDGNRFhmMUTyGAQ2SmvovD62mNchqqBSf6drMwwv/asEh0KvlS0NERHVV9MEOeUbseCJqXjr/1ZiR9xUvP5QT/jok2DohTtGJOL9g1F4aONx5DbIt2sVKM96GZEjf0Rls/hNrotRnibYRsN1uO6mq/Q3RETNhQk9ho/HCKOLbsRXmVAZFolF/u30hCZSvh2rpr+Fw+2b7DtHIiKP1AS1qhlfL45ARPpgPDzxIQS3dV4Eg98UvD7e/gL6NAr2T0HEAC+9i8GN6DXrc6SV2aIgS/5qvK12fRuMoA8ykb99AsJzzsiL/6mYOGgx1lV8i7TBPnL6bQhK+QkoS8P2VRMwpeNDmJj1HXZN80UL3+f152uUoGGhXVc6mee7KQ7rU7rbHVivL5/zq5Ym80xeMxSjvB6VeR5HxpIgBCnL+z6F4fsKZa5KvrWURyHzrFqmhS86TlmDJLvnfeq7jTWfm5Hrz1yGD2b1gtegVfjXyY1Y9aLcbrk+r1Fx2Jhvd1HgUBZtG4Zuy0Uz6vBHRORcuxF49r0zSFvwiZOuaBUo3fEBih77v2p3Seqq9/X601qnFsv6Xtalvsq8QS8jOrtEawOsaVX1vqZGfSwDnJVjh2LsB6dR8WawuozWte4sCtLnYsWkzvBdkaMvX4jsTyNl2drJtEMwV7WHsi2MTUem/TY61N0120r3uL8+S76tHdHakrexOEvuC4fug9Z2zj7N1277ZBu/92k85SvT1X15FDuG2z/vWe0aIOglhB8oqNq37lwjENFlRjQQt7MqjhMRJgiEJIjdlXqaGyrzosQY470i9MAp+e6cKDswTATCJEzLs+U7ZYZUsdxvuAjLLFbeiUrzIjHNZ4gIy/6f9j47TITgVhGYXKS+F+KY2DXVWy03ECj6zN4pvj+pLBMo1/GTmn+AcYyen1xf5iQxSpbbOGazOKSW2375UH091fKMWSM2mM/KlR8Um0e1dtjmmuWRKg+JnWNvEYEbs8WPylvz+2LBE3bL1XcbrftaKY81D/u0wPEidOGX4ohM1/av0bY/Rbkwf9hPGAMWiMQyZcE8kfGGn922KvTtrednSTUpnwcR1e58zhGtXrvRsZ5VyDp5w+CV1eotrV1xWe871J8RImztfq3+lHXxjACjMI58XYyfkSh2lyqJ1ep9Z/WxQtbrCcFy2em7RIGacE6UpAQLkzJfVRvnmObzxCwx6ct8UanX0yaHelmvqwPf1upu2a6kTjVp65Uv23pcqcf6lO0c4S18Yg+o7ZYo2yDmy31h20brMvbtnTXN1oYr7ZffXxJEqrLv5PT85PuFT+8VVXnk7xgi/MdZ9+0RsX+Ov0M56rxGaCLnc9wSearGPh8a+U5OBUoPbsG6Wp+udPbQqPZNT2V5EU7gJgT28JbzGdGmRwBuNxWi6LsC7c5CWS6+K/KGj/eVyjsYOoXh1dUmF32Zu+Dut/KQu7SL/NsHAY8G4NrOk/Dmj7uR2O9f+DByC47HT9e7Msj1+S/Au2uC4bNqDsJTlW+j7Je3qpbn0KEY1ukKWZju6N3/aiBlB5KO6nd8nLAcXYanfzcfG57ooXbfM3QagWfH3AlTSjxilHXWdxvbhWGeOdXxuRn7tCtuR9ikAPSSR4HBdwDuGggUbtqHdPWLr0qcPvUL8KebENBGOUyuRrd+3WHCv5F1slyZgYioWTP4jcST4SeQ/uHfHUYzsxxNwpqnghFg3wJa9tRd7zvUn90R+uSdWv3Z6QHcc8dVqEg9gz4zHkWg0kOher3vrD52ygjve1Jhzg5DiJ5SPc14dygWBPjCgNYw9emHG5GOrV9+r93VKPkEiVH/hWn4fXhYqbsNfRD86kxMN97o9Pkk5+qxPtlu/5JjRK9bumjdztvcjlvlvsC3x5Cl3kVphbYdlHbbnjUfqwqU5+Wi6A/t4NNa+VBawzdkMdZaZ7AcwLZne2DifOu+7YU7wyZipCkJy1ft0wZsqOsagYguO0pt0oxYHxo9hl1TZUVlikRcsRkFY3vAq0ccUs/FIqzdD9ot9AkRmG8fLLXtjh4BKxFz+1gMXbMTaWUGeN+/FIt6/E6fwX2Wo1uQuLs3ul/7R1lVWslK//ZHZKX6DdJTD1+EUXBKcWxPMszvDtK6OagvL7QL2SXXVYDcEz/B0oDbWDfts1AbRLUL3nC88JRSFiKiS8W1uD30AQSsWoXZGcV62nHsev43DLn/Grv6vanq/YtAaScGwsnFfbbajti6dzUQQzCezfgZu0Pa612hh2DEglJ9ortkUNK5Owaufgy3jn4Tr36cLcveBfdueFYdEEL5bDaZ52Ni+5Z62yhf7Seq1wAVh75Xn91VBpNweY1ARJedRg5ytIpM/XKm6lsed2n9bafd1AOP/fMW3PVKFCIchssJxug1K7Bg4GYkjQ5BkPd9CPog5zy+wdG+UfpWf+dANh7d/Y1VlWrDKoL5uyIYp+9CgdBHmqt6FaiBnqHBttFNer/uAb9fhYSWkzFjVbAb3wASETUXss3p9wxGBidj6/IvtLs5JcmYhwfwcDv75q+p6v2LwHAn7o0IwZ0L/4bZ6nMxsu38ahsyKgYjoM/VdgFcw9GeybkGHeaVImfQGqxRvqSsJ0OP+Xg/fTSGp0Zg9l/90dH6jJP+2XxhnIG44spqbaN8VY2MV8c1AhFddhr9To6h22iMH9UaKPwUy1Ly3PxWSVZyX43Fk/2P4uSyE8h8LRQBnWUe1Rg6jcaUjT8gf28U5j6xF2nDQjGo3j+kZg3EtLsnzpY19r0O3Rt8z/nA7wYfVGQcQnp57S1pw2yjO8z4eu69uD1xCCadWo3EEf3QqSFH9CYiagzyon/wuJvho97NKUTuhgRURtxc7Qubpqr3L4bW8B0Ui5kv/oQrX++EFi3aoFNsb/TZvxwb7mivz9OAyjfirdCnMePqrShYOx3R/Tvg/JoKWe673sca8xEcWBeKUbmxiAl+BdFmi/rZ3K0MqpNT2x0i964RiOjy0vhVtuFmhLz0DEaZjuBw+CyEq9801eUEDiZtQ5qpj97f1omS1QhfrfQRlhVl/2i8tPEQdk09iayM4/W+02Ho9ggeDy6yez5FV5aLnD2D8PCjt1yEOxre6DpwMELSpmB42Dv6yDS68iSEr8iBpQG3sU4lnyDpPTOM/frqz+QQEV2KWqPT4NEYadqGrXFv4o2lExA16I/6NJumqfcvBjMyZg/D3HsS8NbGcu1ux+55WHSn70W4i1OB0v0JeGd/b9szOedF5rMtErOVkUT1n5FYkx2H6UV/x56sUv2zSUbSw+HVRvg040D4BqRZfq77GoGILjtNcPVqVB/mjEudhFFYhfhBk/TnS6ytymkU7FuHjHz7H0bT7nKg8LD2TY7SjWpDEg6q/W0rUfFlAv5eXIpWE2ZilHW4zvJc/Ps/reDfT6t4DaZe6Gs8pD3bUr4d8Xt+lqlaF7EaDAMx9I1QBKbMxNCXUrShMi2HsSsmFqtfnIyoftZvw0pR+vNZ+a/9w/jO8rTOdwZFJdrAA87KY73LVbFuKsJ7tdf6HSuvbnvQ4b7r5Yd1pv7beOZHqKu27x4oG+3crGrfVVrn+60ERWfkfNYuGvqdJUt+EjZty9L7pP+CvfEHUFJ+EN98dUbm/Q+kFbj4PQoioqbUbgSeieoi69YPkPr8AMcBB6zcrfer15UKyy8oLlLarFL8WGatW61tga3ed1of6783pnWH0+rWQlhwpuQUfpN/2Z6tcdalrkKfT/71cwlOKUkln2DT0iz9pwT0NkR/Vf1MgCUDW55qgxZBMYi3/9kAB+6sz3YHLPMfypdtZ1GwPw47lHZBUXpQtkMl6nNNI2TblLnzH+p+VYbS3rwzS92+wnE9cWXEbpRckYHZM1boP2Mg152fi4KWd2Ggvwxa9LtxpsK1SHqwBzpWbdN9GB9wF/5suLLOa4SkX3Ld2GYi8iiigZxXVqW7xSfvTRdzlWGS1aEq9ZcyNOfKRJGYd1afUSrbJlao85mEz+TVctoJbfjiwEgRlVUsRPE6EfVprsjZGCwC1XxCqoZi1hSI7Pg+woTewn/Ol+LkOW3YTtt6qw3nrAxZuW+ymK4MhalMN40SoesOqMOFauyHi1ZeJmGK3yiW18jzSLX5rOtxLE9VvpVHxMH4QH0bIIwjF4hF+pDR9d1G8y92Q5aqr1ARtXaECKl6L1+mSLH2+0WO88m0uOLfqoZPVdcTv1/Nb7rRKPf/JpF5stoyDkOYUn0p+5CIaneh54g2xH5d9ZTrel/Lo1q9l76hZl2YebBm+7J+RS11pt1Q1SPfExvMZ+yGb9ZfIYtEYlwXu2WVoaBTxMlq82nDQ1vbAVu67aUNqVxpHd5apjkfUrpE5C49j/XJtnvS/jxxSp3Pvn0qsLVbyj79LEcUy33Z22eybOt3iN2lv4nirbFi6cl/iKRwfbhra9texclnI/Opav/qukaoc5svDmV9RKRp7POhhfI/udILpnyr0kBZEV12eP4QucZzxF2FyIzehqPTxmhDSNux5C/G/W/74/0Fg7Sud5Y0zJ7z/zBjZs+L0JWtmWrkbeZxS2TT2OcDH7YgIiLyCKeR/+GjuLdTAP7i5FlKQ7uuGDLEOujCaRRsT8Pvn+py+QQ4l+U2E12+GOQQERF5hFMoPJ4H84b3Eb7d8ecFlOdgZr/TDgMH/EF9ZmXv7IX46P8mI6zzFfocHu5y3Gaiyxy7qxE1Azx/iFzjOeImeTF/YMO72LIsAW+ma4MgGEfOx4xHH8Skh3pewAhodD543BLZNPb5wCCHqBng+UPkGs8RuhTxuCWyaezzgd3ViIiIiIjIozDIISIiIiIij8Igh4iIiIiIPAqDHCIiIiIi8igMcoiIiIiIyKM0jyCnLA3bV03AlI4PYWLOr3qiGV/P6QyvZ7bgsEVPamxOy0VERJcy5Tdjkt4NwgCvSMSX1KeBKUT2R9FYMakzfFfkQBuguRGUb8S8m9qhb9KJBl7naRSkz2387SEiagTNIMg5ji9iHsIDzyzDwqJWelpz0FzLRURE582yC6tHD8fQSWlI92mhJ7qjAqU7RyL44RiMe7dST7u0WXIi8PSASI/ZHiIie80gyOmCu9/KQ+7SLvp7Kz/c9nIeziU8gj5NUsraykVERJcsQzDGpOZg11RvPcFdRnjfkwpzdhhC9JRG02YYXvpXCQ6FXitL0XAMPeLweVNsDxFRI+AzOURERJcpg6kX+hqL9HdERJ6jiYKcCpRnLcS8YW3QooUvOk7/AnnVukVb+0x3vHEl0uymWfJX4211ucEI+iAT+dsnINz+eZmyNCTP6gXfFi20vKesRHxmiT5RrjdzGT7Q8z2StxiRA7zsnvupu1wKS/5GrHrRV86jrEOWY8kBZFqXd5F/nWUnIqILZ8lExpIgBKl1tHz5PoWh23Lh7FK+Im+XrT4PehnR2db2QmffpgTFYPv3Z/QJ9uzbDr1deDcFaWXWBsT+WZ4slNi3M1M2y/kcl/caFYeN+b/pyzp7bkbm92mknL+dTDsE8/4piJBtTYsWN6JXbLreHinkslXTlHLJ6bM+tysXEZEHEw2kPllV5kWJMcZgEZxiFufkf2VHpoup/b1lHqEiLPt/QhTHiQgT1DwRkiB2V1oXTBXL/YaLsMxi7a15kZjmM0RbRlG2Qczt6y38lxwWP6rvt4kVT7QWME0UUXlnHfMNHC+Gff6dMCffL3x85ovEssq6yyUp65zoP1lEZSllKBf56aPFSKNRmJZni0pX+Rd/5brsdFlrwFORyCO5f46UC/OH/YQxYIFarwuRJzLe8HOox4U4JnZNVer2EBG4Mdt5e6GoPCg2j/AWPtOSxRElKznPyuevE/1hUuv8c+pMsq04MEwEGMfo9bt8nzlJjJJtgXHMZnGoslKUpAQLk9IuyOV8Ji8Rr6fni0ql/ZDtQyB6C//X3hFhazPVcmjtkNamKO2Q/bLO0nyemCUmfanlp2y3yb69UvO6V4QeOKWVS5Yz0KHskmy3pletjxoa63Yim8Y+HxpsbW4XXG80HCvUEpG7tIvMw64RkgFNQrDRMchRKuNWE2wNkFLZbxsvJqnL6HnYz6/QAw/j9F2iQHnvLF+FW+UqETnxt4jA5CJtskpvLE2RIq5YZlhb/i7LTpc7NoRErrl/jmj1dlWdr9S1alBwq13dXa3e1tkHGNagwRjsWJdXZoeJEPtAQdb5K4NaVWs7aq6zxnKK6u2Twkkb4mxZd9KU98HGGbZtdLY+pW1ikHPRsG4nsmns86HRu6tZjq7GsvU3oPu1f6z/A5Rtu6NHwErE3D4WQ9fsRFqZAd73L8WiHr+TGWcgPekEjH2vQ3f7rWo3GIOHe6NifSq2uhgq1K1yyXXs3XwYaYN99Fv/yqsrgheUAoXHkFlo7V7ghKuyExFRA/FGt/HHcG7+3TApXc3WDMcLT+1CoT7VFYPvANw1UFbnm/Yho+IAkpf/E7ilWptSjeXoFiTu7l2t7TDC+/ZHMNL0DdJTD7u17otBGVgg9Vwswtr9oHVvmxCB+U1VGCKiRtbIQU4FyvNy8a3+rt4MwRi9ZgUWDNyMpNEhCPK+D0Ef5Gj9rMtykZvlbJR/H/jd8P/buxP4qKr7DfhPwqRYwSD+Da8TY/UtSCAgKDXaYnhJCE1cWizWoCBbcYGGSgQEwdIGFGVRUNCENQhKiU1ArMqSkECoASJRW5BsCC2QSdIShWxSlWTOe+4yayaTyUoyPt9+hpoz95577r3nnHvOzL2/CWhkEuJhueQ2Cg/2R3hauTIVdXqlIMHdhMVd2YmIqPXoz+QMu24TkrrMxLxNkTDqb3mqe4PXFHturh3XBCM4xIDaY2dQdMUegdGeyXn29n54+B9DcM8f4zG3qQeCiKiTukKBB5rP98bJmJX8X5QcisfSRw8ha2wMRqaehbmxC4qxDwYYf6T/0UzKNoadRN7np5s1OWmo7PwBNiKi1mLCp0vvxV0pozDj4makjA/FjV30tzyk3BEQ5NHV0YDuNwXjNpSi6OxXLvvyencXtBs5AfvkSTw29CTOrTuLvD/HIOymbvp7RETer5273hZ+hV+5GXGbz8iuuxsChy7Ec8nHkDn7HPJzT+O/vkMRFnMzkL4XqSftI5aVo7joIgJmPIiYHg3trofl8g3FsEeCUD7/CYQ7RKiRF5PDf8LCAjeR0tyUnd/mEBG1ksoPkPqmCYbQwQjr3rRLnLn0Yxw6OBKjfzsEPTy81dm370N4JLJcvcUt234x9Zt/La8r8eWJL87iaOouZBkHIbxfU38TiIio82v/z5d6TMKM10MR8EocRuqhLpWQzB9kXpRvpiKxfxgi0r8CLp3H19/JpC9OId86mbiErtMWYOLhMu0Ts5oi/OvfXRES2hsB+DH6PvYiloftROLvlyFRDb/5DUrTZ2Ds1lgsnHCHXEZq6BYEj8r1Pfo8MB5TjCeQH38/Ivy76M/l+KFn0h14KPgqN7fNuSs7ERG1Csu3+rnHkF1jlv14Krbvytc/vLqAQ4k58r8D9duYP0PqnpPaB001u7EpLhE5byxHwt3XyoTeCH9mJqZgCeKeXqOFdDYfR9aObNTIHMqe6o8fz92PMt8IjHkpBuHpCzDmuXQtfLNcLnPREmyW68eHKnnV4lLlRShXpdqvK6FcVRTm6vOQVzvg6wqUWy5zlmvI95Uov6QkWtYtQ/mXpfqHYq5uk3PcxtdyaqXtoyxzYZXcWB5yt6XiqHog6lD7cRJSKy+jpjAbubW1KM/JR76lDERE3kC0kqZlVSoKkyNFuFwHSvjMl/eKjMTewjBhuVjwfr6o1iPAKHlqLz26WcU7Iv7DIrt17cJ/6upM20RSnFFfT+a9KEWk6BHNtMgzdvk6RdZprFyW7dTfxm5xoKrOff4elJ1+uJT6QkQN87yN2EI4q/1s4hFhuqBFEAuYuV3tqzWlomBXrJgTZtD66/C5InaXc58s88qPty5jmPCm+PueySLSMEHEbE63y6tGlByeacvLOFHEvJOjhZ22RulUyqO/otaLw3ssYaAtaUkiL8/5GjJH/OUvw52WWyVSEhzzM8xJF+esYaUtaZmiwhIWG0ro6s3yWnhWiyoXPl/E51+wC0Wtv5yjglKLKceViDTt3R58lH/kRltM+UajlbIi+sFh+yFyj22EOiPWWyKb9m4PV+RxSCIiIiIiorbCSQ4REREREXkVTnKIiIiIiMircJJDRERERERehZMcIiIiIiLyKpzkEBERERGRV+Ekh4iIiIiIvAonOURERERE5FU4ySEiIiIiIq/CSQ4REREREXkVTnKIiIg6kppkLLu9BwannkWtnnTllaHg/YXYMOMmBG4o1MtVi5pPxmGYXywWmr5XU9pEdRZ2b5qGWb0exPTCb/VEIiL3OMkhIiIiN2pRtW8CIkcvwlNv1Olp7eU09i96EA88vg6vlXfV04iIGucjJP2/W8THxwetlBXRDw7bD5F7bCNXnrlwOu7rvxNfrN+Pc0/2g0FPb3tVOLluCIKnDUFswdtI6HeVnt7xsd4S2bR3e+A3OURERERE5FU4ySEiIq9jNqUi9YUBCPTxgY/PbRjwwh5kVZu1N+2f8cj/EpnPBsIn8A/acyXmPOSuiUCEup58BU7CmF1FKFdXrEVN3jq8+0YEet22EVkVWUizbCPieSwsqFTztqbJdccdLtOeX5H5HkmaiyW/CURE+ikUvTtS30Y0It4t1PNXfIPS7KWOz74oeW4Zg4l+v5XlPW0rn33+OnNJMjY9I/enXtmbwX5fIhZh95lL+hs6uU85W+s/K+NQBvnym7gSq/PlsVE5HsMTxasxf5gf/B5PxfHjrtLfw3Hzj/R1FZW2Y+di/5Vnh4o+GodJgdq2fSKew/Td9sdXIY/xkVmYK/O3LBOXU2rLx20dIKJOQ7SSVsyK6AeH7YfIvSa1keptYknA3SIy3SQuyz/rCmJFFIwiYEmOqBSnROZsfzU/IFwMWrxPnDm3SjwbEC5icv4jTH8NFYawFSKluk6uWSxyXwqSy8WI2IL/CVGRIOYalfXkK3yuiH37iDghF6szrRLzwgzCMOFFMXVeijhQpSQeFTsmdhOIShIH6v4nitb21rc5UIQsShEpxd/J/EtFQeIgYZRpg1LOyLJeFpXpkfJvZTmjMK4vEHXO5V20RWwzyXUd8ld2WpL7vewXXdX9PC//tJRLW/dnIjytXFvOE0r+4/1FwLNp6j6K6l1i4x9uEUNdlks/Pvbr6WVQyrRcKYOlnA7HcKoYu+dLYUq7X4Sr+dRPDwhYLs9FjX78Gtl//XwZJmwWGco5qHd8FTWiZO8oEfKU5TydEEdeDpHLWPahxn0daCJlf4hI097todW2xoZM1HxsP0Tued5G9IHunEw5xNXpA9mu1rRKfdDsPHDV0m3rWiYddhOEugyRFGk3aFfpA37jfJFQYUl03oaLvBQuBuuWSZkymdAG5q7K21D+9stoaQbDPLtyeUIf6Efa76OH5ZLHZ8Od19nto4tj4/IYSg2le7T/lvLZL6Nw2r7cxvqguY7HQ594aef9kpqv2zrQBOzbiWzauz3wdjUiIvIe5iIcyyhHwK2BCNCT4DsAP5+fh2+Xj4BRT3LNH32nnsJlZTn1FrFxeHpSJsr0d9uEbzAGDr0BSN+L1JMtCY9sQPebgnEb/oX8czV6miag9jTyypoQ4tmcg7T1/wCG3ILgpo4SfCPxRO7XOBB1rXZb2gujMH5Flf5mW6rCqYNpSDf2wQCj/e1tN+PO6FAYy9KR+skFmE++h+2m5Zh+bRfr7XQ+107HcnmSa4+dQZH5x+1fB4ioTXCSQ0RE3qO6CEUftyDMsf48xrDrNiGpy0zM2xTZyMSo4/DtOxVzZ5cie+suZCrPH5nzkZuWj7LwXyA8yH7g3wjlGOY7PunSFNozOT9Bz2VVKBy5BVtm++vvtKVymL509dSMZfJXiqKz51FVXIT9hnlIqKhTPlJ2fKVNQbgyKurEdYCIbDjJISIi73FNMPoNB8q2H0a2HmfAcyZ8uvRe3JUyCjMubkbK+FDc2EV/q63V+waiGXwHIWLmAswP2Iy3g7vAp8u9GGtegpR3piOmeztd7muS8WrM7zDvhp0ofXsOFg7tifY5hAEIujVAnvhTDXxrFYjgm3vBX054RtR+gazChr5duoJ1gIhaFSc5RETkPXxvwS23Xw2kL8CYZ3fYIqopUb0+TkJqpZuZT+UHSH3TBEPoYIS116RA/wbCMH4kRvdo4TblBGNZ6Dnc8OdMbClVvp0oxfmVkxDTlG9xFD2iET3OH7VbM7DT3fGqpxZVR5Lw+pGBGDCkt+12wXbhjz7DoxGFbOz8+IxdxDV53pVvb8LGIXbodfDt+xAeiUxD6ug4p4hpJuTEbUPexStRB4ioLbAFExGRF+mN8GdmYoqxDOWvPYwIf8uzFz/BTw8NRLg6kWjg1qZrghEcYkBt7jFk15hhLknF9l35+vMYF3AoMQeVl87j6+/kn99XovySPgEwX0BFuXKLXBXOV1uG15ZtXEJ5pf2zNp/ZbidTQhmnz0D8qsfwxxlh+i1RtbhUeRHfy62Wf1mqD8JdlbcKVWpBLPlrE4w3ypY5Pm+ivm7DgCXZyFM2ac7Fe5O6qyGhE0saek5HP4ZYgrin1yBZWc58HFk7slEjy1X2VH/8eO5+fGUtg+U5INutYXmfn5al/g6lRxKw9xM99HTVUSQe/Lrh2+EavE3O1bF03n85oOk3Hy+91EWWLw737itRJzrmkkS8+FgNhv/5EYxWJi2+P0f0U3fAWPY2Un/VD72sx+g+TA27B/17NF4H+HwOUSchWkkrZkX0g8P2Q+Re09rIZVGdt1IsfbSbuh4QJcJXp+khg/UIXmq68rKPmqWsN0NMVEMcy3USjwjThQQxx2AQATO3ixNHnhJR1vWUV4yIzd5mC4lsScs76mIb/7VG6Qp7Y401tLNhwgqxKq/Cun1tGbv8wseJCdYw0Ja8TtiFb7akyX2o3iU2WPfZ+aVHHbNEc5NpDhHo6pHHIj9ezLGW803x9z2TRaRhgojZnC6PZYlTGSyhpS1hm2Va+Fwx40ixuKjukzyeyQWiQo2AZllHvvSoZ1pktPrprs9XA/uvqDshjiaGW0NSGyYsF/GHSuTe2KsRJYdnWvcNxoki5qNCLeR1I3VArUNNoORPRJr2bg8+yj9yoy2mfBLSSlkR/eCw/RC51/nbSC2q9t2LflEVCE7biwNR1+vprag6DQtX/B+mL7zT6Vaxb1C290nE+axCSrT+jjkLi1/+fzBvQX8YtBRqA+zbiWzauz3wdjUiIqLOzpyL1LC5KH90oItnYbrimm6RiPn5/+l/f4PS3Vm4blJvTnCIyGtxkkNERNTmvkP1RSWi13e4UPmN+rxIq7p0Cv/uVoTU9VuRmFepJyrkhCb7Nbzue58W2MCch0OLX8P7/+9MxN7UwmhuREQdGG9XI+oA2H6I3OvcbeQ09j87BJHWH8U0wrh+P8492a9Vv0kxm1KxY2ciEmdkIUtNGYiQRfMw/be/QuyAHmoKtS/27UQ27d0eOMkh6gDYfojcYxuhzoj1lsimU09yiIiIiIiIXOm0k5z2LDiRN2H7IXKPbYQ6I9ZbIpv2bg8MPEBERERERF6FkxwiIiIiIvIqnOQQEREREZFX4SSHiIiIiIi8Cic5RERERETkVTjJIaIflppkLLu9Bwannm3kV+dN+PTlm+D3+Hs4btaTPNaSdYmIOqDqLOzeNA2zej2I6YXf6onN9Q1Ks5diw4ybELihsJG+uL3UouaTcRjmF4uFpu/1NBda9ThQW2rnSU4VTq7ro4aQc3hFb0IWBwJtqBaV7y/Fukoe5M5N+dX0Hk7tJ9B2gTBnYtNIP6f370RE+lfq2tSIyq1Y+FG5/kcbaY9tEJF30Pt0v7n7UaYnXTny+rPoQTzw+Dq8Vt5VT2s+c+Fc/G7YfDz1Rp2e0pracszTuseB2lY7T3L80XfqKQhxCpmz/QHjfCRU1EGkTUE4v1NqO+Z/IO3Fi2iLroTaU2+MeLUSoi4DSZEGICoJB+pKUfpkP8i/ZGuOxJSMy6griEUUjDCuL8Bl8SkORF2vrk267mPx3D8rcSzmZu24qb5ByZ7NyO5q/6PGQbjz+WJcTnoIg5rcP7la19U2iIhcqUVNbhLeyaxF7dYM7LziH1Iq159iFK3trf/dMr79ErBHvVa1gWaPeQzofvc2fHw5EQuDfqSnOWvd40Bti1MLr1eGwnVP4LHjPNVErsnBRP7zmD/hPOra7DfK2mMbROQ9zuLwK2UYveoXMJZ9iHXpxdo39l7E1zgAgw2t/c02xzxk04FqQRkK3l+o35+Zj8r817BsbHf1dpxes3Ygq1oZJFjSfOA3MQHJJfo9kw73R/4XRR+Nw6RA5VadaES8W4gKmbct7TYMWJKNPOVDEfvbewKfR6LySYnDLT9j9PstZdk+nC+33UOW7RhMR2Zh7jBlGbu8rL5BqfV9mUfEc4jLKXXbOZlLNmOlul9KefNQsnsa4gornG7ts912ZC6cjmhLunqr3/coPfQ7bf8insfCgpPYO26jTK9A4Zp7MSL2OGprl2L6tV1s+6nkU5KMTc8E6vnLba/J0fdFHuu8dXj3jQj0uk3mU5GFtBcGIFBZTs2/Uj3m1rTASRh3uMzrOmBv4VBf5Mt664NzXc87jSNJc7HkN4Gyrp1C0bsjEaG+p7Ujh0uROQ+5ayL095U2ugWplnuY7dtj/pfIfFbWscA/6Pc4y/bhsq5qq7rN1+N26G4bzveBK/3KbEwfuRrv1H6BrOgAmZ/W1symVKRa2oBc1/k4Wm+zddGPOK5rdrmNYQue8Oy88J5voh8cc+FKPB64AJP+8CIWRxbi+MZMZFv7OAv9Wi2vxX4jN+Gf52zXdIcxksKhb1X6qkkYs6tI79eVfvEVNZ+r5u6DqWCh3rdaxl/1NixV2q4RdmMAj683DfVrbsupk8t8snWMPqZT9nUlVufLcYnckrsxj8O4Rd23jUjMU9bTyXxztrp61sZ+/CnXm7Mfxa4OCXU8opU0LatTInO2v4BxvkioqJN/XxaV6ZHCKPMAjCJg5hrxYnaJqBM1oiTtfhGOgSLkz6+L2LfzxHm5dF1xvJhiMAjj+gK5jJ6Xum6UCF/9nkgp/k4udExkzDbKbUwUo5euEi/mV8g1a4Tpr6FyOzEituB/SkHkckfFjond7Mpil6YuV+NYtkdfEDM+1spWLy+lvHtHiZCnUsSBKplX3Qlx5OUQp2Wc1GWI9UHjRGyeUj75p2mVeDZglL68Zf9/JsLTytX3NZdFdc5YYYxJFceUzRTEiqBfJ4kMZZv6OgEDN4gD6u5UiqK1vR33T1K2Mz1kpojXj0tJ9mQxwXJMKxLEXKOyv/IVPlce9yPihLIduc68MIMwTHhRTJ1n2Uf9WEUl6duj5mhS+5F1JinS0OAxV+pDlKyryrm8bEmznLs5maJUT1NVbxMvG58S8cUVWj1R67lsb4tStHYkly5IHCTr8EAxKOWMlp9sW/ueHCLCkwu09mh6S6x41FIH/mPXHsPFoMX7xJlzSp0OFzE5F93XVbf51nncDhvehmMeDsdHPWZ27cy+DdgdZ8txrHfs5TlJHLRUpFTLxIbWdd6G1Ph5Uc4BKZrURog6iObV22JxdF643qfp13BX4wiHa/VUEfPax9q12m6MpPVxWj9pCFuh9VEy/9yXgqx5an2Tlo9hwnIRf6hErifHGXkzxESZv2HKDnWsYSuL7NsXbRHbTMpYq/4YwON+TZZ/ThPKqVHSbhEBz6ap+2q9Hoav1NdxPeZRtr10sL8IWXNcvb6I6l1ig3J9MU7Xy2M/lnQ81trxjBSR6SbtuJyYI2YPVZZ1cU7Irfbux1tta00ruPMkR6M1NMfBh6UROzSWeoM8V52AZeLkNKiotw1XZamfn6uy1UtTJyxzHRuWq/LbUxp512l2gxlZ7l1TxQzrfmjls3UyilNi3+Qhetm0/ew6ebvD+3vGupvkVIrCRDmYdJg4OR0HlwNpz44VNV2T2o/l3KidcUMvp3ak1xOD4feOdS0tWgRZl3PdZpwvYkq9D3o6w64+O6/XUJ1wX1cbz1dbxn07dL8NRcN5OO+3qzbgqj1JFWvF2BV51vxcretyG3p53Z8XUij1mqizaVa9leOCp4PWO/UdDYwjXPVT9dK0fsu2fv2+1fVYxflDJFd9u6s0D/s1ZfzjMMlprJzaB7xhhnl2/a/2Ie1jXS1prvpoPc2hL5fq7bOLfVGuf+P9na6nrvaZPNHe/ThvWmxF5pPvYbtpufYVqeWr1munY3kZUHvsDIpcfb15TTD6hW3EoruexJgt+5BV7Qv/+9diVb+r9AV6I/yJ8RixaRMW51ZoSZVp+CBjGmL6KssY0P2mYAzf/DB+NvkV/OlvBSiX69y77YmGgzmYc3Fox3H9thm9nD59ELmiCig7hbwyu6+4qeNSAw+oH1Q4vOQF0cXDnAb4R87H2mGbkLj1H/pX/2dxNLkco4bdYvcAvgu+wRg49AYgfS9ST1bg1ME0mN4YqX/lr7z80CMqE2UoRdHZr9Dwt/ju6mpVo/l6djtkM9pDk/ij76OzMKf8I6R+ckFP+wamlDMY/rgeAKJJWnBeiMgLVaFoWxK+SBpt7bN8+83Cc7P9WxCAQAv6dHn5CBiVW7a2jMPTk5S+tTHdYBwUituQjZ0fn3HTtztrbr/WWDkvofSfR5E94laEXGPp0Lsh8J63sPXbJYjt0UAnL8c82alnYRh8C4LtF+kRjehx7o+r+eRmrNt6K4Jvvp79cSfUKpd9UtSiprgI+w3ztIhxTgPPBiPI+UZi8pYNWDF8B1InRyHC/756zz/49p2MqROzsHPH57Kx/092gOtwcGUUwvT8fPstx1vZkzEuYy4W/yYEvSzPzTSkugiFB/sjPK28fjlFChKsEyzyKr4/x73TBuHin95HqvLcSOFK/K56Pqaqk2VPVcH0ZTkMczJRWq/uaJHe3HUqDdfV8kbz9fQC0+T20FTywnhv3FlkrfhAfyYnBykHRmBUQxfYxrTKeSEir1CzCx9sa+hDyBYEINCfdRl23SYkdZmJeZsiYdTfahPN7dfcllO7TjSZHPMU5bs6agEIujXAzYe72rjuC/0v6nw4yWk12ifII5QHiwtlZ9QEvjdOxqzk/6LkUDyWPnoIWWNjMNL+hwp970BU7CiEvbIWi/NP4O8v34upUTfZDfq0TzK2mE4g550YTCxagkWRf2z4x6yuCUbwsJPI+/y0w2SKvF033Hj/TLwU+hoWp/wTJw/koM9T4fA4PLKxDwYYr1cvCrW5x5Bd05xPFBuqqy3N114T20OT3Yy7Yh5AuPrN1rcwF2Xg04m3t2DA0MLzQkReohZVh7dg9cQvcNn5w56KBMw1nmggAEFjTPh06b24K2UUZlzcjJTxobixi/6WRwLVbzKa1iU1p19rrJz6pETvez2mjHlCDA3fUaNe2xoKGU2dGS+jrci370N4JDINqaPjnKKBmJATt02P7uSkcjPiNp+RXZscmA1diOeSjyFz9jnk59pPQOQEKvRxTIjcifVTZ+GPMVEYbf3UWHaKu+ZjsTKA8x2Au8enYEtBAuaU/x0H8xuYbPmGYtgjQSif/wTCX9hjFzmlFjWH/4SFBYzm5LW6P4DfTApCWfzT+P/ioxBz93X6G+7o37KMHynr3dXoMzwaUVmzMC72dT2ija4mFXEbCt3c0uCurl5uNF/PPr1sRntoMq09jo/4AKnvZ2LvmwEYHfZ/+nvN1KzzQkRexXwQf318MOaP6Vv/m+se4/F4fG85wH8PiZZb1z1VKfuqN00whA5GWPemDPssd6j8snl9UlP7tUbLeTVu+OktMCIVib9/wfEb+prdSDz4tf6HEznmCYu52cXkqBzFRRcRMONBxLj8Jt4A/7sewgTjZ8jOOO7B7X3U0XSgSU4tLlVehPJZa+3XlbioJcJcfR5q4OSvK1BuGT1Zvnr8vhLll5TEKlR9/Z38/0sor7RU4O9QfVEZ1HyHC5Xf6AMk21ePtm3cjDujQ2Es+wzvHS2TAzQllGIiDhZcku/JhtQ/DBHp5118ZemivL4/R/RTd8i83kbqr/qhl/Wr5vswNewe6+1lji6h67QFmGgJwVxThH/9uytCQnsjQH1f5zscDz83HAHZRsQ8dY/jp8Y/ysXieRv0cJFyH0uKUNrlHgwP8Zd/652C+nXs/1DzcRJSK7ujzwPjMcV4Avnx9yPC3/IMkR96Jt2Bh4KvksU6D/WQWo+xZL6AinLl57WqcL7aMuS0fH1sf+yp47I8U3IUhpcm4SmXHbvs0LfuQqY6+ZXtIX0G4lc9hj/OCFPrnXb7ZDfUvjMbcQOu1euOfPU9iJ73/VR2Km5uKXBTVxvL12DXfm2c26HcH7ftwbJ8Gcq/LLV+kKD9XsMx7Zkiy8XS0ga+OIV85xCq1g8KnsQTt9+P0c4XZBfrutyGlSfnhYi8l/L7LrPw9Nhouw8x7flrHwRhF1LnrUKi9Sc0XNyK5Xz9tnyToX9Tbi5JxfZd+fqg/QIOJebAMl2o3foXLNY/ZDKXJOKlObkI2TZN75NcXe9djb8s3PVrsm8uzEZubS3Kc/KRr3STjZbzU5gjl+BNeZ1A1hIsCrG7Tvy6CAE/6ymXcz3m6fvYi1getlNOjpbpx067to3dGouFE+7Qx1uWffkX8s/VqCnoMQkzXg9FwCtxGKn/VIHy8xsfZCqjPssYUft5D+qARCvxLCtLRAqnSFBRq0RKglN61HpxeI8SVcM+LUnk5WlRRhyWdXgpUZP2i3QlCphD2mci32nb1ogaVRkiNc6opU1YIVbllYnCtcFqKOv4nbniaL310sU5NeKHi7yUSB+HZ4o5SphZ5T3jRBHzUaEWstCVindE/IdFojA5UoSreUVZQ+g6UyKsGI22iCuay6Ji5xKx9tzn1n1A+Hw9NLTOGipxohh7qNQaIaTOtE0kWdZRwwbvVsNCWyK5WPZNjSCSvc0WqtKSlnfUKcqXc+Qo8pRy/BqnR7ezHm/lZRclzGXUNRfnRC633viAi6gwtkg2YW+s0UIlyzy0NmFXnxR1J8TRxHC9ztotU68M9tv3oK42lK+LvsN1O0wXZxrchmX/bMvbou3YQmWHvPyxMF2wC82qvupH0dHCij5U/zjqEXvqr+u4DTX8qb0GzwsplGNJ1Nl4VG/r9ZvO/Y2rsZNRBDw0ytpXqi/jfPH2mVWO/Y8aZex7azhodYyReETt45TIZgEzt2s/B2GJNDZzvfir8vMb6rp24xeXffsJp2uSp9ebhvriusbLqag6IPYuUn6eQ1lO+dmRDSLhhN11xOMxj+WnEhTO11f7CJyldmM0pf/eKzISe6vhthe8n9/w+I7qUY5te/JR/pEbbTFlJt1KWZFLtahM+y1GVK7GJ2Nurv9VNnVq7dp+KhPx1Ijr8YfcMU73R9eiat+96BdVgeC0vTgQdb2eTu2iwfNCCl5jqDPqNPVW9j/P9Z+OleMzcU6JbqYntxj7NbLT3u2BVa6TUL42fvF3/fF4tH3AAaImMh9HxoLV+HLJCF5wOhKeFyLyNuzX6ApjtevIapLxyjA/debbJWgD9q36Pe/Vp2Yw4dOXb1LrkU+Xwbjv0stYNdLVtzSunmOjtuPpeSEialsun39uFvZr1HFwxNyRXd0HvX/aVf5HFMKTU5ERw9vUqDl6wtjHCOV/ATO3Y9/rv3Hxqdpp7H82EEGP5KIMJ3B8zC/wE48jmlHzeHJeiIjaknKb8kgE3bQIm8rkX5t+i8H3bXIdDdYj7Neo4+AzOUQdANsPkXtsI9QZsd4S2bR3e+D8moiIiIiIvAonOURERERE5FU4ySEiIiIiIq/CSQ4REREREXkVTnKIiIiIiMircJJDRERERERepWNMcqqzsHvTNMzq9SCmF36rJ2o/KOX3+Hs43qIfpmoBl+UionpqkrHs9h4YnHqWv61DROQt2LdTJ9YBJjmnsX/Rg3jg8XV4rVz54cuOoqOWi+hKO42PFh5Amf4XERF5A/bt5F06wCSnN0a8Woyitb31vy2CcOfzxbic9NAV+rXchspF9MNmNr2D+NI6/S9d97F47p+VOBZzMwx6EhERdR7s28nb8JkcIvJczW5smvMqjl/LroOIyGuwbycvdIVqcy1q8l/DsrHd4eMTiF5z9qPY6bkbsykVqW9EoNdtG5Fl9565ZDNWqutFI+LdPJTsnoY4++dlqrOQ9sIABPr4aHnP2ojEvEr9TbndvHV4V8/3RPFqzB/mZ/fcT+PlUphLkrHpmUC5jLINWY41OcizrO8m/0bLTtQY++fE8r9E5rOyHgb+AQtN32vvm/OQuyYCEdb6vwWplvckx7rrA7+JK7E639I+NGrbs7ah2zDghT3IqpYVWF4ENz45Bk+++w1qX4lU3/ebux9l+A6l2UuxYcZNCNxQ6HjftiftUb7vN3IT/nnOVja/iQlILrGVW9mvnCVKPkoeO5BXnIhxK/Mdt0VE1Fk10rc3PO7QtG/fbj9W0svzRrqWl+V9D/t2jouoTYlW0pSs6orjxRRDpIhMN4nL8n/VJ+aI2UP9ZR4xIrbgf0JUJIi5Rqh5IipJHKizrJgh1geNE7F5FdqfplXi2YBR2jqK6m1i6WB/EbLmuDiv/r1LbHi0m4Bxuogv/s4x3/CpYuyeL4Up7X4RELBcpFTXNV4uSdnm9JCZIj5fKUONKMmeLCYYDMK4vkDUucu/4hP3ZacfNM/azymROVupj0odCxeDFu8TZ84p9ShcxORclJXqmNj35BARnlyg1v8601tihVL/LW2o7qjYMd5fBCzJ0dvHNrE8zODYxmTakoC79TYgVymIFVEw2taRbTAp0iAMczJFqfK3XKoyPVIY1TIZ1XagrKdqYnuMee1jcUKWQ2uHWpvS8qoUhYmDbPnI/cyYGeS4LfJ6nrURoo6lNfp2d+MOtQ9s175djo1yxoowwxR9PCP/zpshJsq+3DBlhzimbM/Tvr2xMR15nfbux1ttax4XXG+MjgOUSlG0trfMwzaZsDQ4h0YqG86crtO0AZJKNsJdU8UMdR09D/vlFXpjszZcV/kqPCqXMtiSg8i0cu1tld45GeeLhAqlFTeQv9uy0w+d5w3fRVvRKRetoKcz9AuUwnKR+plWZ2Xd3HDndXb116nuimKR+1KQ3UVOqjshjrwcIro6tR+HZSTLBdPWflrQHuulnRIZcUYxKOWMrW1WrBVjV+TZtVXydu19cSRqDS3v2z0bd7Rb3y6X2xjR1Wms5HStUXjSt3Nc9IPT3v14u9+uZj65Geu23orgm69v+kNs1wSjX9hGLLrrSYzZsg9Z1b7wv38tVvW7Smaci+zUszAMvgXB9nvVIxrR4/xRuzUDOyvtvtt14lG55DYO7TiOrOgA/Sta5dUHkSuqgLJTyCuzu73GmbuyE7VYFU4dTIPpjZH6rQjKyw89ojJRhlIUnf0Ktb6ReCL3axyIula/lWAUxit118JchGMZ5Qi4NRABehJ8B+Dn8/Pw7fIRMOpJHmlhe3QUgJv6X43jY36FwS/8RbvdrcdUbJsVwgdhici7eTLuaMe+3XzyPaQcGOg0VjLA/66HMMH4GbIzjnsenY3jImpj7TzJqUVNcRG+0P9qMtmQJ2/ZgBXDdyB1chQi/O9DxLuFKFfeqy5CUb6rO/QDEHSrbNZuJyEelktuo/Bgf4SnlStTUadXChLcNUx3ZSdqsXKYviyHYU4mSuvVzVKUPtlPvSBp923/BD2XVaFw5BZsme2vra5Q2tDHTpF1mqtF7dGZP/o++TccedmMi/HjMX1gf/W5HNv930REXsrDcUf79O1uxkpywhIcYkDtsTMo8rRr5riI2tgVCjzQfL43Tsas5P+i5FA8lj56CFljYzAy9SzMjTUwYx8MMP5I/6OZlG0MO4m8z083qxE2VHY+PE0tp00eanOPIbumgStMTTJejfkd5t2wE6Vvz8HCoT3RRX9LpXyqNlzOP7YfRnZL5w+t3R71Tx1NxSlIWdQThtcexi+fef/K/VAwEVF78GTc0W59uwHdbwrGbZa7A/RUe/W+vW8Ex0XUltp5ktPMrzQtKjcjbvMZWfm7IXDoQjyXfAyZs88hP/c0/us7FGExNwPpe5F60j4yRzmKiy4iYMaDiOnR0O56WC7fUAx7JAjl859AuCUqiaoWNYf/hIUFbiKCuCk7P7WglvNHn+HRiMqahXGxrztG1alJRdyGPFQcScLrRwZiwJDetlsW7Pnegltuv1q2oQUY86z9NyWyfn+chFSPby+TZFtpfnt0dhp747QIhb5BMYj58zEUpkcCb+cim9/mEJE3a3Tc8Q2q2rFv9+37EB6JLK8/YVK/cRqJ0b8d4vntbxwXURtr/29yekzCjNdDEfBKHEYuyVZDICpfs36QeVG+mYrE/mGISP8KuHQeX38nk744hXxrg7yErtMWYOLhMtkopJoi/OvfXRESqjTsH6PvYy9iedhOJP5+GRLVEIXfoDR9BsZujcXCCXdojb+h22g8Ktf36PPAeEwxnkB+/P2I8O8Cy7MPPZPuwEPBV7m5Tcdd2Yk8pd2W5opv38mYOrEbat+ZjbgB1+p1U776HkTP+26Fv/4JnPaJ4HcoPZKAvZ9c0lauOorEg9ci/JmZsn6Xofy1h+3q90/w00MDEa5MSvSLpfYNzQUcSsxBGcy4VHkR38v/Kv+yVL84+Te/PVra/veVKL+ktX0/nz9g7DKtXSrHoPRUObqMvxNh17R/F0ZE1Poa6tv9Gxl3dLN+u9IufbvvcIx5KQbhyoTpuXStTzYfR+aiJdgstxEfeq2ylId9O8dF1MZEK2laVqWiMDlShMt1gIEi5OW9IiOxtzBMWC4WvJ8vqvUITEqe2kuPNlLxjoj/sMhu3ShruFyLOtM2kRRn1NeTeS9KESl65A4tSohdvtbIIxbuy2XZTv1t7BYHqurc5+9B2emHS6kvjbJEprHWMbtINhZ1J8TRxHC9jkHW3RVilR6eU6nfBYmDtJCg4XPFjCPF4qIaEce+LirhQFeKpUqoZzUP+d7qNLV+a+zChU54U2wzXbILM6q/7KLpNLU9vn1mlWPbV9tQmfgwPl0U58eLOUpYVCXs6cztdmWiHwKlPhB1Nh7VWw/69obGHZr27ttrRMnhmXp/LNONE0XMOzlqmGiFx337vz/guOgHRjn37clH+UdutMWUTwVaKSuiHxy2HyL32EaoM2K9JbJp7/bAez2IiIiIiMircJJDRERERERehZMcIiIiIiLyKpzkEBERERGRV+Ekh4iIiIiIvEqrRlcjIiIiIiJypT2jqzGENFEHwPZD5B7bCHVGrLdENu3dHni7GhEREREReRVOcoiIiIiIyKtwkkNERERERF6FkxwiIiIiIvIqnOQQEREREZFX6cCTnFrU5K3Duy8MgN/ITcgy68mu1CRj2e09MDj1rFyroypDwfsLsWHGTQjcUNh25TTnIWfrNMwK/j9EpH+lJxI1lQmfvnwT/B5/D8fdtb1WI9v7J+MwzC8WC03f62lNUYuq9HtxU1u2rYa0Z/9TnYXdm2T77vUgphd+qyd2EOZcbB8TyH6HiIg6hCs0yfkGpYcXYtnY7mo4OR+faES8kY6s6lJ8tPCAnA5Ilevx4i+nYWx8Pmq7qCt1YnIAtm8CIkcvwlNv1OlpbaEKJzc8iF9MWIfXTv6/elp7OG07b9R2zJnYNNJPbzOWV6DjpLkyEc8FunnfpVpUvr8U6yrbZTbTRs7iaHI5Rg27BQY9xfucxv5FD+KBx2X7Lu+qp3Ug1bk4urMcRWe/avvJHhERUSOuwCRH+cT2STx2zxHsffBTnBcCQryHv9y5F7vvvxmjL+nxs3vEYllBAuYatT/d6j4Wz/2zEsdibu6gAxwD/H+ZAVNBLKL0lLbhj75TC1GZHglPDltrMZveQXxpW07eSOUbiSkZlyEqtHZhmJOJUlGK0if72eq90m5KBepkXQv6bSqO1Tm974r5H0h78SIcz2AQ7ny+GJeTHsKgduklDOh+9zZ8fDkRC4N+pKc1QWUaPsiYhpi+V+kJ7ajd+p/eGPFqMYrW9tb/7giqcHJdH/hELEJiza8RNX4QRg/riVNrBsPPbz4SO/XEmYiIOrMrMMk5i6Opu5AV9Qjix/RDgJrWDYG/WImlyX/EoAq7i+I1wQgO8d7PZb1CzW5smvMqjl/bge98/KEK7ImARk9LGQrXPYHHjnfm81eLqk8+wM4/D0MYq2E780efB5Zg9XABvzdfwt+Le6Lsb1uxxvAHxGc9jad68IQQEdGV0f5XIPMZnPnnJeCLz5FV6njvvW/QBCwKdHdv2mnsf7aHw204ZuXWt+ylTs+6lKHgw/lYNraHTDsG05FZmDtMuc3nNgxYko08tx8uyvysyyvbkeu8sAdZ1fpK1VlI2zIGE/1+i+n5p5G7JgIRynKBkzDucJnjbRrKsi8MQKDyfsQi7D4j97tRcvuHfodJyi1HEc9jYcFJ7B23EZ/U2t2qFPi89gmpw+1LY+rfo19nspVPuSXw3UKU62+pzHn4ZOsYbVtyGb+JK7E6v1K+oX86q653p36PvX2afuzlBGfjk2Pw5LvfoPaVSHU//ebuV29bM5ckY9Mzgfry9nkrmnB+ZBlt+xCIXrO2INX5mQ3746wusxGJedq2zIXTEW0pg6Vsdmk+0bbnvcwlm7FSvYVSOVZ5KNk9DXEd7bmHZtGfb3sjAr1u24gTxasxXx5vv8c3YPcb92JE7HHU1i7F9Gu7WOuW2ZSKVH15h+fhGqwzGvfnvaFyvIfjl09pz5I5PWviPj8L51vVWrENO9Q/p3xUrvofnZt6adVo/ZbHLP81/dZe+f6c/Si237xFg/k4HvOsCvs+SelfZHnsy1nvGDRyLCXfHgH4yTV1MFV1QU89jYiI6IoTrcTzrGqE6a+hwiiXB6JEeOIRcaJOf8tZXYZIijQIRCWJA+oyNaIkO1bEzMzS17ksKtMj9byMwri+QKY4pgU8+oKY8XGJqLNuN0bEFvxPWdmluuJ4McVwr4jJuSj/uiyqc8aKcD3vOnFKZM72V/cVCBeDFm0R20zfyZWOih0Tu9mVU1LSxvuLgGfTtLJW7xIb/3CLGGotp2t1BbEi6NdJIqNKWUnub9r9ImDgBi1fy3aM80VChb4hS5p1vyz7L/d95nZxQM2nVBQkDpJpA8WglDP6totF7ku32MpnOdbhK0VKtbZt7Xj9TISnlatr2NLs9kFfzzAnU25FZ9n3JTnivPJ39TaxPMxyHus8Pz91x8S+J4eI8OQCNZ8601tixaNOx1nmvXSwvwhZc1zf1i6xQVnGOF3EF8tzI6nn1AiHMlrSrHnJ/VgfNE7E5lVo75tWiWcDRrmtK62pSU2xIkHMddofZ2o9ejpDe19fXq234VPF2D1fCpNSrwKWy3NdI4rW9nasU/bL2x/rxuqM2/Mu/26wHE+IZ8ddraU7nP9G8rOQ+UZGpjue29Zow+r+Btnt3zGRMduor6sc/3Rxrl7/o/OgXnpSv7V9iRSR6SaZt9yXE3PE7KFK+T1rJycu2B/zuSL2ba2/Ver3PHksDRNeFFPnpWj9hItj4O5YavtaqdYfw4Q35XE8K/ZNHiLL9R9RmBwpwgzzbHWqFSj7QNTZsN4S2bR3e2i1rTWt4KXqRTBcufCqLznZWZ2mD8jtOExyLor8VdEiOk252DtSBnRRToMMT9OcKctE2l+c9YGZbUCpXdQdBhn10rQBuyHScTDW+Pa1CUrXydvFMet6p8SesfokxzJAsx+Q1tu2ZZJjPzmRHAYwdepgxXEQokwgJ4vHulrSXOdTbx9cTnIyxIY7r7Nbr365PTk/yt/WgbrKuUz6vtsNylTO56zeOZQc6pb8Wy4zp+s02wBU2dauqWKG9Ry3rSa1H1f746TesXPeXyv9GDrUKane8toA122d8eC8N1oOh8G7B/kp5ylttJwEONbRlrdhSakTBoNje1XTbnPfJjysl43Wb32S57B9F+VsPB9Xx9yTvkTL2/2xtOPqeLUiDhapM2K9JbJp7/ZwhW6YNiL40QxkmrYhKc4o/05H1oxoRAT/rv7tIorv83D4mdsQ+ePX8VHUjW36cK9vvwRkXF6C2B7/1W6pmjYXy5saNsycg7T1/wCG3ILgJh1hA7rfFIzhmx/Gzya/gj/9rQDl6I17tz2B8JaeKd9gDBx6gzzUe5F6sgql/zyK7BG3IuQaS8bdEHjPW9j6rbLvLdyYbySeyP0aB6Ku1cOAj8L4FVX6m57xRRVOHUyD6Y2R+u0+yssPPaIyUYZSNYKT2ZyL7NSzMAx2Os49ohE9zh+1WzOw09MHn68JRr+wjVh015MYs2Ufsqp94X//WqzqdwUeZO+QLjVeZ1rhvDvwKL+z+GT5T/DQXdfpf8vVWqMNK5Q6MRwo/7LU8TZPFLiPIOZRvbzUaP2+fHIz1m29FcE3X++mz/OgnehLNkeTjuU1oQgd0Rthg25o4wAMREREjWvhaLZlfG8ciymvn0P1iQSsVyY7ZW8j+eGXsLje72R8hwvlF1EW/6aL91qbdg/6s7f3w8P/GIJ7/hjvWYQ3e9VFKMpvcAjklm+/5XgrezLGZczF4t+EoJflvvlWVQXTl47DttamPUvxE/RcVoXCkVuwZba//o6nytUyGtQIYuo3jnYvLWKYb4PHOQBBtwbI+nQKeWUe1hc5oJ68ZQNWDN+B1MlRiPC/r/4zTD9o2vloTMvPu6PG8jMXrsSUkF9jtMPEvBXasML357h3bhR+/tpfsFh9Dkjm+8ku5NZGux/Ie1Qvv2qkfvfB/4qL8IW+ZsM8aCf6ks3ThGPpG4qYtEKk3H2tnkBERHTlXIFJjvNvqhjQfUAsnnz9S5j+Ggpj2XtYv+dfjp+S/mgIJq3dgOW91+Gl55OR6fDgb2vSw1sPPYlz684i788xCLupm/5ee9E+Hd9iOoGcd2IwsWgJFkX+sZk/kOiCsQ8GGK/XBlvqtzpt8GB9TTJejfkd5t2wE6Vvz8HCoT3R9J860gaEtbnHkF3TwPnWo+/VHjuDIleLqPvqeThi3xsnY1byf1FyKB5LHz2ErLExGNkRf2DWo6iDBvTqf6MevbA16AN0d3WmVc67nUbzq8KXB3LQ51eD7UKmt2Yblm1x5BIseOYr/PjFG+Hj0x03LhmIQUfWY5u7gbxH9VJrg27rt0c8aCfN1hH6QyIioua5It/kdM1+CevqDdq7wTgoFLch0OXtGV9f8wh+vy4WY5OfwNiE3Db6hF0Pb20chPB+LfgEujm3S6lqUbVrvvZtle8A3D0+BVsKEjCn/O84mN+C234U5iKcyC5HwIwHEdPjKtzw01vkwDAVib9/wfGboprdSDz4tf5Hc8h9OJKE148MxIAhvZs9yDYroWmHRyMqaxbGxb7uGFGrJhVxSnQ331CExdzsYuBdjuKii/q+eljFKzcjbvMZWXo5sB26EM8lH0Pm7HPIzz3d8b7N8b0Ft9x+tZv6ZcJnKRnw7+3uNqemurqROnO+Vc67jQf1yJyLv788EjF3225Va7U2rDIhd/FYLP1lEl5NrtG+HTmwDKt+Huj+uHpUL69upH6fQve7HsIE42fIzjhu96GQMw/aif5n07XmsSQiImpfV2SS0+X2XCya8CdM3213O1B1Jt5buxP7JzyNBb/QBi3m0o9xSLnt4/tKlF8Cuoe8jKW7ojBg/hN2n7DX4lLlRXwvhwG2e+drUVPvVg/LcvK/vq7ERS3RieV2kuPIKpSTCiUs67ZUHFVHGHWo/TgJqZXfuLhtpwpVX38n//8SyiuVQU1vhD8zE1OwBHFPr0FyidyqWea5Ixs1spxlT/XHj/VwxvX8KBeL523Q1lH2o6QIpV3uwfAQZZBxM+6MVr7t+gzvyUJp4bMTcbBACU0tB5/9wxCRXqE+13MbSpG396Ae6lX7LZRxYjWSp4fKvfSFf+QSvDmxG5C1BItCroV2L798/boIAT9TAsEa4C8HWeMNx5C373M1rLMSVnjHvnz1WFv24YJlwK1+an0BhxI/RZ1l+58rE4TvUHokAXs/0cNnVx1VB8SenB/fvpMxVZax9p3ZiBtgV8a+B9Hzvp8qe4G+j72I5WE75cB7GRLVYyaPSfoMjN0ai4UT7tAGx5ZJZ+7H2KmeizzkyPNaqJyy9McREfQ83qmoQtdpCzDR8kxYTRH+9e+uCAltjQF7a9PrV/krWLhok0NYYjX08wsP4MGq1/HmyOv1VKnBW6j0yYt6C9X/UKPWcXmyL52HWqW/OIV8tQ7J+uC2zlxvq3cNnnc5eW6wHJY29C/kn6uR/689n+Yuvz2rV+KF0VFOt6q1VhuWKj/A9rX5yIoOsO2r/vKbmGBto/X7H8/qZaP1u8ckzHhdttdX4jBSD62u3L73QabSOizt/avG87GcS7UfVc6lJNtqRbny869VOF9tOR+WWxItx8CTY6nn1wizaSEe9/NDrznpjYTwJyIiaiWilXie1SnxYfx+caHuhDjyzlQxRwkJK9d1jrCmRSyyRF+TLzUKUJkWEciSFrVOHN6jRBGyWy5qlUhJUCIE2dIcQ71a0hqITGUJ9QolBPNmkVJ8Vttm+HwR/8V+LUqRNR8letEJxzJZI39dFtX58db9U0Ks/n3PZBFpmCBiNqfXjySnuiwqdi4Ra899LlLj9FC1ynbztbDGqqoM63uGCSvEqrwyUbg2WJZ1jYjfma+Fq1W2fSJBrLfk0VD0uqoDYu+iEP24KPu7QSScsNuWPELWKHjGiSLmo0JRIc/LwICZInbjXj0/ua28GWKiEnFJDSOrRCezhKxWyj9XzDhSLC6qx1+WI/kzcVSN4KRsU3u5PT+ynhxNDLdG4tP22b6MchHTNpFk3deBImRRijxvlihpCvtzoby/W+RW7BXrjbfJ45Ks7XPFOyL+wyK7qH9KWbWQvO1BKXtT1RXL/VxtOzbqyy5MsIXrtmS3gDW88UQx9lCpqNMjaFmXt4845rbOuDvvBWrdcV0OPdKX9T0tUlldY/UocYhDlDOrVmvDdtuv91LKmKeXxy7dLoJZ4/VSarR+20eilHm8vFdkJCohm5eLBe9b2rvUQD71zr1yLrO31T+/eUddHBd5DNwdS/t+qRHWkO3WY9t0SrmIOhvWWyKb9m4PPso/cqMtpnxy2EpZEf3gsP10RGXIW7gLJ5+dgtHdHb/0Npesxv0rQ/DWipF2zwNRY8z5r+Fln99jQf+mRy1kG6HOiPWWyKa928MVuV2NiKhj+wYlf/0t7r0xDL92muAofHv0wahRd3CC0xTm40jb2A+jghmWnYiI2h4nOURE9VxE2elimLa9hTj7Zwcl5bmnxa/3wPBh/6enUGOUY/bGC+fw40XRGMSrDhERtQPerkbUAbD9dEBqgIo38N66JLySrT2cb5iwHPN++yvMeLB/BwxI4d3YRqgzYr0lsmnv9sBJDlEHwPZD5B7bCHVGrLdENu3dHnjjABEREREReRVOcoiIiIiIyKtwkkNERERERF6FkxwiIiIiIvIqnOQQEREREZFX6UCTHBM+ffkm+D3+Ho6b9aTOojoLuzdNw6xeD2J64bd64pXen1rU5K3Du29EoNdtG5HV2Y4pdVCyXn0yDsP8YrHQ9L2e1g7Mudg+JhAR6V/pCR2Ey7bvzjcoSbkLV83djzI9hYiIiFrfFZrk1KLy/aVYV+kNI+/T2L/oQTzw+Dq8Vt5VT+sAKtfjxV9Ow9gZWSgP5Bd21NbauE1X5+LoznIUnf1KbqmjaE7b/w+Kjhbhu2NnUMQPHoiIiNrMlRn9mv+BtBcvok7/UxOEO58vxuWkhzrZL2L3xohXi1G0trf+t8UV3p8esVhmykBSpEFPIGoNBnS/exs+vpyIhUE/0tMkl226papwcl0f+EQsQmLNrxE1fhBGD+uJU2sGw89vPhKv+IckDbX9+syF0xHtE42R+36EIVG/QNDDd2NIYRwm+g3qeN9OEREReYErMPwuQ+G6J/DYcX67QOQd2qpN+6PPA0uweriA35sv4e/FPVH2t61YY/gD4rOexlM9Ok8f4ts3FvGrf4FHTr2Ktw8CfQr3YP5fQ/DTlWvx5sjr9aWIiIiotbTzKEEOhtbcixGxx1FbuxTTr+0Cn8Dn1U9kzaZUpNZ7fuQblB76HSYF+sAn4nksLDiJveNs75tLNmPl2O7w8YlGxLt5KNk9DXGFFdqnvz5yHZ879U9J9U+E1bRABG4otLvlRW7jyCzMHeanvR/xHOJyShu5JaYWNfmvYZm67UD0mrMfxU4fKjdnfxzzVcoq9+uNdGRVWxYoQ8H7C7Fhxk1yH46hJP0BRPjchsGpZ/XylqHoo3Fa/sqnxunfuvxk3VySjE3PBNq2sSYHeeomHJ/jOVG8GvPlcbE8V+T6eHvyHAK1FqVevbtlDMZfNR+Jxf/Adst5VOtTpb5UA+dx4izMstRzvd3BnIlNI/U0nzH6cyUN1zOzOQ85W+2fQXHVpv+Al164Rc+zsTbovk349gjAT66pg6mqC3pqSc1j/+xM/pfIfFYeN1lO9bkiuU+5ayLkPiplk6/ASRizqwjl+qqNt1uLShS9O1LLR+Yx7nCZvo+S73XoeaMBvv+phblnFz2RiIiI2oxoJZ5nVSmK1vYWMM4XCRV1WlJFgphrhJoHopLEAT25riBWBP06SWRUKQk1oiTtfhEwcIP2fl2GWB80TsTmVWjLmlaJZwNGidiC/6nLmv4aKoz4mQhPK1fft6UZhXF9gbisp5XsHSVCnkoRB5Rt1J0QR14OkcvE6Pm4VlccL6YYIkVkuknmc1lUn5gjZg/1l+XX12vO/ij55IwVYYYp+j7Jv/NmiIkyH8OUHeJYXZ2oTI+UZVPyNYqAR1eIhH+fFBkzg0TAkhxxXnyr7p8hLF4kmL6T65eKgsRwEXmXwbEM8jhND5kp4vOVbcgyZE8WEwwG9ZjU2Zc7fKoYu+dLYVLKGLBcpFR84uZ4U0t51H5knU+KlOdTOT/GiSLmnRxxQjmv1bvEhke7ybTpIr5Ynnu357FQ7JioLGvX/uqOamlq/a1xU892ivdmK/Vcec++jbho0x62QfdtQsvXMOFNsc10VuybPERu8z+iMDlStpN5dttqzCmRaS13uBi0eJ84c06pv+EiJuc/ertZIVKqlfyKRe5LQQ7750kZ1XwXbZHllMffcjyd2n6kYYIYe8gkLqZFi6D1J0RFfryY2fc6u+ND7njURog6GNZbIpv2bg+ttjXPC+5qQCRZBnDWgcFldbDVdfJ2OcBXl5BOiT1j9cGFHMjN6TpNG9Sp5PK7pooZ6sBEW9dxgKUNNKLsJznqRGmuYzn0AaJhTqacJrigDGDG+9tNlBSWgY7dwK+p+yOX3xjR1Snf+vtRbx902sTrIbuBp1SvDJWiMHGI06BKHwBazke9dXRujze1lOftx+l86bTzr01WLXXb5Xl0uX79+ttQPXNZ1122aU/aYCNtwp5S/+z3r8lclVuhpdvau3O5Gyujm+NRb1sK/fjXOy/UGA4WqTNivSWyae/20IFvajeg+03BGL75Yfxs8iv4098KUI7euHfbEwhXSn1NMPqFbcSiu57EmC37kFXtC//712JVv6u01T1gPvketpuWa7fYWG5VuXY6lpcBtQ1EPzKf3Ix1W29F8M3XyxI2hfv9UcqScmCgU74G+N/1ECYYP0N2xnE0HHK2Cqd2bcWmgGAMMNo9DO7MnItDO44jKzrAtr8+fRC5ogooO4W8MjchgVvheFPb8Q0chnuGy9O4/TCyXdTbjqmRNm7vmlCEjuiNsEE3NLHdNcYffaeewuXlI2CszkLalnF4elKmXVtrQhk9cgOCQwfAGD4AAzpw70tERNTZdejLrG+/5XgrezLGZczF4t+EoJf9cwe+kZi8ZQNWDN+B1MlRiPC/DxHvFtrdR9+YWtQUF2G/YR4SKuqUqaXjK22Ki0GMts4X+l9N1fD+uMlXTi6CQwwNTro05TB96cGeVxeh8GB/hKeV199fkYIEdxOWFh9vovrctnF7vqGISStEyt3X6gmtSH8mZ9h1m5DUZSbmbYqEUX9L4XEZPdINNz5yGKXz70aAnkJEREStr4N/ltgNgfe8hS2mE8h5JwYTi5ZgUeQfrT9C6HvjZMxK/i9KDsVj6aOHkDU2BiOtD+E3RvuEdkTtF8gqrNLT2lpD+2NWy3IbShv8HRDD4FsQ3NKzpUyYhp1E3uenmzU5adnxpvbQKvWkXblv423PhE+X3ou7UkZhxsXNSBkfihvrxQW40mUkIiKipurAw6FaVO2aj8XKQMJ3AO4en4ItBQmYU/53HMyXk5LKzYjbfEYuJQcgQxfiueRjyJx9Dvm5ygDes93y7fsQHolMQ+roOKdoSibkxG1zET3J09vHXHG/P1pZyuvfbqR++zISo387xOHTZUc3487oUBjL0pH6yQU9zQXfUAx7JAjl859A+At77KK21aLm8J+wsMBNpDS3x5uuOP1burCRg9zUk46mkTbeHio/QOqbJhhCByOsu6t+owOUkYiIiJrsCkxyrsYNP71FDsiVZ0D+h5qPk5CqhLK9dB5ffyff/uIU8i2D7x/lYvG8DUguUT4xlQPxkiKUdrkHw0P85d+X0HXaAky0hGmtKcK//t0VIaG9ESB3S5mMjDccQ96+z9XwyEro3R378vG9nJqUPdUfP567H2W+YYh+6g5ZlreR+qt+6GV9TuU+TA27B2Gujk6PSZjxeigCXonDyCXZWt4lyfgg86J8MxWJ/cO0kLlN3R/f4RjzUgzC0xdgzHPpWkhn83FkLlqCzc/MRHyocptOQ7e1yclX5BK8ObEQWZNnq6FrzUrY24zNciIj305/HBFBSsjg7ujzwHhMMZ5Afvz9iPC3PIvkh55Jd+Ch4KvUwXJRvqvvZtwdb2p3ZR8iITlPm2Aq9eTFxXht4kKssvzmSoPn0TIh/gzvHdXrSXYiDhZcku9Z6u95N7dlVqFKrdj/Qv65Gi3JZZv2pA0eQKXbNu4Zs2khHvfzQ685ertxqYFbOi23g+YeQ3aNWbblVGzfla9/gHEBhxI/aaSMlnwvobzS8iGB5RjZpxEREVG7Eq2kSVlZQ95OFGMPlQqH0MXqS4lKVCMqdi4Ra899LlLjjFp6+Hw99LFU8Y6I/7BIDScbrq4TJcKTC8R57V2p1PaeEm73o0JRURArBgbMFLEb92oho1U1ouTwTDEnzKBtQ1/Wlo8rdnljoAh5ea/ISFRC3S4XC97PF9XN2R+Vi7JYwgRbIzbZ8q0XAa4qw5a3cmw//lCsHeovQhZtFQknbNupM20TSZbllPIv2q0eDy3ylS1/h2hZjR5vagnleHvGEh0tTqx6J9pWB/VzqHB7HhV29cQwYYVYlVcmCtcGi4CZa0T8zlxxtMF6pm/b+p5d9DWnNq1FQGusDX7vQZtonBpZTm1vjpHcrCyR5qzltl/OFqpdrdOJR4TpghbJLWDmdvdldJnvCadj1ECZqMmU40nU2bDeEtm0d3vwUf6RG20x5RuBVsqK6AfH8/ZzGvufHYLIbdORULAYsZ3oV//bmjn/Nbzs83ss6M+If96I1xjqjFhviWzauz1whEREnZ/5ONI29sMo5ZZLIiIi+sHjJIeoMzFfQEV5nfyPKpyvZlw7hfKszxsvnMOPF0VjEHs0IiIikni7GlEH4FH7qUzEc/21H6vVxCC24G33v29E5CV4jaHOiPWWyKa92wMnOUQdANsPkXtsI9QZsd4S2bR3e+DNHURERERE5FVa9ZscIiIiIiIiV9rzm5xWm+QQERERERF1BLxdjYiIiIiIvAonOURERERE5FU4ySEiIiIiIq/CSQ4REREREXkVTnKIiIiIiMircJJDRERERERehZMcIiIiIiLyKpzkEBERERGRFwH+fwMTn52J+aeDAAAAAElFTkSuQmCC" alt="" width="825" height="475" vspace="0" hspace="0" border="0" style="width:825px;height:475px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /><br /><img src="data:image/png;base64,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" alt="" width="805" height="295" vspace="0" hspace="0" border="0" style="width:805px;height:295px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /><br />Symptoms suggestive of hypersensitivity (* marked in the table above) have been noted, overall in approximately 3% of the patients. Onset of such symptoms has occurred during or shortly after infusions. These symptoms generally respond to treatment with antihistamines and/or corticosteroids. Patients should be advised to discontinue infusion of the product and contact their physician if these symptoms occur.<br /><u>Reporting of suspected adverse reactions</u><br />&nbsp;<strong>To report any side effect(s):</strong><br /><strong>Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; SFDA call center : 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported. In patients dosages up to 240 U/kg body weight once every two weeks have been used.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Enzymes-Imiglucerase (recombinant macrophage targeted glucocerebrosidase), ATC code: A16AB02.<br /><br /><u>Mechanism of action</u><br />Gaucher disease is a rare recessively inherited metabolic disorder that results from a deficiency of the lysosomal enzyme acid -glucosidase. This enzyme breaks down glucosylceramide, a key component of the lipid structure of cell membranes, into glucose and ceramide. In individuals with Gaucher disease, glucosylceramide degradation is insufficient, leading to accumulation of large quantities of this substrate within the lysosomes of macrophages (termed &lsquo;Gaucher cells&rsquo;), leading to widespread secondary pathology.<br />Gaucher cells are typically found in liver, spleen and bone marrow and occasionally in lung, kidney and intestine. Clinically, Gaucher disease is a heterogeneous phenotypic spectrum. The most frequent disease manifestations are hepatosplenomegaly, thrombocytopenia, anaemia, and skeletal pathology, The skeletal abnormalities are frequently the most debilitating and disabling features of Gaucher disease. These skeletal manifestations include bone marrow infiltration, osteonecrosis, bone pain and<br />bone crises, osteopenia and osteoporosis, pathological fractures, and growth impairment. Gaucher disease is associated with increased glucose production and increased resting energy expenditure rate, which may contribute to fatigue and cachexia. Patients with Gaucher disease may also have a low grade inflammatory profile. In addition, Gaucher disease has been associated with an increased risk of immunoglobulin abnormalities such as hyperimmunoglobulinemia, polyclonal gammopathy, monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. The natural history of Gaucher disease usually shows progression, with the risk of irreversible complications arising in various organs over time. The clinical manifestations of Gaucher disease can adversely affect quality of life. Gaucher disease is associated with increased morbidity and early mortality. Signs and symptoms presenting in childhood typically represent more severe Gaucher disease. In children, Gaucher disease can lead to growth retardation and delayed puberty.<br />Pulmonary hypertension is a known complication of Gaucher disease. Patients who have undergone a splenectomy have an increased risk of pulmonary hypertension. Cerezyme therapy reduces the requirement for splenectomy in most cases and early treatment with Cerezyme has been associated with a reduced risk of pulmonary hypertension. Routine evaluation to detect the presence of pulmonary hypertension after diagnosis of Gaucher disease and over time is recommended. Patients diagnosed with pulmonary hypertension, in particular, should receive adequate doses of Cerezyme to ensure control of underlying Gaucher disease as well as be evaluated for the need of additional pulmonary hypertension specific treatments.<br /><br /><u>Pharmacodynamic effects</u><br />Imiglucerase (recombinant macrophage targeted acid &szlig;-glucosidase) replaces the deficient enzyme activity, hydrolysing glucosylceramide, thus correcting initial pathophysiology and preventing secondary pathology. Cerezyme reduces spleen and liver size, improves or normalises thrombocytopenia and anaemia, improves or normalises bone mineral density and bone marrow burden, and reduces or eliminates bone pain and bone crises. Cerezyme reduces resting energy expenditure rate. Cerezyme has been shown to improve both mental and physical aspects in the quality of life of Gaucher disease. Cerezyme decreases chitotriosidase, a biomarker for glucosylceramide accumulation in macrophages and response to treatment. In children, Cerezyme has been shown to enable normal pubertal development, and to induce catch-up growth, leading to normal height and bone mineral density in adulthood.<br /><br /><u>Clinical efficacy and safety</u><br />The rate and extent of response to Cerezyme treatment is dose-dependent. Generally, improvements in organ systems with a faster turnover rate, such as the haematological, can be noted far more rapidly than in those with a slower turnover, such as the bone.<br />In an ICGG Gaucher Registry analysis of a large cohort of patients (n=528) with Gaucher disease type 1, a time- and dose-dependent effect for Cerezyme was observed for haematological and visceral parameters (platelet count, haemoglobin concentration, spleen and liver volume) within the dose range of 15, 30 and 60 U/kg body weight once every 2 weeks. Patients treated with 60 U/kg body weight every 2 weeks showed a faster improvement and a greater maximum treatment effect as compared to patients receiving the lower doses.<br />Similarly, in an ICGG Gaucher Registry analysis of bone mineral density using dual-energy X-ray absorptiometry (DXA) in 342 patients, after 8 years of treatment normal bone mineral density was achieved with a Cerezyme dose of 60 U/kg body weight once every 2 weeks, but not with lower doses of 15 and 30 U/kg body weight once every 2 weeks (Wenstrup et al, 2007).<br />In a study investigating 2 cohorts of patients treated with a median dose of 80 U/kg body weight every 4 weeks and a median dose of 30 U/kg body weight every 4 weeks, among the patients with bone marrow burden score  6, more patients in the higher dose cohort (33%; n=22) achieved a decrease in the score of 2 points after 24 months of Cerezyme treatment compared with patients in the lower dose cohort (10%; n=13) (de Fost et al, 2006).<br />Treatment with Cerezyme at a dose of 60 U/kg body weight once every 2 weeks, showed improvement in bone pain as early as 3 months, decrease in bone crises within 12 months, and improvement in bone mineral density after 24 months of treatment (Sims et al, 2008).<br />The usual frequency of infusion is once every 2 weeks (see section 4.2). Maintenance therapy every 4 weeks (Q4) at the same cumulative dose as the bi-weekly (Q2) dose has been studied in adult patients with stable residual Gaucher disease type 1. Changes from baseline in hemoglobin, platelets, liver and spleen volumes, bone crisis, and bone disease comprised a predefined composite endpoint; achievement or maintenance of established Gaucher disease therapeutic goals for the hematologic and visceral parameters comprised an additional endpoint. Sixty-three percent of Q4- and 81% of Q2treated patients met the composite endpoint at Month 24; the difference was not statistically significant based on the 95% CI (-0.357, 0.058). Eighty-nine percent of Q4- and 100% of Q2-treated patients met the therapeutic goals-based endpoint; the difference was not statistically significant based on the 95% CI (-0.231, 0.060). A Q4 infusion regimen may be a therapeutic option for some adult patients with stable residual Gaucher disease type 1, but clinical data are limited.<br />No controlled clinical studies have been conducted on the efficacy of Cerezyme on neurological manifestations of the disease. Therefore no conclusions on the effect of enzyme replacement therapy on the neurological manifestations of the disease can be drawn.<br />Medical or healthcare professionals are encouraged to register Gaucher patients, including those with chronic neuronopathic manifestations of the disease, in the &ldquo;ICGG Gaucher Registry&rdquo;. Patient data will be anonymously collected in this Registry. The objectives of the &ldquo;ICGG Gaucher Registry&rdquo; are to enhance the understanding of Gaucher disease and to evaluate the effectiveness of enzyme replacement therapy, ultimately leading to improvement in the safe and efficacious use of Cerezyme.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During 1 hour intravenous infusions of 4 doses (7.5, 15, 30, 60 U/kg) of imiglucerase, steady-state enzymatic activity was achieved by 30 minutes. Following infusion, plasma enzymatic activity declined rapidly with a half-life ranging from 3.6 to 10.4 minutes. Plasma clearance ranged from 9.8 to 20.3 ml/min/kg, (mean &plusmn; S.D, 14.5 &plusmn; 4.0 ml/min/kg). The volume of distribution corrected for weight ranged from 0.09 to 0.15 l/kg (mean &plusmn; S.D 0.12 &plusmn; 0.02 l/kg). These variables do not appear to be influenced by dose or duration of infusion, however, only 1 or 2 patients were studied at each dose level and infusion rate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single and repeated dose toxicity and genotoxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol,<br />sodium citrate (to adjust pH),citric acid monohydrate (to adjust pH), polysorbate 80.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vials:
3 years
Diluted solution:
From a microbiological safety point of view, the product should be used immediately. If not used immediately, in-use storage and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2C - 8C under protection from light.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2C &ndash; 8C).<br />For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cerezyme is supplied in type I borosilicate (clear) glass 20 ml vials. The closure consists of a siliconised butyl stopper with a tamper proof flip-off cap.<br />To provide sufficient volume to allow accurate dispensing, each vial is formulated to contain an overfill of 0.6 ml.<br />Pack sizes: 1, 5 or 25 vials per carton.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each vial of Cerezyme is for single use only.<br />The powder for concentrate for solution for infusion has to be reconstituted with water for injections, diluted with 0.9% sodium chloride intravenous solution and then administered by intravenous infusion.<br />Determine the number of vials to be reconstituted based on the individual patient&#39;s dosage regimen and remove the vials from the refrigerator.<br />Occasionally, small dosage adjustments may be made to avoid discarding partially used vials. Dosages may be rounded to the nearest full vial, as long as the monthly administered dosage remains substantially unaltered.<br /><u>Use Aseptic Technique</u><br /><em>Reconstitution</em><br />Reconstitute each vial with 10.2 ml water for injections; avoid forceful impact of water for injections on the powder and, by mixing gently, avoid foaming of the solution. The reconstituted volume is 10.6 ml. The pH of the reconstituted solution is approximately 6.2.<br />After reconstitution it is a clear, colourless liquid, free from foreign matter. The reconstituted solution must be further diluted. Before further dilution, visually inspect the reconstituted solution in each vial for foreign particles and discoloration. Do not use vials exhibiting foreign particles or discoloration. After reconstitution, promptly dilute vials and do not store for subsequent use.<br /><em>Dilution</em><br />The reconstituted solution contains 40 units imiglucerase per ml. The reconstituted volume allows accurate withdrawal of 10.0 ml (equal to 400 units) from each vial. Withdraw 10.0 ml reconstituted solution from each vial and combine the withdrawn volumes. Then dilute the combined volumes with <u>0.9% sodium chloride intravenous solution</u> to a total volume of 100 to 200 ml. Mix the infusion solution gently.<br /><em>Administration</em><br />It is recommended to administer the diluted solution through an in-line low protein-binding 0.2 &mu;m filter to remove any protein particles. This will not lead to any loss of imiglucerase activity. It is recommended that the diluted solution be administered within 3 hours. The product diluted in 0.9% sodium chloride intravenous solution will retain chemical stability if stored up to 24 hours at 2&deg;C and 8&deg;C under protection from light; but microbiological safety will depend on the reconstitution and dilution having been performed aseptically.<br />Cerezyme contains no preservatives. Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sanofi B.V., Paasheuvelweg 25, 1105 BP, Amsterdam, the Netherlands
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2023 April
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>